Albumin-binding compounds

Abstract

The present invention relates to a compound of formula (la) or (lb) wherein each -D- is independently a drug moiety; each -AB1 and -AB2 is independently an albumin-binding moiety; each -L1 - is independently a linker moiety covalently and reversibly connected to -D-; each -L2 - is independently a spacer moiety; x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25; and y is an integer selected from the group consisting of 2, 3, 4 and 5.

Description

[0001]Ascendis Pharma A / S 1 CPX75146PC09 July 2025Albumin-binding compounds The present invention relates to a compound or a pharmaceutically acceptable salt thereof of formula (Ia) or (Ib), to pharmaceutical compositions comprising at least one such compound,their uses and other related aspects.Whereas some classes of therapeutic proteins, including antibodies, have long inherent half- lives, many other molecules, particularly protein or peptide hormones are often susceptible to enzymatic degradation, renal clearance and / or rapid receptor-mediated clearance, which leads to a short plasma elimination half-life. Furthermore, due to the challenges associated with oraldelivery, most peptide- or protein-based drugs require parenteral administration, whichcombined with a short half-life necessitates frequent injections, resulting in discomfort and inconvenience for the patient. This may negatively impact adherence and, ultimately, limit treatment efficacy and outcomes. Injecting lipidated peptides has been demonstrated to have slower absorption from the subcutaneous tissue compared to the non-derivatized peptide as well as longer circulatory half-life due to reversible binding to albumin. The half-life of endogenous albumin in the circulationis approximately 3 weeks. This long half-life can be attributed both to its large molecular size, which minimizes renal clearance, as well as to recycling via the neonatal Fc receptor (FcRn).In the circulation, the large molecular size protects the bound peptide from renal clearance andreduces the rate of distribution to the extravascular compartment.The slower absorption is thought to be due to a reduced rate of diffusion in the tissue by amechanism involving interaction of the fatty acid side chain with cell membranes and / orproteins such as albumin present at the injection site. The rate of diffusion in the tissue following injection and the passage over the capillary wall would expectedly be reduced due to the large molecular size of the albumin-peptide complex. Molecules with a molecular sizegreater than approximately 16 kDa are preferentially alternatively be absorbed via a lymphaticroute compared to direct absorption into blood across the capillary wall.Thus, slower absorption and reversible albumin binding has enabled extension of dosingintervals for drugs, such as peptide drugs, to up to a week. However, an even further extensionof the dosing intervals would be desirable.Ascendis Pharma A / S 2 CPX75146PC09 July 2025It is an object of the present invention to overcome the shortcomings of current therapies at least partially.This object is achieved with a compound or a pharmaceutically acceptable salt thereof offormula (Ia) or (Ib) (Ib), wherein each -D- is independently a drug moiety;each -AB1and -AB2is independently an albumin-binding moiety; each -L1- is independently a linker moiety covalently and reversibly connected to -D-;each -L2- is a spacer moiety;x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25; and y is an integer selected from the group consisting of 2, 3, 4 and 5.The compounds of formula (Ia) and (Ib) may also be referred to as “prodrugs” that release adrug moiety-AB2 conjugate, which may also be written as H-D-AB2, wherein H- is hydrogen.“H-D-AB2” may also be referred to as “parent drug” or “corresponding free drug” of theconjugates of formula (Ia) or (Ib) as described herein.Applicant discovered that the compounds of the present invention have an increased circulationhalf-life that allows for a less frequent administration than is required for their corresponding parent drug. Within the present invention the terms are used having the meaning as follows. As used herein, the term “GLP-1 receptor agonist” refers to agonists of the GLP-1 receptor (GLP1R) and optionally in addition agonists of one or more other receptors, such as for example a receptor for gastric inhibitory polypeptide (GIPR), a receptor for glucagon (GCGR), a receptor for amylin, a receptor for peptide YY (PYYR) or a receptor for glucagon-likeAscendis Pharma A / S 3 CPX75146PC09 July 2025peptide-2 (GLP2R). An “agonist” of a receptor, such as an agonist of the GLP-1 receptor, is a chemical compound that activates such receptor to produce a biological response. If a GLP-1 receptor agonist is in addition to being a GLP1R agonist also an agonist of one receptor other than GLP1R, such as an agonist of GIPR, GCGR, an amylin receptor, a PYYR or GLP2R, such GLP-1 receptor agonist is also referred to as being a “dual GLP-1 receptor agonist” or short “dual agonist”. Likewise, if a GLP-1 receptor agonist is in addition to being a GLP1R agonist also an agonist of two other receptors, which may be selected from the group consisting of GIPR, GCGR, an amylin receptor, a PYYR or GLP2R, such GLP-1 receptor agonist is also referred to as being a “triple GLP-1 receptor agonist” or short “triple agonist”. As used herein, the term “peptide” as used herein refers to a chain of at least 2 and up to and including 50 amino acid monomer moieties, which may also be referred to as “amino acid residues”, linked by peptide (amide) linkages. The amino acid monomers may be selected from the group consisting of proteinogenic amino acids and non-proteinogenic amino acids and maybe D- or L-amino acids. The term “peptide” also includes peptidomimetics, such as peptoids,beta-peptides, cyclic peptides and depsipeptides and covers such peptidomimetic chains withup to and including 50 monomer moieties. The cyclic peptides may be mono-, bi-, tri- ortetracyclic peptides. The term “peptide” also includes lasso peptides. As used herein, the term “protein” refers to a chain of more than 50 amino acid monomer moieties, which may also be referred to as “amino acid residues”, linked by peptide linkages, in which preferably no more than 12000 amino acid monomers are linked by peptide linkages, such as no more than 10000 amino acid monomer moieties, no more than 8000 amino acid monomer moieties, no more than 5000 amino acid monomer moieties or no more than 2000 amino acid monomer moieties. As used herein, the term “small molecule drug” refers to drugs that are organic compounds with a molecular weight of less than 1000 Da, such as less than 900 Da or less than 800 Da. It is understood that nucleobase-based drug moieties, such as adenine or guanine analogues, may also be a type of small molecule drug. As used herein, the term “medium molecule drug” or “medium size molecule drug” refer to drugs that are organic compounds which are not peptides and which are not proteins and have a molecular weight ranging from and including 1 kDa to 7.5 kDa.Ascendis Pharma A / S 4 CPX75146PC09 July 2025As used herein, the terms “oligonucleotide” refers to double- or single-stranded RNA and DNAwith preferably 2 to 1000 nucleotides and any modifications thereof. Modifications include, for example, those which provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include for example, 2’-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridines, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine. Modifications can also include 3’ and 5’ modifications such as capping and change of stereochemistry. The term also includes aptamers. As used herein, the term “peptide nucleic acids” refers to organic polymers having a peptidic backbone, i.e., a backbone in which the monomers are connected to each other through peptide linkages, to which nucleobases such as adenine, cytosine, guanine, thymine and uracil, are attached. In certain embodiments, the peptide backbone comprises N-(2-aminoethyl)-glycine. As used herein, the term "random coil" relates to any conformation of a polymeric molecule, including proteins, in which the individual monomeric elements that form said polymeric structure are essentially randomly oriented towards the adjacent monomeric elements while still being chemically bound to said adjacent monomeric elements. In particular, a polypeptide or protein having random coil conformation substantially lacks a defined secondary and tertiary structure. The nature of polypeptide random coils and their methods of experimental identification are known to the person skilled in the art. In particular, the lack of secondary and tertiary structure of a protein may be determined by circular dichroism (CD) measurements. CD spectroscopy represents a light absorption spectroscopy method in which the difference inabsorbance of right- and left-circularly polarized light by a substance is measured. Thesecondary structure of a protein can be determined by CD spectroscopy using far-ultraviolet spectra with a wavelength between approximately 190 and 250 nm. At these wavelengths the different secondary structures commonly found in conformations each give rise to a characteristic shape and magnitude of the CD spectrum. Accordingly, by using CD spectrometry the skilled artisan is readily capable of determining whether an amino acid polymer adopts random coil conformation at physiological conditions.Ascendis Pharma A / S 5 CPX75146PC09 July 2025When determining whether a peptide or protein adopts random coil conformation under experimental conditions using the methods as described herein, the biophysical parameters such as temperature, pH, osmolarity and protein content may be different to the physiological conditions normally found in vivo. Temperatures between 1 °C and 42 °C or preferably 4 °C to 25 °C may be considered useful to test and / or verify the biophysical properties and biological activity of a peptide or protein under physiological conditions in vitro. Several buffers, in particular in experimental settings (for example in the determination of protein structures, in particular in circular dichroism (CD) measurements and other methods that allow the person skilled in the art to determine the structural properties of a protein / polypeptide or peptide stretch) or in buffers, solvents and / or excipients for pharmaceutical compositions, are considered to represent "physiological solutions" or "physiological conditions" in vitro. Examples of such buffers are, e.g. phosphate-buffered saline (PBS: 115 mM NaCl, 4 mM KH2PO4, 16 mM Na2HPO4 pH 7.4), Tris buffers, acetate buffers, citrate buffers or similar buffers such as those used in the appended examples. Generally, the pH of a buffer representing physiological conditions should lie in a range from 6.5 to 8.5, preferably in a range from 7.0 to 8.0, most preferably in a range from 7.2 to 7.7 and the osmolarity should lie in a range from 10 to 1000 mmol / kg H2O, more preferably in a range from 50 to 500 mmol / kg H2O and most preferably in a range from 200 to 350 mmol / kg H2O. Optionally, the protein content of a buffer representing physiological conditions may lie in a range from 0 to 100 g / l, neglecting the protein with biological activity itself, whereby typical stabilizing proteins may be used, for example human or bovine serum albumin. Other established biophysical methods for determining random coil conformation includenuclear magnetic resonance (NMR) spectroscopy, absorption spectrometry, infrared andRaman spectroscopy, measurement of the hydrodynamic volume via size exclusion chromatography, analytical ultracentrifugation and dynamic / static light scattering as well as measurements of the frictional coefficient or intrinsic viscosity. As used herein the term “physiological conditions” refers to aqueous buffer at pH 7.4, 37°C. As used herein the term “pharmaceutical composition” refers to a composition containing oneor more active ingredients, such as for example at least one compound of the present invention,Ascendis Pharma A / S 6 CPX75146PC09 July 2025and one or more excipients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients of the composition, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, a pharmaceutical composition of the present invention encompasses any composition made by admixing one ormore compound of the present invention and one or more pharmaceutically acceptableexcipient. As used herein, the term "excipient" refers to a diluent, adjuvant, or vehicle with which the therapeutic, such as a drug or prodrug, is administered. Such pharmaceutical excipient may be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is an example for an excipient when the pharmaceutical composition is administered orally. Saline and aqueous dextrose are examples of excipients when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are in certain embodiments employed as liquid excipients for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, mannitol, trehalose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The pharmaceutical composition, if desired, can also contain minor amounts of wetting or emulsifying agents, pH buffering agents, like, for example, acetate, succinate, tris, carbonate, phosphate, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), or can contain detergents, like Tween, poloxamers, poloxamines, CHAPS, Igepal, or amino acids like, for example, glycine, lysine, or histidine. These pharmaceutical compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, or sustained-release formulations. The pharmaceutical composition may be formulated as a suppository, with traditional binders andexcipients such as triglycerides. Oral formulation can include standard excipients such aspharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Such compositions will contain a therapeutically effective amount of the drug or drug moiety, together with a suitable amount of excipient so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.Ascendis Pharma A / S 7 CPX75146PC09 July 2025As used herein the term “liquid composition” refers to a mixture comprising a water-soluble compound and one or more solvents, such as water. The term “suspension composition” relates to a mixture comprising at least one water-insoluble compound and one or more solvents, such as water. As used herein, the term “dry composition” means that a pharmaceutical composition is provided in a dry form. Suitable methods for drying are spray-drying and lyophilization, i.e., freeze-drying. Such dry composition has a residual water content of a maximum of 10%, such as less than 5% or less than 2%, determined according to Karl Fischer. In certain embodiments such dry pharmaceutical composition is dried by lyophilization. The term “drug” as used herein refers to a substance used in the treatment, cure, prevention, or diagnosis of a disease or used to otherwise enhance physical or mental well-being. If a drug is conjugated to another moiety, the moiety of the resulting product that originated from the drug is referred to as “drug moiety”. As used herein the term “prodrug” refers to a covalent conjugate in which a drug moiety is reversibly and covalently connected to a specialized protective group through a reversiblelinker moiety, also referred to as “reversible prodrug linker moiety” or “reversible linkermoiety”, which is conjugated through a reversible linkage to the drug moiety and wherein the specialized protective group alters or eliminates undesirable properties in the parent molecule. This also includes the enhancement of desirable properties in the drug and the suppression of undesirable properties. The specialized non-toxic protective group is referred to as “carrier”. A prodrug releases the reversibly and covalently bound drug moiety in the form of its corresponding drug. In other words, a prodrug is a conjugate comprising a drug moiety which is covalently and reversibly conjugated to a carrier moiety via a reversible linker moiety, which covalent and reversible conjugation of the carrier to the reversible linker moiety is eitherdirectly or through a spacer moiety. Such conjugate releases the formerly conjugated drugmoiety in the form of a free unmodified drug. A “reversible linkage” is a linkage that is degradable, i.e., cleavable, in the absence of enzymes under physiological conditions (aqueous buffer at pH 7.4, 37°C) with a half-life ranging from 1 hour to three months. A “stable linkage” is a linkage having a half-life under physiologicalAscendis Pharma A / S 8 CPX75146PC09 July 2025conditions (aqueous buffer at pH 7.4, 37°C) in the absence of enzymes of more than three months. As used herein, the terms “traceless prodrug linker” or “traceless linker” means a reversible prodrug linker, i.e., a linker moiety reversibly and covalently connecting a drug moiety with acarrier, such as -AB1, which upon cleavage releases the drug in its free form. As used herein,the term “free form” of a drug or “free drug” means the drug in its unmodified, pharmacologically active form, i.e., as H-D-AB2. As used herein, the term “reagent” means a chemical compound which comprises at least one functional group for reaction with the functional group of another chemical compound or drug. It is understood that a drug comprising a functional group, such as a primary or secondary amine or hydroxyl functional group, is also a reagent. As used herein, the term “moiety” means a part of a molecule, which lacks one or more atom(s) compared to the corresponding reagent. If, for example, a reagent of the formula “H-X-H” reacts with another reagent and becomes part of the reaction product, the corresponding moiety of the reaction product has the structure “H–X–” or “–X–”, whereas each indicates attachment to another moiety. Accordingly, a drug moiety is released from a prodrug as a drug. If a chemical structure of a group of atoms is provided, which group of atoms is attached to at least one other moiety, said chemical structure may be attached to the at least one other moiety in either orientation, unless explicitly stated otherwise. For example, a moiety “-C(O)N(R1)-”may be attached to two moieties either as “-C(O)N(R1)-” or as “-N(R1)C(O)-”. Similarly, amoiety may be attached to two moieties either asAscendis Pharma A / S 9 CPX75146PC09 July 2025 . As used herein, the term “functional group” means a group of atoms which can react with other groups of atoms. Functional groups are for example selected from the group consisting of carboxylic acid, primary or secondary amine, maleimide, thiol, sulfonic acid, carbonate, carbamate, hydroxyl, aldehyde, ketone, hydrazine, isocyanate, isothiocyanate, phosphoric acid, phosphonic acid, haloacetyl, alkyl halide, acryloyl, aryl fluoride, hydroxylamine, disulfide, sulfonamides, sulfuric acid, vinyl sulfone, vinyl ketone, diazoalkane, oxirane and aziridine. As used herein, the term “pharmaceutically acceptable salt(s) thereof” refers to salts that retain the biological effectiveness or properties of the compound and that typically are not biologically or otherwise undesirable. In certain embodiments, the compound is capable of forming acid / or base salts by virtue of the presence of amino and / or carboxylic functional groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide / hydrobromide, bicarbonate / carbonate, bisulfate / sulfate, camphorsulfonate, chloride / hydrochloride, chlortheophyllinate, citrate, ethanedisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide / iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulfate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, subsalicylate, tartrate, tosylate and trifluoroacetate salts. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and thelike. Pharmaceutically acceptable base addition salts can be formed with inorganic and organicbases. Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts areAscendis Pharma A / S 10 CPX75146PC09 July 2025derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine, or tromethamine. The pharmaceutically acceptable salts can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods. The term "pharmaceutically acceptable" means a substance that does not cause harm when administered to a patient and in certain embodiments means approved by a regulatory agency, such as the EMA (Europe) and / or the FDA (US) and / or any other national regulatory agencyfor use in animals, in particular for use in humans.As used herein the terms “about” or “approx.” in combination with a numerical value is used to indicate a range ranging from and including the numerical value plus and minus no more than 10% of said numerical value. For example, the phrases “about 200” or “approx.200” isused to mean a range ranging from and including 200 + / - 10%, i.e. ranging from and including180 to 220. It is understood that a percentage given as “about 20%” or “approx.20%” does notmean “20% + / - 10%”, i.e. ranging from and including 10 to 30%, but “about 20%” or “approx.20%” means ranging from and including 18 to 22%, i.e. plus and minus 10% of the numerical value which is 20. As used herein, the term “polymer” means a molecule comprising repeating structural units, i.e., the monomers, connected by chemical bonds in a linear, circular, branched, crosslinked or dendrimeric way or a combination thereof, which may be of synthetic or biological origin or a combination of both. It is understood that a polymer may also comprise one or more other chemical groups and / or moieties, such as, for example, one or more functional groups. In certain embodiments a soluble polymer has a molecular weight of at least 0.5 kDa, e.g., a molecular weight of at least 1 kDa, a molecular weight of at least 2 kDa, a molecular weight of at least 3 kDa or a molecular weight of at least 5 kDa. If the polymer is soluble, it in certain embodiments has a molecular weight of at most 1000 kDa, such as at most 750 kDa, such as at most 500 kDa, such as at most 300 kDa, such as at most 200 kDa, or such as at most 100 kDa. It is understood that for water-insoluble polymers, such as hydrogels, no meaningful molecularAscendis Pharma A / S 11 CPX75146PC09 July 2025weight ranges can be provided. It is understood that also a peptide or protein is a polymer in which the amino acids are the repeating structural units, even though the side chains of each amino acid may be different. As used herein, the term “polymeric” means a reagent or a moiety comprising one or more polymers or polymer moieties. A polymeric reagent or moiety may optionally also comprise one or more other moiety / moieties, which are in certain embodiments selected from the group consisting of: ^C1-50 alkyl, C2-50 alkenyl, C2-50 alkynyl, C3-10 cycloalkyl, 3- to 10-memberedheterocyclyl, 8- to 11-membered heterobicyclyl, phenyl, naphthyl, indenyl, indanyl,and tetralinyl; and ^linkages selected from the group comprising wherein dashed lines indicate attachment to the remainder of the moiety or reagent, and -R and -Raare independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2- methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2- dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl. The person skilled in the art understands that the polymerization products obtained from a polymerization reaction do not all have the same molecular weight, but rather exhibit a molecular weight distribution. Consequently, the molecular weight ranges, molecular weights, ranges of numbers of monomers in a polymer and numbers of monomers in a polymer as used herein, refer to the number average molecular weight and number average of monomers, i.e.,Ascendis Pharma A / S 12 CPX75146PC09 July 2025to the arithmetic mean of the molecular weight of the polymer or polymeric moiety and thearithmetic mean of the number of monomers of the polymer or polymeric moiety. Accordingly, in a polymeric moiety comprising “x” monomer units any integer given for “x” therefore corresponds to the arithmetic mean number of monomers. Any range of integers given for “x” provides the range of integers in which the arithmetic mean numbers of monomers lie. An integer for “x” given as “about x” means that the arithmetic mean numbersof monomers lie in a range of integers of x + / - 10%.As used herein, the term “number average molecular weight” means the ordinary arithmeticmean of the molecular weights of the individual polymers.As used herein the term “water-soluble” with reference to the compound of the presentinvention means that at least 1 g of the compound may be dissolved in one liter of water at20°C to form a homogeneous solution. Accordingly, the term “water-insoluble” with referenceto the compound means that less than 1 g of the compound may be dissolved in one liter ofwater at 20°C to form a homogeneous solution. As used herein, the term “PEG-based” in relation to a moiety or reagent means that said moiety or reagent comprises PEG. In certain embodiments a PEG-based moiety or reagent comprises at least 10% (w / w) PEG, such as at least 20% (w / w) PEG, such as at least 30% (w / w) PEG, such as at least 40% (w / w) PEG, such as at least 50% (w / w), such as at least 60 (w / w) PEG, such as at least 70% (w / w) PEG, such as at least 80% (w / w) PEG, such as at least 90% (w / w) PEG, such as at least 95%. The remaining weight percentage of the PEG-based moiety or reagent are other moieties that in certain embodiments are selected from the following moieties and linkages: ^C1-50 alkyl, C2-50 alkenyl, C2-50 alkynyl, C3-10 cycloalkyl, 3- to 10-memberedheterocyclyl, 8- to 11-membered heterobicyclyl, phenyl, naphthyl, indenyl, indanyl,and tetralinyl; and ^linkages selected from the group comprisingAscendis Pharma A / S 13 CPX75146PC09 July 2025 wherein dashed lines indicate attachment to the remainder of the moiety or reagent, and -R and -Raare independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2- methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2- dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl. The term “hyaluronic acid-based” is used accordingly. The term “substituted” as used herein means that one or more -H atom(s) of a molecule or moiety are replaced by a different atom or a group of atoms, which are referred to as “substituent”. In certain embodiments the one or more further optional substituents are independently of each other selected from the group consisting of halogen, -CN, -COORx1, -ORx1, -C(O)Rx1, -C(O)N(Rx1Rx1a), -S(O)2N(Rx1Rx1a), -S(O)N(Rx1Rx1a), -S(O)2Rx1, -S(O)Rx1, -N(Rx1)S(O)2N(Rx1aRx1b), -SRx1, -N(Rx1Rx1a), -NO2, -OC(O)Rx1, -N(Rx1)C(O)Rx1a, -N(Rx1)S(O)2Rx1a, -N(Rx1)S(O)Rx1a, -N(Rx1)C(O)ORx1a, -N(Rx1)C(O)N(Rx1aRx1b), -OC(O)N(Rx1Rx1a), -T0, C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl; wherein -T0, C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl are optionally substituted with one or more -Rx2, which are thesame or different, and wherein C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl are optionallyinterrupted by one or more groups selected from the group consisting of -T0-, -C(O)O-, -O-, -C(O)-, -C(O)N(Rx3)-, -S(O)2N(Rx3)-, -S(O)N(Rx3)-, -S(O)2-, -S(O)-, -N(Rx3)S(O)2N(Rx3a)-,-S-, -N(Rx3)-, -OC(ORx3)(Rx3a)-, -N(Rx3)C(O)N(Rx3a)- and -OC(O)N(Rx3)-;Ascendis Pharma A / S 14 CPX75146PC09 July 2025-Rx1, -Rx1a, -Rx1bare independently of each other selected from the group consisting of -H, -T0, C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl; wherein -T0, C1-50 alkyl, C2-50 alkenyl and C2-50alkynyl are optionally substituted with one or more -Rx2, which are the same or different, andwherein C1-50alkyl, C2-50alkenyl and C2-50alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T0-, -C(O)O-, -O-, -C(O)-, -C(O)N(Rx3)-, -S(O)2N(Rx3)-, -S(O)N(Rx3)-; -S(O)2-, -S(O)-, -N(Rx3)S(O)2N(Rx3a)-, -S-,-N(Rx3)-, -OC(ORx3)(Rx3a)-, -N(Rx3)C(O)N(Rx3a)- and -OC(O)N(Rx3)-;each T0is independently selected from the group consisting of phenyl, naphthyl, indenyl,indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-memberedheterobicyclyl; wherein each T0is independently optionally substituted with one or more -Rx2, which are the same or different; each -Rx2is independently selected from the group consisting of halogen, -CN, oxo (=O), -COORx4, -ORx4, -C(O)Rx4, -C(O)N(Rx4Rx4a), -S(O)2N(Rx4Rx4a), -S(O)N(Rx4Rx4a), -S(O)2Rx4, -S(O)Rx4, -N(Rx4)S(O)2N(Rx4aRx4b), -SRx4, -N(Rx4Rx4a), -NO2, -OC(O)Rx4, -N(Rx4)C(O)Rx4a, -N(Rx4)S(O)2Rx4a, -N(Rx4)S(O)Rx4a, -N(Rx4)C(O)ORx4a, -N(Rx4)C(O)N(Rx4aRx4b), -OC(O)N(Rx4Rx4a) and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different;each -Rx3, -Rx3a, -Rx4, -Rx4a and -Rx4b is independently selected from the group consisting of -Hand C1-6alkyl; wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different. In certain embodiments the one or more further optional substituents are independently of each other selected from the group consisting of halogen, -CN, -COORx1, -ORx1, -C(O)Rx1, -C(O)N(Rx1Rx1a), -S(O)2N(Rx1Rx1a), -S(O)N(Rx1Rx1a), -S(O)2Rx1, -S(O)Rx1, -N(Rx1)S(O)2N(Rx1aRx1b), -SRx1, -N(Rx1Rx1a), -NO2, -OC(O)Rx1, -N(Rx1)C(O)Rx1a, -N(Rx1)S(O)2Rx1a, -N(Rx1)S(O)Rx1a, -N(Rx1)C(O)ORx1a, -N(Rx1)C(O)N(Rx1aRx1b), -OC(O)N(Rx1Rx1a), -T0, C1-10alkyl, C2-10alkenyl and C2-10alkynyl; wherein -T0, C1-10alkyl, C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more -Rx2, which are thesame or different, and wherein C1-10 alkyl, C2-10 alkenyl and C2-10 alkynyl are optionallyinterrupted by one or more groups selected from the group consisting of -T0-, -C(O)O-, -O-, -C(O)-, -C(O)N(Rx3)-, -S(O)2N(Rx3)-, -S(O)N(Rx3)-, -S(O)2-, -S(O)-, -N(Rx3)S(O)2N(Rx3a)-, -S-, -N(Rx3)-, -OC(ORx3)(Rx3a)-, -N(Rx3)C(O)N(Rx3a)- and -OC(O)N(Rx3)-;Ascendis Pharma A / S 15 CPX75146PC09 July 2025each -Rx1, -Rx1a, -Rx1b, -Rx3 and -Rx3a is independently selected from the group consisting of -H,halogen, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; each T0is independently selected from the group consisting of phenyl, naphthyl, indenyl,indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-memberedheterobicyclyl; wherein each T0is independently optionally substituted with one or more -Rx2, which are the same or different; each -Rx2is independently selected from the group consisting of halogen, -CN, oxo (=O), -COORx4, -ORx4, -C(O)Rx4, -C(O)N(Rx4Rx4a), -S(O)2N(Rx4Rx4a), -S(O)N(Rx4Rx4a), -S(O)2Rx4, -S(O)Rx4, -N(Rx4)S(O)2N(Rx4aRx4b), -SRx4, -N(Rx4Rx4a), -NO2, -OC(O)Rx4, -N(Rx4)C(O)Rx4a, -N(Rx4)S(O)2Rx4a, -N(Rx4)S(O)Rx4a, -N(Rx4)C(O)ORx4a, -N(Rx4)C(O)N(Rx4aRx4b), -OC(O)N(Rx4Rx4a) and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different;each -Rx4, -Rx4a and -Rx4b is independently selected from the group consisting of -H, halogen,C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl. In certain embodiments the one or more further optional substituents are independently of each other selected from the group consisting of halogen, -CN, -COORx1, -ORx1, -C(O)Rx1, -C(O)N(Rx1Rx1a), -S(O)2N(Rx1Rx1a), -S(O)N(Rx1Rx1a), -S(O)2Rx1, -S(O)Rx1, -N(Rx1)S(O)2N(Rx1aRx1b), -SRx1, -N(Rx1Rx1a), -NO2, -OC(O)Rx1, -N(Rx1)C(O)Rx1a, -N(Rx1)S(O)2Rx1a, -N(Rx1)S(O)Rx1a, -N(Rx1)C(O)ORx1a, -N(Rx1)C(O)N(Rx1aRx1b), -OC(O)N(Rx1Rx1a), -T0, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; wherein -T0, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are optionally substituted with one or more -Rx2, which are the sameor different, and wherein C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are optionally interrupted byone or more groups selected from the group consisting of -T0-, -C(O)O-, -O-, -C(O)-, -C(O)N(Rx3)-, -S(O)2N(Rx3)-, -S(O)N(Rx3)-, -S(O)2-, -S(O)-, -N(Rx3)S(O)2N(Rx3a)-, -S-,-N(Rx3)-, -OC(ORx3)(Rx3a)-, -N(Rx3)C(O)N(Rx3a)- and -OC(O)N(Rx3)-;each -Rx1, -Rx1a, -Rx1b, -Rx2, -Rx3 and -Rx3a is independently selected from the group consistingof -H, halogen, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; each T0is independently selected from the group consisting of phenyl, naphthyl, indenyl,indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-memberedheterobicyclyl; wherein each T0is independently optionally substituted with one or more -Rx2, which are the same or different.Ascendis Pharma A / S 16 CPX75146PC09 July 2025In certain embodiments a maximum of 6 -H atoms of an optionally substituted molecule are independently replaced by a substituent, e.g. 5 -H atoms are independently replaced by a substituent, 4 -H atoms are independently replaced by a substituent, 3 -H atoms are independently replaced by a substituent, 2 -H atoms are independently replaced by a substituent, or 1 -H atom is replaced by a substituent.The term “interrupted” means that a moiety is inserted between two carbon atoms or – if theinsertion is at one of the moiety’s ends – between a carbon or heteroatom and a hydrogen atom,in certain embodiments between a carbon and a hydrogen atom. As used herein, the term “C1-4 alkyl” alone or in combination means a straight-chain or branched alkyl moiety having 1 to 4 carbon atoms. If present at the end of a molecule, examples of straight-chain or branched C1-4alkyl are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. When two moieties of a molecule are linked by the C1-4 alkyl, then examples for such C1-4 alkyl groups are -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-, -CH(C2H5)-, -C(CH3)2-. Each hydrogen of a C1-4 alkyl carbon may optionally be replaced by a substituent as defined above. Optionally, a C1-4alkyl may be interrupted by one or more moieties as defined below. As used herein, the term “nucleophile” refers to a reagent or functional group that forms a bondto its reaction partner, i.e., the electrophile by donating both bonding electrons.As used herein, the term “C1-6alkyl” alone or in combination means a straight-chain or branched alkyl moiety having 1 to 6 carbon atoms. If present at the end of a molecule, examplesof straight-chain and branched C1-6 alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl,isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2- methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl. When two moieties of a molecule are linked by the C1-6 alkyl group, then examples for such C1-6 alkyl groups are -CH2-, -CH2-CH2-, -CH(CH3)-, -CH2-CH2-CH2-,-CH(C2H5)- and -C(CH3)2-. Each hydrogen atom of a C1-6 carbon may optionally be replacedby a substituent as defined above. Optionally, a C1-6 alkyl may be interrupted by one or more moieties as defined below.Ascendis Pharma A / S 17 CPX75146PC09 July 2025Accordingly, “C1-10 alkyl”, “C1-20 alkyl” or “C1-50 alkyl” means an alkyl chain having 1 to 10, 1 to 20 or 1 to 50 carbon atoms, respectively, wherein each hydrogen atom of the C1-10, C1-20 or C1-50carbon may optionally be replaced by a substituent as defined above. Optionally, a C1-10or C1-50alkyl may be interrupted by one or more moieties as defined below. As used herein, the term “C2-6alkenyl” alone or in combination means a straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon double bond having 2 to 6 carbon atoms. If present at the end of a molecule, examples are -CH=CH2, -CH=CH-CH3, -CH2-CH=CH2, -CH=CHCH2-CH3 and -CH=CH-CH=CH2. When two moieties of a molecule are linked by the C2-6alkenyl group, then an example for such C2-6alkenyl is -CH=CH-. Each hydrogen atom of a C2-6 alkenyl moiety may optionally be replaced by a substituent as defined above. Optionally, a C2-6 alkenyl may be interrupted by one or more moieties as defined below. Accordingly, the term “C2-10 alkenyl”, “C2-20 alkenyl” or “C2-50 alkenyl” alone or in combination means a straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon double bond having 2 to 10, 2 to 20 or 2 to 50 carbon atoms. Each hydrogenatom of a C2-10 alkenyl, C2-20 alkenyl or C2-50 alkenyl group may optionally be replaced by asubstituent as defined above. Optionally, a C2-10 alkenyl, C2-20 alkenyl or C2-50 alkenyl may beinterrupted by one or more moieties as defined below. As used herein, the term “C2-6 alkynyl” alone or in combination means straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon triple bond having 2 to 6 carbon atoms. If present at the end of a molecule, examples are -C≡CH, -CH2-C≡CH, CH2-CH2-C≡CH and CH2-C≡C-CH3. When two moieties of a molecule are linked by the alkynyl group, then an example is -C≡C-. Each hydrogen atom of a C2-6 alkynyl group may optionally be replaced by a substituent as defined above. Optionally, one or more double bond(s) may occur. Optionally, a C2-6alkynyl may be interrupted by one or more moieties as defined below. Accordingly, as used herein, the term “C2-10alkynyl”, “C2-20alkynyl” and “C2-50alkynyl” alone or in combination means a straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon triple bond having 2 to 10, 2 to 20 or 2 to 50 carbon atoms, respectively.Each hydrogen atom of a C2-10 alkynyl, C2-20 alkynyl or C2-50 alkynyl group may optionally bereplaced by a substituent as defined above. Optionally, one or more double bond(s) may occur.Ascendis Pharma A / S 18 CPX75146PC09 July 2025Optionally, a C2-10 alkynyl, C2-20 alkynyl or C2-50 alkynyl may be interrupted by one or moremoieties as defined below. As mentioned above, a C1-4alkyl, C1-6alkyl, C1-10alkyl, C1-20alkyl, C1-50alkyl, C2-6alkenyl,C2-10 alkenyl, C2-20 alkenyl, C2-50 alkenyl, C2-6 alkynyl, C2-10 alkynyl, C2-20 alkenyl or C2-50alkynyl may optionally be interrupted by one or more moieties which in certain embodiments are selected from the group consisting of , wherein dashed lines indicate attachment to the remainder of the moiety or reagent; and -R and -Raare independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2- methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2- dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl. As used herein, the term "C3-10cycloalkyl" means a cyclic alkyl chain having 3 to 10 carbon atoms, which may be saturated or unsaturated, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl. Each hydrogenatom of a C3-10 cycloalkyl carbon may be replaced by a substituent as defined above. The term"C3-10 cycloalkyl" also includes bridged bicycles like norbornane or norbornene.The term “8- to 30-membered carbopolycyclyl” or “8- to 30-membered carbopolycycle” meansa cyclic moiety of two or more rings with 8 to 30 ring atoms, where two neighboring rings share at least one ring atom and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated). In certainAscendis Pharma A / S 19 CPX75146PC09 July 2025embodiments an 8- to 30-membered carbopolycyclyl means a cyclic moiety of two, three, fouror five rings, in certain embodiments of two, three or four rings.As used herein, the term "3- to 10-membered heterocyclyl" or "3- to 10-membered heterocycle"means a ring with 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un- saturated) wherein at least one ring atom up to 4 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)2-), oxygen and nitrogen (including =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon ornitrogen atom. Examples for 3- to 10-membered heterocycles include but are not limited toaziridine, oxirane, thiirane, azirine, oxirene, thiirene, azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine, tetrazolidine, diazepane,azepine and homopiperazine. Each hydrogen atom of a 3- to 10-membered heterocyclyl or 3-to 10-membered heterocyclic group may be replaced by a substituent as defined below.As used herein, the term "8- to 11-membered heterobicyclyl" or "8- to 11-memberedheterobicycle" means a heterocyclic moiety of two rings with 8 to 11 ring atoms, where at least one ring atom is shared by both rings and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)2-), oxygen and nitrogen (including =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examplesfor an 8- to 11-membered heterobicycle are indole, indoline, benzofuran, benzothiophene,benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline,dihydroisoquinoline, benzazepine, purine and pteridine. The term 8- to 11-memberedheterobicycle also includes spiro structures of two rings like 1,4-dioxa-8-azaspiro[4.5]decaneor bridged heterocycles like 8-aza-bicyclo[3.2.1]octane. Each hydrogen atom of an 8- to 11-Ascendis Pharma A / S 20 CPX75146PC09 July 2025membered heterobicyclyl or 8- to 11-membered heterobicycle carbon may be replaced by asubstituent as defined below.Similary, the term “8- to 30-membered heteropolycyclyl” or “8- to 30-memberedheteropolycycle” means a heterocyclic moiety of more than two rings with 8 to 30 ring atoms, in certain embodiments of three, four or five rings, where two neighboring rings share at least one ring atom and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or unsaturated), wherein at least one ring atom up to 10 ring atoms are replaced by a heteroatom selected from the group of sulfur (including -S(O)- and -S(O)2-), oxygen and nitrogen (including =N(O)-) and wherein the ring is linked to the rest of a molecule via a carbon or nitrogen atom. It is understood that the phrase “the pair Rx / Ryis joined together with the atom to which theyare attached to form a C3-10 cycloalkyl or a 3- to 10-membered heterocyclyl” in relation with amoiety of the structure means that Rxand Ryform the following structure: ,wherein R is C3-10 cycloalkyl or 3- to 10-membered heterocyclyl.It is also understood that the phrase “the pair Rx / Ry is joint together with the atoms to whichthey are attached to form a ring A” in relation with a moiety of the structure means that Rxand Ryform the following structure: .Ascendis Pharma A / S 21 CPX75146PC09 July 2025As used herein, "halogen" means fluoro, chloro, bromo or iodo. In certain embodiments halogen is fluoro or chloro. In general, the term “comprise” or “comprising” also encompasses “consist of” or “consisting of”.In certain embodiments -AB1 and -AB2 are positioned such that -AB1 and -AB2 are capable ofbinding to two different albumin molecules. This may be achieved by a suitably long and / orflexible spacer moiety between -AB1 and -AB2. Each one of -AB1 and -AB2 may bind to a highaffinity binding site on their respective albumin molecule, only one may bind to a high affinitybinding site and the other may bind to a low affinity site or both may bind to a low affinity site.This however does not mean that in the presence of albumin both -AB1 and -AB2 are alwaysbound to two different albumin molecules. Rather, there is a balance between thebound / unbound state for each of -AB1 and -AB2 at any given time and thus either both of -AB1and -AB2are bound to albumin, which may be the same or different, only one or none. If amolecule is capable of binding to two albumin molecules the risk that both moieties -AB1and -AB2are unbound is minimized, because even if one of -AB1and -AB2dissociates fromalbumin, the other one remains bound to albumin. This is advantageous because it minimizesthe time when the compound of formula (Ia) or (Ib) is not bound to albumin and is exposed toclearance, such as renal clearance. It is understood that if there is more than one one moiety -AB1or -AB2in a compound they each moiety -AB1and -AB2may independently bind to the same or a different albumin molecule.It is understood that any reference to “albumin binding” of moieties -AB1 and / or -AB2 requiresthe presence of albumin, such as in a suitable experimental setting or after administration to a patient. Such patient may be a mammalian patient, such as a human patient, which may be an adult or pediatric patient.In certain embodiments a pharmaceutical formulation comprising at least one compound disclosed herein does not comprise albumin.In certain embodiments the binding affinity of the compound for a single albumin is at least 2-fold, at least 3-fold, at least 4-fold or at least 5-fold higher than the binding affinity for a singlealbumin of the corresponding free drug, i.e., H-D-AB2.Ascendis Pharma A / S 22 CPX75146PC09 July 2025When the compound binds to albumin via -AB1and / or -AB2, such albumin bound to the compound is capable of binding to the neonatal Fc receptor. In certain embodiments the compound is capable of binding to the neonatal Fc receptor (FcRn).In certain embodiments the distance between -AB1- and -AB2 is at least 0.1 nm when measuredunder physiological conditions. In certain embodiments the circulation half-life of the compound is such that it allows for administration to a patient once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks or once every eight weeks.In certain embodiments the compounds of the present invention release the corresponding freedrug H-D-AB2with a Tmax that is at least two times longer than the Tmax of the corresponding free drug administered via the same administration route. Such administration may be administration via external application, injection or infusion, including intraarticular, periarticular, intradermal, subcutaneous, intramuscular, intravenous, intraosseous, intraperitoneal, intrathecal, intracapsular, intraorbital, intravitreal, intratympanic, intravesical, intracardiac, transtracheal, subcuticular, subcapsular, subarachnoid, intraspinal, intraventricular, intrasternal injection and infusion; direct delivery to the brain via implanted device allowing delivery of the invention or the like to brain tissue or brain fluids (e.g., Ommaya Reservoir), direct intracerebroventricular injection or infusion, injection or infusion into brain or brain associated regions, injection into the subchoroidal space, retro-orbital injection and ocular instillation. In certain embodiments the administration is subcutaneous administration, such as subcutaneous injection, in particular subcutaneous injection with a pen injector. In certain embodiments Tmaxis at least 3 times longer, at least 4 times longer, at least 5 times longer, at least 6 times or at least 7 times than the Tmaxof the corresponding free drug. In certain embodiments the compounds of the present invention release H-D-AB2with a pharmacokinetic profile that exhibits a peak-to-trough ratio of less than 2.5 within oneadministration interval. In certain embodiments the peak-to-trough ratio is less than 2.Administration may be as described above. In particular, the administration interval is one month. In certain embodiments the administration interval is two months. The term “administration interval" refers to the time between two consecutive administrations.Ascendis Pharma A / S 23 CPX75146PC09 July 2025In certain embodiments a single subcutaneous administration of the conjugate provides aplasma concentration ranging from 20 to 200 nM H-D-AB2 for at least two weeks, at least threeweeks or at least four weeks, if H-D-AB2is semaglutide. In certain embodiments one administration every four weeks provides a pharmaceuticallyeffective plasma concentration of the released drug H-D-AB2. Such effective plasmaconcentration may range from 20 nM H-D-AB2 to 200 nM H-D-AB2, if H-D-AB2 issemaglutide. In certain embodiments the compound releases the drug H-D-AB2with a half-life of at least 10days, of at least 12 days or of at least 14 days. Suitably, the release half-life does not exceed30 days. The release half-life may be measured under physiological conditions. In certain embodiments the compound is of formula (Ia). In certain embodiments x of formula (Ia) is 1. In certain embodiments x of formula (Ia) is 2. In certain embodiments x of formula (Ia) is 3. In certain embodiments x of formula (Ia) is 4. In certain embodiments x of formula (Ia) is 5. In certain embodiments x of formula (Ia) is 6. In certain embodiments x of formula (Ia) is 7. In certain embodiments x of formula (Ia) is 8. In certain embodiments x of formula (Ia) is 9. In certain embodiments x of formula (Ia) is 10. In certain embodiments x of formula (Ia) is 11. In certain embodiments x of formula (Ia) is 12. In certain embodiments x of formula (Ia) is 13. In certain embodiments x of formula (Ia) is 14. In certain embodiments x of formula (Ia) is 15. In certain embodiments x of formula (Ia) is 16. In certain embodiments x of formula (Ia) is 17. In certain embodiments x of formula (Ia) is 18. In certain embodiments x of formula(Ia) is 19. In certain embodiments x of formula (Ia) is 20. In certain embodiments x of formula(Ia) is 21. In certain embodiments x of formula (Ia) is 22. In certain embodiments x of formula (Ia) is 23. In certain embodiments x of formula (Ia) is 24. In certain embodiments x of formula (Ia) is 25. In certain embodiments the compound is of formula (Ia) with x = 1. In certain embodiments the compound is of formula (Ib). In certain embodiments y of formula (Ib) is 1. In certain embodiments y of formula (Ib) is 2. In certain embodiments y of formulaAscendis Pharma A / S 24 CPX75146PC09 July 2025(Ib) is 3. In certain embodiments y of formula (Ib) is 4. In certain embodiments y of formula (Ib) is 5. In certain embodiments the compound is of formula (Ib) with y = 2.In certain embodiments -D- is a drug moiety selected from the group consisting of smallmolecule drug moieties, medium size molecule drug moieties, oligonucleotide drug moieties, peptide nucleic acid drug moieties, peptide drug moieties and protein drug moieties.In certain embodiments -D- is a peptide drug moiety. In certain embodiments -D- is a smallmolecule drug moiety. In certain embodiments -D- is a medium size drug moiety. In certainembodiments -D- is an oligonucleotide drug moiety. In certain embodiments -D- is a peptidenucleic acid drug moiety. In certain embodiments -D- is a protein drug moiety.In certain embodiments -D- or -D-AB2 is a GLP-1 receptor agonist moiety. Accordingly, theconjugate of the present invention may be a GLP-1 receptor agonist conjugate.In certain embodiments -D- or -D-AB2 is a mono agonist of the GLP-1 receptor, i.e., onlyactivates the GLP-1 receptor.In certain embodiments -D- or -D-AB2 is an agonist of the GLP-1 receptor and an agonist of afurther receptor, i.e., -D- or -D-AB2 is a dual GLP-1 receptor agonist. Such further receptormay be selected from the group consisting of the GIP receptor, the GCG receptor, an amylinreceptor, a PYY receptor and the GLP-2 receptor.In certain embodiments -D- or -D-AB2 is an agonist of the GLP-1 receptor and of the GIPreceptor. In certain embodiments -D- or -D-AB2 is an agonist of the GLP-1 receptor and of theGCG receptor. In certain embodiments -D- or -D-AB2 is an agonist of the GLP-1 receptor andof an amylin receptor. In certain embodiments -D- or -D-AB2 is an agonist of the GLP-1receptor and of a PYY receptor. In certain embodiments -D- or -D-AB2 is an agonist of theGLP-1 receptor and of the GLP-2 receptor.Ascendis Pharma A / S 25 CPX75146PC09 July 2025In certain embodiments -D- or -D-AB2 is an agonist of the GLP-1 receptor andgrowth / differentiation factor 15 (GDF15). In certain embodiments -D- or -D- AB2 is an agonistof the GLP-1 receptor and fibroblast growth factor 21 (FGF21).In certain embodiments -D- or -D-AB2 is an agonist of the GLP-1 receptor and an agonist oftwo further receptors, i.e., -D- or -D-AB2 is a triple GLP-1 receptor agonist. These furtherreceptors are in certain embodiments selected from the group consisting of the GIP receptor(GIPR), the GCG receptor (GCGR), an amylin receptor, a PYY receptor (PYYR) and the GLP-2 receptor (GLP2R).In certain embodiments -D- or -D-AB2 is a triple GLP-1 receptor agonist that activates theGLP-1 receptor, the GIP receptor and the GCG receptor. In certain embodiments -D- or -D-AB2is a triple GLP-1 receptor agonist that activates the GLP-1 receptor, the GIP receptor and anamylin receptor. In certain embodiments -D- or -D-AB2 is a triple GLP-1 receptor agonist thatactivates the GLP-1 receptor, the GIP receptor and a PYY receptor. In certainembodiments -D- or -D-AB2 is a triple GLP-1 receptor agonist that activates the GLP-1receptor, the GIP receptor and the GLP-2 receptor. In certain embodiments -D- or -D-AB2 is atriple GLP-1 receptor agonist that activates the GLP-1 receptor, the GCG receptor and anamylin receptor. In certain embodiments -D- or -D-AB2 is a triple GLP-1 receptor agonist thatactivates the GLP-1 receptor, the GCG receptor and a PYY receptor. In certainembodiments -D- or -D-AB2 is a triple GLP-1 receptor agonist that activates the GLP-1receptor, the GCG receptor and the GLP-2 receptor. In certain embodiments -D- or -D-AB2 isa triple GLP-1 receptor agonist that activates the GLP-1 receptor, an amylin receptor and aPYY receptor. In certain embodiments -D- or -D-AB2 is a triple GLP-1 receptor agonist thatactivates the GLP-1 receptor, an amylin receptor and the GLP-2 receptor. In certainembodiments -D- or -D-AB2 is a triple GLP-1 receptor agonist that activates the GLP-1receptor, a PYY receptor and the GLP-2 receptor.In certain embodiments -D- is a human GLP-1 of SEQ ID NO:1:HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG.In certain embodiments -D- is human GLP-1 analog of SEQ ID NO:1, which peptide sequencemay comprise one or more amino acid changes compared to SEQ ID NO:1. Such amino acidchanges may be the addition of at least one amino acid residue, the deletion of at least oneAscendis Pharma A / S 26 CPX75146PC09 July 2025amino acid residue, the replacement of at least one amino acid residue with a different aminoacid residue or may be any combination thereof. Such amino acid change may occur at the N-terminus, the C-terminus and / or at an internal site of the GLP-1 of SEQ ID NO:1. In certainembodiments such human GLP-1 analog has a maximum of 3 amino acid changes comparedto SEQ ID NO:1, i.e., a maximum of three amino acids of SEQ ID NO:1 are added to, deletedfrom and / or replaced with a different amino acid residue compared to the sequence of SEQ IDNO:1.In certain embodiments -D- has the sequenceHX1EGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO:2), wherein X1 is 2-aminoisobutyric acid (Aib).In certain embodiments -D- has the sequenceHX1EGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO:3),wherein X1 is Aib and the C-terminal glycine, i.e., the glycine at position 31, is amidated as aC-terminal primary amide.In certain embodiments -D- is exenatide. Exenatide has the sequenceHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO:4).In certain embodiments -D- has the sequenceHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS (SEQ ID NO:5),wherein the C-terminal serine, i.e., the serine at position 39, is amidated as a C-terminal primaryamide.In certain embodiments -D- is lixisenatide. Lixisenatide has the sequenceHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK (SEQ ID NO:6),wherein the C-terminal lysine, i.e., the lysine at position 44, is amidated as a C-terminalprimary amide.In certain embodiments -D- has the sequenceHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK (SEQ ID NO:7).In certain embodiments -D- has the sequenceAscendis Pharma A / S 27 CPX75146PC09 July 2025HX1EGTFTSDLSKQX2EEEAVRLFIEWLKQGGPSSGAPPPC (SEQ ID NO:8), wherein X1 is D-alanine and X2 is norleucine (Nle).In certain embodiments -D- has the sequenceHX1EGTFTSDLSKQX2EEEAVRLFIEWLKQGGPSSGAPPPC (SEQ ID NO:9), wherein X1is D-alanine, X2is Nle and the C-terminal cysteine, i.e., the cysteine at position 39, is amidated as a C-terminal primary amide.In certain embodiments -D- is PEG-loxenatide. PEG-loxenatide has the sequenceHX1EGTFTSDLSKQX2EEEAVRLFIEWLKQGGPSSGAPPPC (SEQ ID NO:10), wherein X1 is D-alanine; X2 is Nle; the cysteine at position 39 is chemically modified through conjugation to the thiol group of the cysteine side-chain with , wherein the dashed line indicates attachment to the thiol group of the cysteine side chain of the cysteine at position 39, and each mPEG is methoxypoly(ethylene glycol) with a molecular weight of approx.20 kDa.In certain embodiments -D- has the sequenceHX1EGTFTSDLSKQX2EEEAVRLFIEWLKQGGPSSGAPPPC (SEQ ID NO:11), wherein X1 is D-alanine; X2 is Nle; the cysteine at position 39 is chemically modified through conjugation to the thiol group of the cysteine side-chain with , wherein the dashed line indicates attachment to the thiol group of the cysteine side chain of the cysteine at position 39, each mPEG is methoxypoly(ethylene glycol) with a molecularAscendis Pharma A / S 28 CPX75146PC09 July 2025weight of approx. 20 kDa, and the C-terminal cysteine, i.e., the cysteine at position 39, is amidated as a C-terminal primary amide.In certain embodiments -D- has the sequenceHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO:12).In certain embodiments -D- has the sequenceHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO:13),and the C-terminal glycine, i.e., the glycine at position 31, is amidated as a C-terminal primaryamide.In certain embodiments -D- has the sequenceHVEGTFTSDVSSYLEEQAAREFIKWLVRGRG (SEQ ID NO:14).In certain embodiments -D- has the sequenceHVEGTFTSDVSSYLEEQAAREFIKWLVRGRG (SEQ ID NO:15),and the C-terminal glycine, i.e., the glycine at position 31, is amidated as a C-terminal primaryamide.In certain embodiments -D- has the sequenceHGEGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO:16).In certain embodiments -D- has the sequenceHGEGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO:17),and the C-terminal glycine, i.e., the glycine at position 31, is amidated as a C-terminal primaryamide.In certain embodiments -D- has the sequenceHX1EGTFTSDVSSYLEGQAAKEFIAWLVRGRGL (SEQ ID NO:18),wherein X1is Aib.In certain embodiments -D- has the sequenceHX1EGTFTSDVSSYLEGQAAKEFIAWLVRGRGL (SEQ ID NO:19),Ascendis Pharma A / S 29 CPX75146PC09 July 2025wherein X1 is Aib and the C-terminal leucine, i.e., the leucine at position 32, is amidated as aC-terminal primary amide.In certain embodiments -D- has the sequenceYX1EGTFTSDYSIX2LDKIAQKAFVQWLIAGGPSSGAPPPS (SEQ ID NO:20),wherein X1is Aib, X2is Aib and the C-terminal serine, i.e., the serine at position 39, is amidated as a C-terminal primary amide.In certain embodiments -D- has the sequenceYX1EGTFTSDYSIX2LDKIAQKAFVQWLIAGGPSSGAPPPS (SEQ ID NO:21), wherein X1 is Aib and X2 is Aib.In certain embodiments -D- has the sequenceHSQGTFTSDKSEYLDSERARDFVAWLEAGG (SEQ ID NO:22).In certain embodiments -D- has the sequenceHSQGTFTSDKSEYLDSERARDFVAWLEAGG (SEQ ID NO:23),wherein the C-terminal glycine, i.e., the glycine at position 30, is amidated as a C-terminalprimary amide.In certain embodiments -D- has the sequenceHX1QGTFTSDYSKYLDERAAKDFIKWLESA (SEQ ID NO:24),wherein X1is 1-amino-cyclobutanecarboxylic acid (Ac4c); and the C-terminal alanine, i.e. the alanine at position 29, is amidated as a C-terminal primary amide.In certain embodiments -D- has the sequenceHX1QGTFTSDYSKYLDERAAKDFIKWLESA (SEQ ID NO:25),wherein X1 is 1-amino-cyclobutanecarboxylic acid (Ac4c).In certain embodiments -D- has the sequenceHX1QGTFTSDYSKYLDEKAAKEFIQWLLQT (SEQ ID NO:26),wherein X1 is Aib and the glutamic acid at position 16 and the lysine at position 20 areconnected via a lactam bridge.Ascendis Pharma A / S 30 CPX75146PC09 July 2025In certain embodiments -D- has the sequenceHX1QGTFTSDYSKYLDEKAAKEFIQWLLQT (SEQ ID NO:27),wherein X1 is Aib, the glutamic acid at position 16 and the lysine at position 20 are connectedvia a lactam bridge and the C-terminal threonine, i.e., the threonine at position 29, is amidated as a C-terminal primary amide.In certain embodiments -D- has the sequenceHX1QGTFTSDYSKYLDEKKAKEFVEWLLEGGPSSG (SEQ ID NO:28),wherein X1 is Aib and the C-terminal glycine, i.e., the glycine at position 34, is amidated as aC-terminal primary amide.In certain embodiments -D- has the sequenceHX1QGTFTSDYSKYLDEKKAKEFVEWLLEGGPSSG (SEQ ID NO:29), wherein X1 is Aib.In certain embodiments -D- has the sequenceHX1EGSFTSELATILDKQAARDFIAWLIQHKITD (SEQ ID NO:30), wherein X1 is Aib.In certain embodiments -D- has the sequenceHX1EGSFTSELATILDKQAARDFIAWLIQHKITD (SEQ ID NO:31), wherein X1 is Aib and the C-terminal aspartic acid, i.e., the aspartic acid at position 33, is amidated as a C-terminal primary amide.In certain embodiments -D- has the sequenceYX1QGTFTSDYSIX2LDKKAQX3AFIEYLLEGGPSSGAPPPS (SEQ ID NO:32), wherein X1is Aib, X2is α-methyl-leucine (αMeL), X3is Aib; and the C-terminal serine, i.e. the serine at position 39, is amidated as a C-terminal primary amide.In certain embodiments -D- has the sequenceYX1QGTFTSDYSIX2LDKKAQX3AFIEYLLEGGPSSGAPPPS (SEQ ID NO:33), wherein X1 is Aib, X2 is α-methyl-leucine (αMeL) and X3 is Aib.In certain embodiments -D- has the sequenceAscendis Pharma A / S 31 CPX75146PC09 July 2025HX1EGTFTSDVSSYLEEEAAKEFIAWLVRGGPSSGAPPPSK (SEQ ID NO:54), wherein X1 is Aib.In certain embodiments -D- has the sequenceHX1EGTFTSDVSSYLEEQAAKEFIAWLVRGGG (SEQ ID NO:55), wherein X1is Aib.In certain embodiments -D- has the sequenceHX1EGTFTSDVSSYLEEQAAKEFIAWLVRGGGGAQPGAQPGAQPGAQPGAQPGAQPGAQPGAQPGAQPGQKP (SEQ ID NO:56),wherein X1 is Aib.In certain embodiments -D- has the sequenceYX1EGTFTSDYSIX2LDKIAQKAFVQWLIAGGPSSGAPPPS (SEQ ID NO:57), wherein X1 and X2 are both Aib.In certain embodiments -D- is a drug selected from the group consisting of insulins; amylinand amylin / calcitonin; PYY; GIP; MSH; C5a binders; GDF15; PCSK9 I; immune stimulants; urocortin2; MIC-1; IL-1R antagonists; leptin; gastrin; glucagon; exendin-4; GLP-1; GLP-2; and GIP.In certain embodiments -D- is a drug moiety selected from the group consisting of insulin;insulin analogues; amylin; dual amylin / calcitonin agonists; PYY; GIP; MSH; C5 inhibitors or modulators; GDF15; PCSK9 inhbitors; immune stimulants; urocortin II; MIC-1; IL-1R antagonists; leptin; gastrin; glucagon; oxyntomodulin; neurokinin A; tachykinin / neurokinin receptor 2 (NK2R) agonists; neurokinin receptor (NKR) agonists and GLP-2.In certain embodiments -D- is an insulin, such as insulin detemir, insulin degludec or insulin.In certain embodiments -D- is amylin or amylin / calcitonin, such as for example cagrilintide. Incertain embodiments -D- is PYY, such as NNC0165-1875. In certain embodiments -D- is GIP.In certain embodiments -D- is MSH. In certain embodiments -D- is a C5a binder, such aszilucoplan. In certain embodiments -D- is GDF15, such as NN LA-GDF15. In certainembodiments -D- is PCSK9 i. In certain embodiments -D- is an immune stimulant, such asromurtide or mifamurtide. In certain embodiments -D- is muramyl dipeptide. In certainAscendis Pharma A / S 32 CPX75146PC09 July 2025embodiments -D- is urocortin2. In certain embodiments -D- is MIC-1. In certainembodiments -D- is an IL-1R antagonist. In certain embodiments -D- is leptin. In certainembodiments -D- is gastrin.In certain embodiments -D- is selected from the list consisting of growth hormones, such ashuman growth hormone; FGF21; EGF(a); and coagulations factors.In certain embodiments -D- is a growth hormone, such as a human growth hormone, such assomapacitan. In certain embodiments -D- is FGF21, such as NNC0194 0499. In certainembodiments -D- is EGF(a). In certain embodiments -D- is a coagulation factor.In certain embodiments -D- is selected from cytotoxic small molecule drugs; chemotherapysmall molecule drugs; and immune activating small molecule drugs.In certain embodiments -D- is a cytotoxic small molecule drug. In certain embodiments -D- isa chemotherapy small molecule drug. In certain embodiments -D- is and immune activatingsmall molecule drug, such as telratolimod.In certain embodiments -D- is paclitaxel. In certain embodiments -D- is doxorubicin. In certainembodiments -D- is 5-FU.In certain embodiments -D- is a PTH moiety.A moiety -AB1 is conjugated to -D- via -L2-L1-, wherein -L2- is conjugated to -AB1 and -L1- isconjugated to -D-. Upon cleavage of the linkage between -L1- and -D- the moiety -AB1 remainsconjugated to -L2-. A moiety -AB2is directly conjugated to -D-, such as through a stablelinkage. This means that upon cleavage of the linkage between -L1- and -D- a conjugate H-D-AB2 is released, wherein H- is hydrogen. Accordingly, the moiety “H-D-AB2” is also referredto as the corresponding free drug of a conjugated moiety -D-AB2. A moiety -AB1and -AB2binds to albumin, such as human albumin, under physiological conditions (aqueous buffer pH 7.4, 37.4°C).Ascendis Pharma A / S 33 CPX75146PC09 July 2025In certain embodiments -AB1and -AB2have a different structure. In certain embodiments -AB1and -AB2have the same structure. Each -AB1and -AB2may independently be a fatty acid-based albumin-binding moiety or a peptidic albumin binding moiety.In certain embodiments -AB1 and -AB2 are independently a fatty acid-based albumin-bindingmoiety. In certain embodiments -AB1and -AB2are both a fatty acid-based albumin-binding moiety and have the same structure. In certain embodiments -AB1and -AB2are both a fatty acid-based albumin-binding moiety but have a different structure.In certain embodiments -AB1 and / or -AB2 are independently of formula (A): wherein the dashed line indicates attachment to -L2- or -D-, respectively;-F0is of formula (a-1) wherein the dashed line indicates attachment to -LA-; -R0is selected from the group consisting of -CR1R1aR1b, -COOR1, -R1, -R1aand -R1bare selected from the group consisting of -H, methyl, ethyl, propyl and isopropyl;n is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;-LA- is absent or is of formula (a-2) wherein the unmarked dashed line indicates attachment to -LB-; the dashed line marked with the asterisk indicates attachment to -F0;Ascendis Pharma A / S 34 CPX75146PC09 July 2025 -Ra- is selected from the group consisting of ,wherein the dashed line marked with the asterisk indicates attachment to -F0; the unmarked dashed line indicates attachment to the remainder of -LA- ; mis 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;-LB- is absent or is of formula (a-3) wherein the unmarked dashed line indicates attachment to -L2- or -D-;the dashed line marked with the asterisk indicates attachment to -LA; -Rd- is selected from the group consisting of C1-50 alkyl, C2-50 alkenyl and C2-50alkynyl, wherein C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl may be substituted with one or more -R1, which may be the same or different, and which C1-50alkyl, C2-50 alkenyl or C2-50 alkynyl may be interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R2)-, -S(O)2N(R2)-, -S(O)N(R2)-, -S(O)2-, -S(O)-, -N(R2)S(O)2N(R2a)-, -S-, -N(R2)-, -OC(OR2)(R2a)-, -N(R2)C(O)N(R2a)- and -OC(O)N(R2)-; each -T- is independently selected from the group consisting of phenyl,naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-memberedheterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-memberedcarbopolycyclyl and 8- to 30-membered heteropolycyclyl; whereineach -T- may independently be substituted with one or more -R1, which maybe the same or different; each -R1is independently selected from the group consisting of halogen, -CN, oxo (=O), -COOR3, -OR3, -C(O)R3, -C(O)N(R3R3a), -S(O)2N(R3R3a), -S(O)NAscendis Pharma A / S 35 CPX75146PC09 July 2025(R3R3a), -S(O)2R3, -S(O)R3, -N(R3)S(O)2N(R3aR3b), -SR3,-N(R3R3a), -NO2, -OC(O)R3, -N(R3)C(O)R3a, -N(R3)S(O)2R3a, -N(R3)S(O)R3a, -N(R3)C(O)OR3a, -N(R3)C(O)N(R3aR3b), -OC(O)N(R3R3a) and C1-6alkyl; wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different; each -R2, -R2a, -R3, -R3aand -R3bis independently selected from the group consisting of -H and C1-6alkyl, wherein C1-6alkyl may be substituted with one or more halogen, which may be the same or different; and-Re- is selected from the group consisting of -CH2-, .If -Rb- is and -LB- is not absent, then -Rc- is and if -Rb- is and -LB- isnot absent, then - In certain embodiments -LA- is of formula (a-2), i.e., is not absent. In certainembodiments -LA- is absent.a In certain embodiments -R - is , wherein the dashed line marked with the asteriskindicates attachment to -F0and the unmarked dashed line indicates attachment to the remainder of -LA-. a In certain embodiments -R - is , wherein the dashed line marked with the asteriskindicates attachment to -F0and the unmarked dashed line indicates attachment to the remainder of -LA-.In certain embodiments -Rb- is . In certain embodiments -Rb- is .Ascendis Pharma A / S 36 CPX75146PC09 July 2025In certain embodiments m of formula (a-2) is 1. In certain embodiments m of formula (a-2) is 2. In certain embodiments m of formula (a-2) is 3. In certain embodiments m of formula (a-2) is 4. In certain embodiments m of formula (a-2) is 5. In certain embodiments m of formula (a- 2) is 6. In certain embodiments m of formula (a-2) is 7. In certain embodiments m of formula (a-2) is 8. In certain embodiments m of formula (a-2) is 9. In certain embodiments m of formula (a-2) is 10. In certain embodiments p of formula (a-2) is 1. In certain embodiments p of formula (a-2) is 2. In certain embodiments p of formula (a-2) is 3. In certain embodiments p of formula (a-2) is 4. In certain embodiments p of formula (a-2) is 5. In certain embodiments p of formula (a-2) is 6. In certain embodiments p of formula (a-2) is 7. In certain embodiments p of formula (a-2) is 8. In certain embodiments p of formula (a-2) is 9. In certain embodiments p of formula (a-2) is 10.In certain embodiments -LB- is of formula (a-3). In certain embodiments -LB- is absent.If -LB- is absent, the unmarked dashed line in formula (a-2) indicates attachment to -L2- or -D-,respectively.In certain embodiments -Rc- is . In certain embodiments -Rc- is .In certain embodiments -Re- is -CH2-. In certain embodiments -Re- is . In certainembodiments - In certain embodiments both -LA- and -LB- are absent. If both -LA- and -LB- are absent, thedashed line in formula (a-1) indicates attachment to -L2- or -D-, respectively.In certain embodiments -F0is selected from the group consisting of Ascendis Pharma A / S 37 CPX75146PC09 July 2025 Ascendis Pharma A / S 38 CPX75146PC09 July 2025 Ascendis Pharma A / S 39 CPX75146PC09 July 2025 wherein dashed lines indicate attachment to -LA-.If -LA- is absent, the dashed lines in formulas (a-4) to (a-39) indicate attachment to -LB-. Ifboth -LA- and -LB- are absent, the dashed lines in formulas (a-4) to (a-39) indicate attachmentto -D-. In certain embodiments -F0is of formula (a-4). In certain embodiments -F0is of formula (a-5). In certain embodiments -F0is of formula (a-6). In certain embodiments -F0is of formula (a-7). In certain embodiments -F0is of formula (a-8). In certain embodiments -F0is of formula (a-9). In certain embodiments -F0is of formula (a-10). In certain embodiments -F0is of formula (a-11). In certain embodiments -F0is of formula (a-12). In certain embodiments -F0is of formula (a-13). In certain embodiments -F0is of formula (a-14). In certain embodiments -F0is of formula (a-15). In certain embodiments -F0is of formula (a-16). In certain embodiments -F0Ascendis Pharma A / S 40 CPX75146PC09 July 2025is of formula (a-17). In certain embodiments -F0is of formula (a-18). In certain embodiments -F0is of formula (a-19). In certain embodiments -F0is of formula (a-20). In certain embodiments -F0is of formula (a-21). In certain embodiments -F0is of formula (a-22). In certain embodiments -F0is of formula (a-23). In certain embodiments -F0is of formula (a-24). In certain embodiments -F0is of formula (a-25). In certain embodiments -F0is of formula (a-26). In certain embodiments -F0is of formula (a-27). In certain embodiments -F0isof formula (a-28). In certain embodiments -F0 is of formula (a-29). In certain embodiments -F0is of formula (a-30). In certain embodiments -F0is of formula (a-31). In certain embodiments -F0is of formula (a-32). In certain embodiments -F0is of formula (a-33). In certain embodiments -F0is of formula (a-34). In certain embodiments -F0is of formula (a-35). In certain embodiments -F0is of formula (a-36). In certain embodiments -F0is of formula (a- 37). In certain embodiments -F0is of formula (a-38). In certain embodiments -F0is of formula (a-39).In certain embodiments -F0 is of formula (a-4) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-5) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-6) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-7) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-8) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-9) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-10) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-11) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-12) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-13) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-14) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-15) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-16) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-17) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-18) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-19) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-20) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-21) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-22) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-23) and both -LA- and -LB- are absent. In certainAscendis Pharma A / S 41 CPX75146PC09 July 2025embodiments -F0 is of formula (a-24) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-25) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-26) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-27) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-28) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-29) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-30) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-31) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-32) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-33) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-34) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-35) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-36) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-37) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-38) and both -LA- and -LB- are absent. In certainembodiments -F0 is of formula (a-39) and both -LA- and -LB- are absent.In certain embodiments -LA- is selected from the group consisting of Ascendis Pharma A / S 42 CPX75146PC09 July 20255 Ascendis Pharma A / S 43 CPX75146PC09 July 2025 wherein a dashed line marked with an asterisk indicates attachment to -F0- and an unmarkeddashed line indicates attachment to -LB-. If -LB- is absent an unmarked dashed indicatesattachment to -D-.In certain embodiments -LA- is of formula (a-40). In certain embodiments -LA- is of formula(a-41). In certain embodiments -LA- is of formula (a-42). In certain embodiments -LA- is offormula (a-43). In certain embodiments -LA- is of formula (a-44). In certainembodiments -LA- is of formula (a-45). In certain embodiments -LA- is of formula (a-46). Incertain embodiments -LA- is of formula (a-47). In certain embodiments -LA- is of formula (a-48). In certain embodiments -LA- is of formula (a-49). In certain embodiments -LA- is offormula (a-50). In certain embodiments -LA- is of formula (a-51). In certainembodiments -LA- is of formula (a-52). In certain embodiments -LA- is of formula (a-53). Incertain embodiments -LA- is of formula (a-54). In certain embodiments -LA- is of formula (a-55). In certain embodiments -LA- is of formula (a-56). In certain embodiments -LA- is offormula (a-57). In certain embodiments -LA- is of formula (a-58). In certainembodiments -LA- is of formula (a-59). In certain embodiments -LA- is of formula (a-60). Incertain embodiments -LA- is of formula (a-61). In certain embodiments -LA- is of formula (a-62). In certain embodiments -LA- is of formula (a-63). In certain embodiments -LA- is offormula (a-64). In certain embodiments -LA- is of formula (a-65). In certainembodiments -LA- is of formula (a-66). In certain embodiments -LA- is of formula (a-67). Incertain embodiments -LA- is of formula (a-68). In certain embodiments -LA- is of formula (a-69). In certain embodiments -LA- is of formula (a-70). In certain embodiments -LA- is offormula (a-71). In certain embodiments -LA- is of formula (a-72). In certainembodiments -LA- is of formula (a-73). In certain embodiments -LA- is of formula (a-74). Incertain embodiments -LA- is of formula (a-75). In certain embodiments -LA- is of formula (a-76). In certain embodiments -LA- is of formula (a-77). In certain embodiments -LA- is offormula (a-78). In certain embodiments -LA- is of formula (a-79). In certainAscendis Pharma A / S 44 CPX75146PC09 July 2025embodiments -LA- is of formula (a-80). In certain embodiments -LA- is of formula (a-81). Incertain embodiments -LA- is of formula (a-82).In certain embodiments -LB- is selected from the group consisting of (a-92),Ascendis Pharma A / S 45 CPX75146PC09 July 2025 (a-94), wherein the dashed line marked with the asterisk indicates attachment to -LA-; the unmarked dashed line indicates attachment to -L2- or -D-, respectively; andq is an integer ranging from and including 2 to 50.If -LA- is absent, the dashed line marked with the asterisk in formulas (a-83) to (a-94) indicatesattachment to -F0. In certain embodiments q of formula (a-84) is an integer ranging from and including 3 to 45. In certain embodiments q of formula (a-84) is an integer ranging from and including 4 to 40. In certain embodiments q of formula (a-84) is an integer ranging from and including 5 to 35. In certain embodiments q of formula (a-84) is an integer ranging from and including 6 to 30. In certain embodiments q of formula (a-84) is an integer ranging from and including 7 to 25. In certain embodiments q of formula (a-84) is an integer ranging from and including 10 to 20.In certain embodiments q of formula (a-84) is 23.In certain embodiments -LB- is of formula (a-83). In certain embodiments -LB- is of formula(a-84). In certain embodiments -LB- is of formula (a-84) with q = 23. In certainembodiments -LB- is of formula (a-85). In certain embodiments -LB- is of formula (a-86). Incertain embodiments -LB- is of formula (a-87). In certain embodiments -LB- is of formula(a-88). In certain embodiments -LB- is of formula (a-89). In certain embodiments -LB- is offormula (a-90). In certain embodiments -LB- is of formula (a-91). In certainembodiments -LB- is of formula (a-92). In certain embodiments -LB- is of formula (a-93). Incertain embodiments -LB- is of formula (a-94).Ascendis Pharma A / S 46 CPX75146PC09 July 2025In certain embodiments -AB1and / or -AB2is of formula (i) wherein the dashed line indicates attachment to -L2- or -D-, respectively;n is an integer ranging from and including 14 to 22; and the stereocenter marked with the asterisk is either in S- or R-configuration.In certain embodiments -AB1and / or -AB2is of formula (i) and n is 14. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 15. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 16. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 17. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 18. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 19. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 20. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 21. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 22. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 14 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 15 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 16 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 17 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 18 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 19 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 20 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 21 and the stereocenter marked with the asterisk is in R-configuration. In certainembodiments -AB1 and / or -AB2 is of formula (i) and n is 22 and the stereocenter marked withthe asterisk is in R-configuration.Ascendis Pharma A / S 47 CPX75146PC09 July 2025In certain embodiments -AB1and / or -AB2is of formula (i) and n is 14 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 15 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 16 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 17 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 18 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 19 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 20 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 21 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (i) and n is 22 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (i-a): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (i-b): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (i-c): Ascendis Pharma A / S 48 CPX75146PC09 July 2025wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (i-d): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (i-e): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (i-f): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (ii) wherein the dashed line indicates attachment to -L2- or -D-, respectively;n is an integer ranging from 14 to 22; and the stereocenter marked with the asterisk is either in S- or R-configuration.Ascendis Pharma A / S 49 CPX75146PC09 July 2025In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 14. In certainembodiments - and / or or -AB2 is of formula (ii) and n is 15. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 16. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 17. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 18. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 19. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 20. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 21. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 22. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 14 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 15 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 16 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 17 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 18 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 19 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 20 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 21 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 22 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 14 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 15 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 16 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 17 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 18 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 19 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 20 and the stereocenterAscendis Pharma A / S 50 CPX75146PC09 July 2025marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 21 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii) and n is 22 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (ii-a): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (ii-b): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (ii-c): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (ii-d): wherein the dashed line indicates attachment to -L2- or -D-, respectively.Ascendis Pharma A / S 51 CPX75146PC09 July 2025In certain embodiments -AB1and / or -AB2is of formula (ii-e): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (ii-f): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (iii) wherein the dashed line indicates attachment to -L2- or -D-, respectively;t is an integer ranging from and including 14 to 22; and the stereocenter marked with the asterisk is either in S- or R-configuration.In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 14. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 15. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 16. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 17. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 18. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 19. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 20. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 21. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 22.Ascendis Pharma A / S 52 CPX75146PC09 July 2025In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 14 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 15 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 16 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 17 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 18 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 19 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 20 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 21 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 22 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 14 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 15 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 16 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 17 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 18 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 19 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 20 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 21 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii) and t is 22 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (iii-a)Ascendis Pharma A / S 53 CPX75146PC09 July 2025 (iii-a), wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (iii-b) (iii-b), wherein the dashed line indicates attachment to -L2- or -D-, respectively;In certain embodiments -AB1and / or -AB2is of formula (iii-c) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (iii-d) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (iii-e)Ascendis Pharma A / S 54 CPX75146PC09 July 2025 wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (iii-f) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (iv) the dashed line indicates attachment to -L2- or -D-, respectively, andu is an integer ranging from and including 14 to 22. In certain embodiments -AB1and / or -AB2is of formula (iv) and u is 14. In certain embodiments -AB1and / or -AB2is of formula (iv) and u is 15. In certain embodiments -AB1and / or -AB2is of formula (iv) and u is 16. In certain embodiments -AB1and / or -AB2is of formula (iv) and u is 17. In certain embodiments -AB1and / or -AB2is of formula (iv) and u is 18. In certain embodiments -AB1and / or -AB2is of formula (iv) and u is 19. In certain embodiments -AB1and / or -AB2is of formula (iv) and u is 20. In certain embodiments -AB1and / or -AB2is of formula (iv) and u is 21. In certain embodiments -AB1and / or -AB2is of formula (iv) and u is 22. In certain embodiments -AB1and / or -AB2is of formula (v)Ascendis Pharma A / S 55 CPX75146PC09 July 2025 wherein the dashed line indicates attachment to -L2- or -D-, respectively;v is an integer ranging from and including 14 to 22; and the stereocenter marked with the asterisk is either in S- or R-configuration.In certain embodiments -AB1and / or -AB2is of formula (v) and v is 14. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 15. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 16. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 17. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 18. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 19. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 20. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 21. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 22. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 14 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 15 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 16 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 17 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 18 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 19 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 20 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 21 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 22 and the stereocenter marked with the asterisk is in R-configuration.Ascendis Pharma A / S 56 CPX75146PC09 July 2025In certain embodiments -AB1and / or -AB2is of formula (v) and v is 14 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 15 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 16 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 17 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 18 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 19 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 20 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 21 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (v) and v is 22 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (v-a) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (v-b) wherein the dashed line indicates attachment to -L2- or -D-, respectively;In certain embodiments -AB1and / or -AB2is of formula (v-c)Ascendis Pharma A / S 57 CPX75146PC09 July 2025 wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (v-d) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (vi-e) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (vi-f) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (vii)Ascendis Pharma A / S 58 CPX75146PC09 July 2025 (vii), wherein the dashed line indicates attachment to -L2- or -D-, respectively;w is an integer ranging from and including 14 to 22; and the stereocenter marked with the asterisk is either in S- or R-configuration.In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 14. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 15. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 16. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 17. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 18. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 19. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 20. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 21. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 22. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 14 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 15 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 16 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 17 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 18 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 19 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 20 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 21 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 22 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 14 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is ofAscendis Pharma A / S 59 CPX75146PC09 July 2025formula (vii) and w is 15 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 16 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 17 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 18 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 19 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 20 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 21 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii) and w is 22 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (vii-a): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (vii-b): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (vii-c): wherein the dashed line indicates attachment to -L2- or -D-, respectively.Ascendis Pharma A / S 60 CPX75146PC09 July 2025In certain embodiments -AB1and / or -AB2is of formula (vii-d): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (vii-e): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (vii-f): wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (viii) wherein the dashed line indicates attachment to -L2- or -D-, respectively;w is an integer ranging from and including 14 to 22; and the stereocenter marked with the asterisk is either in S- or R-configuration.In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 14. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 15. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 16. In certain embodiments -AB1and / or -AB2is ofAscendis Pharma A / S 61 CPX75146PC09 July 2025formula (viii) and x is 17. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 18. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 19. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 20. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 21. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 22. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 14 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 15 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 16 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 17 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 18 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 19 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 20 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 21 and the stereocenter marked with the asterisk is in R-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 22 and the stereocenter marked with the asterisk is in R-configuration.In certain embodiments -AB1 and / or -AB2 is of formula (viii) and x is 14 and the stereocentermarked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is offormula (viii) and x is 15 and the stereocenter marked with the asterisk is in S-configuration.In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 16 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 17 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 18 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 19 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 20 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 21 and the stereocenter marked with the asterisk is in S-configuration.Ascendis Pharma A / S 62 CPX75146PC09 July 2025In certain embodiments -AB1and / or -AB2is of formula (viii) and x is 22 and the stereocenter marked with the asterisk is in S-configuration. In certain embodiments -AB1and / or -AB2is of formula (viii-a) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (viii-b) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (viii-c) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (viii-d) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (viii-e) wherein the dashed line indicates attachment to -L2- or -D-, respectively.Ascendis Pharma A / S 63 CPX75146PC09 July 2025In certain embodiments -AB1and / or -AB2is of formula (viii-f) wherein the dashed line indicates attachment to -L2- or -D-, respectively.In certain embodiments -AB1and / or -AB2is of formula (ix-i) with Ph being phenyl, a is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; b is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; d is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; n is 10, 11, 12, 13 ,14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 ; p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. In certain embodiments -AB1and / or -AB2is of formula (ix-i) with a being 1, b being 1, c being 1, d being 1, m being 1, n being 18 and m being 1.In certain embodiments -AB1 and / or -AB2 is of formula (ix-i) and X1- is and -X2 is. In certain embodiments -AB1 and / or -AB2 is of formula (ix-i) and X1- isAscendis Pharma A / S 64 CPX75146PC09 July 2025 and / or -AB2 is of formula certainembodiments -AB1 and / or -AB2 is of formula ce 1 2 rtain embodiments -AB and / or -ABis of formula (ix-i) and X1- . In certain embodiments -AB1and / or -AB2 is of formula certainembodiments -AB1 and / or -AB2 is of formula .In certain embodiments -AB1 and / or -AB2 is of formula (ix-i) and X1- is and -X2 is . In certain embodiments -AB1 and / or -AB2 is of formula (ix-i) and In certain embodiments -AB1and / or -AB2is a peptidic albumin-binding moiety.Ascendis Pharma A / S 65 CPX75146PC09 July 2025If -D- is a peptide or protein drug moiety, a peptidic moiety -AB2 may be fused to the N- or C-terminus of -D-, either directly or with a peptidic spacer moiety between -D- and -AB2.In certain embodiments -AB1and / or -AB2is selected from the group consisting of WWEQDRDWDFDVFGGGTP (SEQ ID NO:34); DICLPRWGCLW (SEQ ID NO:35), wherein the cysteines at position 3 and 9 are connected via a disulfide bridge; RLIEDICLPRWGCLWEDD (SEQ ID NO:36), wherein the cysteines at position 7 and 13 are connected via a disulfide bridge; LAEAKVLANRELDKYGVSDFYKRLINKAKTVEGVEALKLHILAALP (SEQ ID NO:37); IAEAKEAANAELDSYGVSDFYKRLIDKAKTVEGVEALKDAILAALP (SEQ ID NO:38); and X1EYEX2EYE (SEQ ID NO:39), wherein X1 is fluorescein-(AEEA), X2 is K(palmitate), and AEEA is 2-(2-(2- aminoethoxy)acetyl. In certain embodiments -AB1and / or -AB2is of SEQ ID NO:34. In certain embodiments -AB1and / or -AB2is of SEQ ID NO:35. In certain embodiments -AB1and / or -AB2is of SEQ ID NO:36. In certain embodiments -AB1and / or -AB2is of SEQ ID NO:37. In certain embodiments -AB1and / or -AB2is of SEQ ID NO:38. In certain embodiments -AB1and / or -AB2is of SEQ ID NO:39. In certain embodiments -AB1is of formula (XIX) wherein the dashed line indicates attachment to -L2-; and a is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24. In certain embodiments a of formula (XIX) is 18.In certain embodiments -AB1 and / or -AB2 is of formula (A-a):Ascendis Pharma A / S 66 CPX75146PC09 July 2025(A-a), wherein the dashed line indicates attachment to -L2- or -D-, respectively;-F0 and -LA- are used as defined in formula (A),-LB’- is a polymeric moiety.The moiety -LB’- is a polymeric moiety, meaning that it comprises at least one polymer moiety.In certain embodiments the one or more polymer moiety has a molecular weight of at least 450Da, at least 1 kDa, at least 1.5 kDa, at least 2 kDa, at least 2.5 kDa, at least 3 kDa, at least 3.5kDa, at least 4 kDa or at least 5 kDa. In certain embodiments the one or more polymer moietyhas a maximum molecular weight of 160 kDa, a maximum molecular weight of 120 kDa, amaximum molecular weight of 100 kDa, a maximum molecular weight of 80 kDa, a maximummolecular weight of 70 kDa, a maximum molecular weight of 60 kDa, a maximum molecularweight of 50 kDa or a maximum molecular weight of 40 kDa. In certain embodiments the oneor more polymer moiety has a molecular weight of about 450 Da, of about 1 kDa, of about 1.5kDa, of about 2 kDa, of about 2.5 kDa, of about 3 kDa, of about 3.5 kDa, of about 4 kDa, ofabout 4.5 kDa, of about 5 kDa, of about 5.5 kDa, of about 6 kDa, of about 6.5 kDa, of about 7kDa, of about 7.5 kDa, of about 8 kDa, of about 8.5 kDa, of about 9 kDa, of about 9.5 kDa orof about 10 kDa. It is understood that if -LB’- comprises one polymer moiety the minimum andmaximum molecular weights provided above apply to this one polymer moiety andif -LB’- comprises more than one polymer moiety the minimum and maximum molecularweights provided above refer to the minimum and maximum molecular weight of all polymer moieties together.In certain embodiments the one or more polymer moiety of -LB’- has a Flory radius of at least1.2 nm, of at least 1.5 nm, of at least 2 nm, of at least 2.5 nm, of at least 3 nm, of at least 3.5nm, of at least 4 nm, of at least 4.5 nm or of at least 5 nm. In certain embodiments the one ormore polymer moiety of -LB’- has a Flory radius of no more than 200 nm, no more than 175nm, no more than 150 nm, no more than 125 nm, no more than 100 nm, no more than 75 nm,no more than 50 nm, no more than 45 nm, no more than 40 nm, no more than 35 nm or no morethan 30 nm. In certain embodiments the one or more polymer moiety of -LB’- has a Flory radiusof about 1.2 nm, of about 1.5 nm, of about 2 nm, of about 2.5 nm, of about 3 nm, of about 3.5nm, of about 4 nm, of about 4.5 nm, of about 5 nm, of about 5.5 nm, of about 6 nm, of aboutAscendis Pharma A / S 67 CPX75146PC09 July 20256.5 nm, of about 7 nm, of about 8 nm, of about 8.5 nm, of about 9 nm, of about 9.5 nm or ofabout 10 nm. It is understood that if -LB’- comprises one polymer moiety the Flory radiusprovided above applies to this one polymer moiety and if -LB’- comprises more than onepolymer moiety the Flory radius provided above refers to the Flory radius of all polymer moieties together.-LB’- comprises one or more polymer moiety, such as polymer moiety selected from the groupconsisting of poly(2-methacryloyl-oxyethyl phosphoyl cholins), poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates), poly(hydroxyethyl- oxazolines), poly(hydroxymethacrylates), poly(hydroxypropylmethacrylamides), poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines), poly(iminocarbonates), poly(lactic acids), poly(lactic-co-glycolic acids), poly(methacrylamides), poly(methacrylates), poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters), poly(oxazolines), poly(propylene glycols), poly(siloxanes), poly(urethanes), poly(vinyl alcohols), poly(vinyl amines), poly(vinylmethylethers), poly(vinylpyrrolidones), silicones, celluloses, carbomethyl celluloses, hydroxypropyl methylcelluloses, chitins, chitosans, dextrans, dextrins, gelatins, hyaluronic acids and derivatives, functionalized hyaluronic acids, alginate, mannans, pectins, rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches and other carbohydrate-based polymers, xylans, and copolymers thereof.In certain embodiments -LB’- comprises a PEG-based polymer. In certainembodiments -LB’- comprises a hyaluronic acid-based polymer. In certainembodiments -LB’- comprises a random coil polymer. In certain embodiments -LB’- comprisesa poly-sarcosine polymer.In certain embodiments -LB’- of formula (A-a) is of formula (a-3’) whereinAscendis Pharma A / S 68 CPX75146PC09 July 2025the unmarked dashed line indicates attachment to -L2- or -D-;the dashed line marked with the asterisk indicates attachment to -LA; -Rd’- is a polymeric moiety; and-Re- is selected from the group consisting of -CH2-, . If -Rb- of formula (A-a) is then -Rc- of formula (a-3’) is and if -Rb- of formula(A-a) is then -Rc- of formula (a-3’) is .The moiety -Rd’- of formula (a-3’) is a polymeric moiety, meaning that it comprises at leastone polymer moiety. In certain embodiments the one or more polymer moiety has a molecularweight of at least 450 Da, of at least 1 kDa, of at least 1.5 kDa, of at least 2 kDa, of at least 2.5kDa, of at least 3 kDa, of at least 3.5 kDa, of at least 4 kDa or of at least 5 kDa. In certainembodiments the one or more polymer moiety has a maximum molecular weight of 160 kDa,a maximum molecular weight of 120 kDa, a maximum molecular weight of 100 kDa, amaximum molecular weight of 80 kDa, a maximum molecular weight of 70 kDa, a maximummolecular weight of 60 kDa, a maximum molecular weight of 50 kDa or a maximum molecularweight of 40 kDa. In certain embodiments the one or more polymer moiety has a molecularweight of about 450 Da, of about 1 kDa, of about 1.5 kDa, of about 2 kDa, of about 2.5 kDa,of about 3 kDa, of about 3.5 kDa, of about 4 kDa, of about 4.5 kDa, of about 5 kDa, of about5.5 kDa, of about 6 kDa, of about 6.5 kDa, of about 7 kDa, of about 7.5 kDa, of about 8 kDa,of about 8.5 kDa, of about 9 kDa, of about 9.5 kDa or of about 10 kDa. It is understood thatif -Rd’- of formula (a-3’) comprises one polymer moiety the minimum and maximum molecularweights provided above apply to this one polymer moiety and if -Rd’- of formula (a-3’)comprises more than one polymer moiety the minimum and maximum molecular weights provided above refer to the minimum and maximum molecular weight of all polymer moieties together.Ascendis Pharma A / S 69 CPX75146PC09 July 2025In certain embodiments the one or more polymer moiety of -Rd’- of formula (a-3’) has a Floryradius of at least 1.2 nm, of at least 1.5 nm, of at least 2 nm, of at least 2.5 nm, of at least 3 nm,of at least 3.5 nm, of at least 4 nm, of at least 4.5 nm or of at least 5 nm. In certain embodimentsthe one or more polymer moiety has a Flory radius of no more than 200 nm, of no more than175 nm, of no more than 150 nm, of no more than 125 nm, of no more than 100 nm, of no morethan 75 nm, of no more than 50 nm, of no more than 45 nm, of no more than 40 nm, of no morethan 35 nm or if no more than 30 nm. In certain embodiments the one or more polymer moietyhas a Flory radius of about 1.2 nm, of about 1.5 nm, of about 2 nm, of about 2.5 nm, of about3 nm, of about 3.5 nm, of about 4 nm, of about 4.5 nm, of about 5 nm, of about 5.5 nm, ofabout 6 nm, of about 6.5 nm, of about 7 nm, of about 7.5 nm, of about 8 nm, of about 8.5 nm,of about 9 nm or of about 10 nm. It is understood that if -Rd’- of formula (a-3’) comprises onepolymer moiety the Flory radius provided above applies to this one polymer moiety andif -Rd’- of formula (a-3’) comprises more than one polymer moiety the Flory radius providedabove refers to the Flory radius of all polymer moieties together.-Rd’- of formula (a-3’) comprises one or more polymer moiety, such as polymer moiety selectedfrom the group consisting of poly(2-methacryloyl-oxyethyl phosphoyl cholins), poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates), poly(hydroxyethyl- oxazolines), poly(hydroxymethacrylates), poly(hydroxypropylmethacrylamides), poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines), poly(iminocarbonates), poly(lactic acids), poly(lactic-co-glycolic acids), poly(methacrylamides), poly(methacrylates), poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters), poly(oxazolines), poly(propylene glycols), poly(siloxanes), poly(urethanes), poly(vinyl alcohols), poly(vinyl amines), poly(vinylmethylethers), poly(vinylpyrrolidones), silicones, celluloses, carbomethyl celluloses, hydroxypropyl methylcelluloses, chitins, chitosans, dextrans, dextrins, gelatins, hyaluronic acids and derivatives, functionalized hyaluronic acids, alginate, mannans, pectins, rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches and other carbohydrate-based polymers, xylans, and copolymers thereof.Ascendis Pharma A / S 70 CPX75146PC09 July 2025In certain embodiments -Rd’- of formula (a-3’) comprises a PEG-based polymer. In certainembodiments -Rd’- of formula (a-3’) comprises a hyaluronic acid-based polymer. In certainembodiments -Rd’- of formula (a-3’) comprises a random coil polymer. In certainembodiments -Rd’- of formula (a-3’) comprises a poly-sarcosine polymer.In certain embodiments -D- is a protein or peptide drug moiety and -AB2 is conjugated to afunctional group of -D- provided by the N-terminal amine, the C-terminal carboxyl or a sidechain of an amino acid residue. In certain embodiments -AB2is conjugated to the N-terminal amine functional group of -D-. In certain embodiments -AB2is conjugated to the C-terminal carboxyl functional group. In certain embodiments -AB2is conjugated to a functional groupprovided by an amino acid residue of -D-, such as by a lysine, serine, aspartic acid, glutamicacid, arginine, histidine, threonine, glutamine, asparagine, cysteine, proline, tyrosine or tryptophan. In certain embodiments -AB2is conjugated to the functional group of the side chainof a lysine of -D-. In certain embodiments -AB2 is conjugated to the functional group of theside chain of a serine of -D-. In certain embodiments -AB2 is conjugated to the functional groupof the side chain of an aspartic acid of -D-. In certain embodiments -AB2 is conjugated to thefunctional group of the side chain of a glutamic acid of -D-. In certain embodiments -AB2 isconjugated to the functional group of the side chain of an arginine of -D-. In certainembodiments -AB2 is conjugated to the functional group of the side chain of a histidine of -D-.In certain embodiments -AB2is conjugated to the functional group of the side chain of athreonine of -D-. In certain embodiments -AB2 is conjugated to the functional group of the sidechain of a glutamine of -D-. In certain embodiments -AB2 is conjugated to the functional groupof the side chain of an asparagine of -D-. In certain embodiments -AB2 is conjugated to thefunctional group of the side chain of a cysteine of -D-. In certain embodiments -AB2 isconjugated to the functional group of the side chain of a proline of -D-. In certainembodiments -AB2 is conjugated to the functional group of the side chain of a tyrosine of -D-.In certain embodiments -AB2is conjugated to the functional group of the side chain of atryptophan of -D-.In certain embodiments -D-AB2is selected from the group consisting of semaglutide, liraglutide, ecnoglutide, GZR18, GL0034, tirzepatide, cotadutide, BI-456906, pemvidutide, mazdutide, dapiglutide and retatrutide.Ascendis Pharma A / S 71 CPX75146PC09 July 2025In certain embodiments -D-AB2is selected from the group consisting of semaglutide, liraglutide, ecnoglutide, GZR18 and GL0034. In certain embodiments -D-AB2is semaglutide. Semaglutide is a compound of formula HX1EGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO:40),wherein X1is α-aminoisobutyric acid (Aib); and the lysine at position 20 is chemically modified through conjugation to the epsilon-amine group of the lysine side-chain with wherein the dashed line indicates attachment to the epsilon-amine group of the lysine side chain of the lysine at position 20. Semaglutide may be prepared using methods known to those skilled in the art, such as those described in WO2006 / 097537. In certain embodiments -D-AB2is liraglutide. Liraglutide is a compound of formula HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO:41), wherein the lysine at position 20 is chemically modified through conjugation to the epsilon-amine group of the lysine side chain with , wherein the dashed line indicates attachment to the epsilon-amine group of the lysine side chain of the lysine at position 20. In certain embodiments -D-AB2is ecnoglutide. Ecnoglutide is a compound of formulaAscendis Pharma A / S 72 CPX75146PC09 July 2025HVEGTFTSDVSSYLEEQAAREFIKWLVRGRG (SEQ ID NO:42), wherein the lysine at position 24 is chemically modified through conjugation to the epsilon-amine group of the lysine side chain with , wherein the dashed line indicates attachment to the epsilon-amine group of the lysine side chain of the lysine at position 24. In certain embodiments -D-AB2is GZR18. GZR18 is a compound of formula HGEGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO:43), wherein the lysine at position 20 is chemically modified through conjugation to the epsilon-amine group of the lysine side-chain with , wherein the dashed line indicates attachment to the epsilon amine group of the lysine side chain of the lysine at position 20. In certain embodiments -D-AB2is GL0034. GL0034 is also known as utreglutide and is a compound of formula HX1EGTFTSDVSSYLEGQAAKEFIAWLVRGRGL (SEQ ID NO:44), wherein X1is Aib; and the lysine at position 20 is chemically modified through conjugation to the epsilon-aminegroup of the lysine side-chain with , wherein the dashed line indicates attachment to the epsilon amine group of the lysine side chain of the lysine at position 20.Ascendis Pharma A / S 73 CPX75146PC09 July 2025In certain embodiments -D-AB2is a dual GLP-1 receptor agonist selected from the group consisting of tirzepatide, cotadutide, BI-456906, pemvidutide and mazdutide. In certain embodiments -D-AB2is a dual GLP-1 receptor agonist that activates the GLP-1 receptor and the GIP receptor. An example for such dual GLP-1 receptor agonist is tirzepatide. In certain embodiments -D-AB2is tirzepatide. Tirzepatide is a compound of formula YX1EGTFTSDYSIX2LDKIAQKAFVQWLIAGGPSSGAPPPS (SEQ ID NO:45), wherein X1 is Aib; X2 is Aib; the lysine at position 20 is chemically modified through conjugation to the epsilon-amine group of the lysine side-chain with ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO- (CH2)18-CO2H; and the C-terminal serine, i.e. the serine at position 39, is amidated as a C-terminal primary amide. The moiety ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γGlu)1-CO-(CH2)18-CO2H has the following structure , wherein the dashed line indicates attachment to -D-.In certain embodiments -D-AB2is a dual GLP-1 receptor agonist that activates the GLP-1 receptor and the glucagon receptor selected from the group consisting of cotadutide, BI- 456906, pemvidutide and mazdutide. In certain embodiments -D-AB2is cotadutide. Cotadutide is a compound of formula HSQGTFTSDKSEYLDSERARDFVAWLEAGG (SEQ ID NO:46), whereinAscendis Pharma A / S 74 CPX75146PC09 July 2025the lysine at position 10 is chemically modified through conjugation to the epsilon- amine group of the lysine side-chain with γ-Glu-palmitoyl. The moiety γ-Glu-palmitoyl has the following structure: , wherein the dashed line indicates attachment to -D-.In certain embodiments -D-AB2is BI-456906. BI-456906 is also known as survodutide and is a compound of formula HX1QGTFTSDYSKYLDERAAKDFIKWLESA (SEQ ID NO:47), wherein X1is 1-amino-cyclobutanecarboxylic acid (Ac4c); the lysine at position 24 is chemically modified through conjugation to the epsilon-amine group of the lysine side-chain with [l7-carboxy-heptadecanoyl]-isoGlu-GSGSGG; and the C-terminal alanine, i.e. the alanine at position 29, is amidated as a C-terminal primary amide. The moiety [l7-carboxy-heptadecanoyl]-isoGlu-GSGSGG has the following structure: , wherein the dashed line indicates attachment to -D-.In certain embodiments -D-AB2is pemvidutide. Pemvidutide is a compound of formula HX1QGTFTSDYSKYLDEKAAKEFIQWLLQT (SEQ ID NO:48), wherein X1 is Aib;Ascendis Pharma A / S 75 CPX75146PC09 July 2025the glutamic acid at position 16 and the lysine at position 20 are connected via a lactambridge; the lysine at position 17 is chemically modified through conjugation to the epsilon-amine group of the lysine side-chain with glucuronic acid C-18, which is a moiety of formula , wherein the dashed line indicates attachment to the epsilon-amine group of the lysine at position 17; and the C-terminal threonine, i.e., the threonine at position 29, is amidated as a C-terminalprimary amide In certain embodiments -D-AB2is mazdutide. Mazdutide is a compound of formula HX1QGTFTSDYSKYLDEKKAKEFVEWLLEGGPSSG (SEQ ID NO:49), wherein X1 is Aib, the lysine at position 20 is chemically modified by conjugation of the epsilon-amine group of the lysine side chain with ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO- (CH2)18-CO2H; and the C-terminal glycine, i.e. the glycine at position 34, is amidated.The moiety ([2-(2-amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)18-CO2H has thefollowing structure: , wherein the dashed line indicates attachment to -D-.In certain embodiments -D-AB2is a dual GLP-1 receptor agonist that activates the GLP-1 receptor and the GLP-2 receptor, such as dapiglutide. Dapiglutide is a compound of formula HX1EGSFTSELATILDKQAARDFIAWLIQHKITD (SEQ ID NO:50), wherein X1 is Aib; andAscendis Pharma A / S 76 CPX75146PC09 July 2025the lysine in position 16 is chemically modified by conjugation of the epsilon-amino- group of the lysine side chain with [17-carboxy-heptadecanoyl]-isoGlu.The moiety [17-carboxy-heptadecanoyl]-isoGlu has the following structure: , wherein the dashed line indicates attachment to -D-.In certain embodiments -D-AB2is retatrutide, which is a triple GLP-1 receptor agonist that activates the GLP-1 receptor, the GIP receptor and the GCG receptor. Retatrutide is a compound of formula YX1QGTFTSDYSIX2LDKKAQX3AFIEYLLEGGPSSGAPPPS (SEQ ID NO:51), wherein X1is Aib; X2is α-methyl-leucine (αMeL); X3 is Aib; the lysine at position 17 is chemically modified by conjugation of the epsilon-amine group of the lysine side chain with (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)-(γGlu)-CO- (CH2)18-CO2H; and the C-terminal serine, i.e. the serine at position 39, is amidated. Retatrutide can also be described as Y-Aib-QGTFTSDYSI-αMeL-LDKK ((2-[2-(2-amino- ethoxy)-ethoxy]-acetyl)-(γGlu)-CO-(CH2)18-CO2H) AQ-Aib-AFIEYLLEGGPSSGAPPPS- NH2(SEQ ID NO:51). The moiety (2-[2-(2-amino-ethoxy)-ethoxy]-acetyl)-(γGlu)-CO-(CH2)18-CO2H has the following structure: .Ascendis Pharma A / S 77 CPX75146PC09 July 2025In certain embodiments -D-AB2is noiiglutide, also known as SHR20004. In certain embodiments -D-AB2is ZT002. with Ph being phenyl.The moiety -D- of formula (b-1) has the sequence of SEQ ID NO:57YX1EGTFTSDYSIX2LDKIAQKAFVQWLIAGGPSSGAPPPS, with X1 and X2 being Aib. The compounds of formula (b-1) are disclosed in WO2022159395 and WO2023 / 044290, the content of which is herewith incorporated by reference in its entirety.In certain embodiments -D-AB is of formula (b-1) and X1- is . Incertain embodiments D-AB is of formula (b-1) and X1- is Ascendis Pharma A / S 78 CPX75146PC09 July 2025. In certain embodiments D-AB is of formula (b-1) and X1- is and -X2 is . In certain embodiments D-AB is of formula (b-1) and X1- is formula embodiments D-AB isof formula In certain embodiments -D-AB2is selected from the group consisting of semaglutide, liraglutide, ecnoglutide, GZR18, GL0034, tirzepatide, cotadutide, BI-456906, pemvidutide, mazdutide, dapiglutide and retatrutide. In certain embodiments -D-AB2is petrelintide. In certain embodiments -D-AB2is of formulaAscendis Pharma A / S 79 CPX75146PC09 July 2025k(γE-(miniPEG)2-γE-COC16H32CO2H)(N-Me)GSVSEIQLMHNLGKHLNSMERVEW LRKKLQDVHK(γE-(miniPEG)2-γE-COC16H32CO2H)-OH (SEQ ID NO:52), wherein k is d-Lys; γE is the l-isomer of gamma, glutamic acid; miniPEG is COCH2OCH2CH2OCH2CH2NH; COC16H32CO2H is C18 diacid; (N-Me)G is sarcosine; K is l-isomer of lysine; and -OH designates the C-terminal amino acid has a terminal carboxylic acid. In certain embodiments -D-AB2is of formula k(γE-(miniPEG)2-γE-COC16H32CO2H)(N-Me)GSVSEIQLMHNLGKHLNSMERVEW LRKKLQDVHK(γE-(miniPEG)2-γE-COC16H32CO2H)-OH (SEQ ID NO:53), wherein k is d-Lys; γE is the l-isomer of gamma, glutamic acid; (miniPEG)2 is COCH2OCH2CH2OCH2CH2NH; COC16H32CO2H is C18 diacid; (N-Me)G is sarcosine; K is l-isomer of lysine; and -OH designates the C-terminal amino acid has a terminal carboxylic acid.If -D- is a peptide or protein drug moiety, -L1- is either conjugated to a functional group of aside chain of an amino acid residue of -D-, to the N-terminal amine functional group or to theC-terminal carboxyl functional group of -D- or to a nitrogen atom in the backbone chain of -D-.If -D- is a peptide or protein drug moiety, -L1- is in certain embodiments conjugated to afunctional group of -D- selected from the group consisting of carboxylic acid, primary amine,secondary amine, maleimide, thiol, sulfonic acid, carbonate, carbamate, hydroxyl, aldehyde,ketone, hydrazine, isocyanate, isothiocyanate, phosphoric acid, phosphonic acid, haloacetyl, alkyl halide, acryloyl, aryl fluoride, hydroxylamine, sulfate, disulfide, vinyl sulfone, vinylketone, diazoalkane, oxirane, guanidine and aziridine. If -D- is a peptide or protein drugmoiety, -L1- is in certain embodiments conjugated to a functional group of -D- selected fromAscendis Pharma A / S 80 CPX75146PC09 July 2025the group consisting of hydroxyl, primary amine, secondary amine and guanidine. If -D- is apeptide or protein drug moiety, -L1- is in certain embodiments conjugated to a functional groupof -D- selected from the group consisting of primary amine and secondary amine. If -D- is apeptide or protein drug moiety, -L1- is in certain embodiments conjugated to a primary amineof -D-.If -D- is a peptide or protein drug moiety, -L1- may be conjugated to a functional group of theside chain of an amino acid residue of -D-, which may be a proteinogenic amino acid residueor a non-proteinogenic amino acid residue.If -D- is a peptide or protein drug moiety, -L1- is in certain embodiments conjugated to afunctional group of the side chain of a proteinogenic amino acid residue of -D-. In certain embodiments such amino acid residue is selected from the group consisting of histidine, lysine, tryptophan, serine, threonine, tyrosine, aspartic acid, glutamic acid and arginine. In certain embodiments such amino acid residue is selected from the group consisting of lysine, aspartic acid, arginine and serine. In certain embodiments such amino acid residue is selected from the group consisting of lysine, arginine and serine.If -D- is a peptide or protein drug moiety, -L1- is in certain embodiments conjugated to afunctional group of a lysine residue of -D-. If -D- is a peptide or protein drug moiety, -L1- is incertain embodiments conjugated to a functional group of a histidine residue of -D-. If -D- is apeptide or protein drug moiety, -L1- is in certain embodiments conjugated to a functional groupof a tryptophan residue of -D-. If -D- is a peptide or protein drug moiety, -L1- is in certainembodiments conjugated to a functional group of a serine residue of -D-. If -D- is a peptide orprotein drug moiety, -L1- is in certain embodiments conjugated to a functional group of athreonine residue of -D-. If -D- is a peptide or protein drug moiety, -L1- is in certainembodiments conjugated to a functional group of a tyrosine residue of -D-. If -D- is a peptideor protein drug moiety, -L1- is in certain embodiments conjugated to a functional group of anaspartic acid residue of -D-. If -D- is a peptide or protein drug moiety, -L1- is in certainembodiments conjugated to a functional group of a glutamic acid residue of -D-. If -D- is apeptide or protein drug moiety, -L1- is in certain embodiments conjugated to a functional groupof an arginine residue of -D-.Ascendis Pharma A / S 81 CPX75146PC09 July 2025If -D- is a peptide or protein drug moiety, -L1- is in certain embodiments conjugated to afunctional group of the side chain of a non-proteinogenic amino acid residue of -D-.It is understood that not every peptide or protein drug moiety -D- may comprise all of theseamino acid residues.If -D- is a peptide or protein drug moiety, -L1- is in certain embodiments conjugated to the N-terminal amine functional group of -D-.If -D- is a peptide or protein drug moiety, -L1- is in certain embodiments conjugated to the C-terminal functional group of -D-.The moiety -L1- may be connected to -D- through any type of linkage, provided that it isreversible. In certain embodiments -L1- is connected to -D- through a linkage selected from thegroup consisting of amide, ester, carbamate, acetal, aminal, imine, oxime, hydrazone, disulfideand acylguanidine. In certain embodiments -L1- is connected to -D- through a linkage selectedfrom the group consisting of amide, ester, carbamate and acylguanidin. It is understood thatsome of these linkages per se are not reversible, but that in the present invention neighboringgroups present in -L1- render these linkages reversible.In certain embodiments -L1- is connected to -D- through an amide linkage. In certainembodiments -L1- is connected to -D- through a carbamate linkage. In certainembodiments -L1- is connected to -D- through an ester linkage. In certain embodiments -L1- isconnected to -D- through an acylguanidine linkage.The moiety -L1- is a reversible prodrug linker from which the drug, i.e., H-D-AB2, is releasedin its free form, i.e. it is a traceless prodrug linker. It is understood that the “H-” in “H-D-AB” is a hydrogen. Suitable prodrug linkers are known in the art, such as for example the reversible prodrug linker moieties disclosed in WO 2005 / 099768 A2, WO 2006 / 136586 A2, WO 2011 / 089216 A1 and WO 2013 / 024053 A1, which are incorporated by reference herewith.In certain embodiments -L1- is as disclosed in WO 2009 / 095479 A2. Accordingly, in certainembodiments the moiety -L1- is of formula (II):Ascendis Pharma A / S 82 CPX75146PC09 July 2025 , wherein the dashed line indicates attachment to a nitrogen, hydroxyl or thiol of -D-;-X- is selected from the group consisting of -C(R4R4a)-; -N(R4)-; -O-; -C(R4R4a)-C(R5R5a)-; -C(R5R5a)-C(R4R4a)-; -C(R4R4a)-N(R6)-; -N(R6)-C(R4R4a)-; -C(R4R4a)-O-; -O-C(R4R4a)-; and -C(R7R7a)-; X1is selected from the group consisting of C; and S(O);-X2- is selected from the group consisting of -C(R8R8a)-; and -C(R8R8a)-C(R9R9a)-;=X3is selected from the group consisting of =O; =S; and =N-CN; -R1, -R1a, -R2, -R2a, -R4, -R4a, -R5, -R5a, -R6, -R8, -R8a, -R9, and -R9aare independently selected from the group consisting of -H; and C1-6 alkyl; -R3, and -R3aare independently selected from the group consisting of -H; and C1-6alkyl, provided that in case one of -R3, -R3aor both are other than -H they are connected to N to which they are attached through an SP3-hybridized carbon atom; -R7is selected from the group consisting of -N(R10R10a); and -NR10-(C=O)-R11; -R7a, -R10, -R10a, and -R11are independently of each other selected from the group consisting of -H; and C1-6 alkyl; optionally, one or more of the pairs -R1a / -R4a, -R1a / -R5a, -R1a / -R7a, -R4a / -R5a, and -R8a / -R9aform a chemical bond; optionally, one or more of the pairs -R1 / -R1a, -R2 / -R2a, -R4 / -R4a, -R5 / -R5a, -R8 / -R8a, and -R9 / -R9aare joined together with the atom to which they are attached to form a C3-10 cycloalkyl; or 3- to 10-membered heterocyclyl;optionally, one or more of the pairs -R1 / -R4, -R1 / -R5, -R1 / -R6, -R1 / -R7a, -R4 / -R5, -R4 / -R6, -R8 / -R9, and -R2 / -R3are joined together with the atoms to which they are attached to form a ring A; optionally, R3 / R3aare joined together with the nitrogen atom to which they are attachedto form a 3- to 10-membered heterocycle;A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl;C3-10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8- to 11-memberedheterobicyclyl; andAscendis Pharma A / S 83 CPX75146PC09 July 2025wherein -L1- is substituted with at least one -L2- and wherein -L1- is optionally furthersubstituted, provided that the hydrogen marked with the asterisk in formula (II) is not replaced by -L2- or a substituent.In certain embodiments -L1- of formula (II) is substituted with one moiety -L2-.In certain embodiments -L1- of formula (II) is not further substituted.It is understood that if -R3 / -R3aof formula (II) are joined together with the nitrogen atom towhich they are attached to form a 3- to 10-membered heterocycle, only such 3- to 10-memberedheterocycles may be formed in which the atoms directly attached to the nitrogen are SP3-hybridized carbon atoms. In other words, such 3- to 10-membered heterocycle formedby -R3 / -R3atogether with the nitrogen atom to which they are attached has the following structure: , wherein the dashed line indicates attachment to the rest of -L1-; the ring comprises 3 to 10 atoms comprising at least one nitrogen; and R#and R##represent an sp3-hydridized carbon atom.It is also understood that the 3- to 10-membered heterocycle may be further substituted.Exemplary embodiments of suitable 3- to 10-membered heterocycles formed by -R3 / -R3a offormula (II) together with the nitrogen atom to which they are attached are the following: , wherein dashed lines indicate attachment to the rest of the molecule; andAscendis Pharma A / S 84 CPX75146PC09 July 2025-R is selected from the group consisting of -H and C1-6 alkyl.-L1- of formula (II) may optionally be further substituted. In general, any substituent may beused as far as the cleavage principle is not affected, i.e., the hydrogen marked with the asterisk in formula (II) is not replaced and the nitrogen of the moiety of formula (II) remains part of a primary, secondary or tertiary amine, i.e., -R3and -R3aare independently of each other -H or are connected to –N< through an sp3-hybridized carbon atom. In one embodiment -R1or -R1aof formula (II) is substituted with -L2-. In another embodiment -R2or -R2aof formula (II) is substituted with -L2-. In another embodiment -R3or -R3aof formula (II) is substituted with -L2-. In another embodiment -R4of formula (II) is substituted with -L2-. In another embodiment -R5or -R5aof formula (II) is substituted with -L2-. In another embodiment -R6of formula (II) is substituted with -L2-. In another embodiment -R7or -R7a of formula (II) is substituted with -L2-. In another embodiment -R8 or -R8a of formula(II) is substituted with -L2-. In another embodiment -R9or -R9aof formula (II) is substituted with -L2-. In another embodiment -R10is substituted with -L2-. In another embodiment -R11is substituted with -L2-. In certain embodiments -R3of formula (II) is substituted with -L2-.In certain embodiments -X- of formula (II) is selected from the group consistingof -C(R4R4a)-, -N(R4)- and -C(R7R7a)-. In certain embodiments -X- of formula (II)is -C(R4R4a)-. In certain embodiments -X- of formula (II) is -C(R7R7a)-.In certain embodiments -R7 of formula (II) is -NR10-(C=O)-R11.In certain embodiments -R7a of formula (II) is selected from -H, methyl and ethyl. In certainembodiments -R7aof formula (II) is -H.In certain embodiments -R10 is selected from -H, methyl and ethyl. In certain embodiments -R10is methyl.Ascendis Pharma A / S 85 CPX75146PC09 July 2025In certain embodiments -R11 is selected from -H, methyl and ethyl. In certain embodiments -R11is -H. In certain embodiments -R11 is substituted with -L2-.In certain embodiments -X- of formula (II) is -N(R4)-.In certain embodiments -R4is selected from the group consisting of -H, methyl and ethyl. In certain embodiments -R4is -H.In certain embodiments X1 of formula (II) is C.In certain embodiments =X3 of formula (II) is =O.In certain embodiments -X2- of formula (II) is -C(R8R8a)-.In certain embodiments -R8and -R8aof formula (II) are independently selected from the group consisting of -H, methyl and ethyl. In certain embodiments at least one of -R8and -R8aof formula (II) is -H. In certain embodiments both -R8and -R8aof formula (II) are -H. In certain embodiments -R1and -R1aof formula (II) are independently selected from the group consisting of -H, methyl and ethyl. In certain embodiments at least one of -R1and -R1aof formula (II) is -H. In certain embodiments -R1and -R1aof formula (II) are -H. In certain embodiments at least one of -R1and -R1aof formula (II) is methyl. In certain embodiments both -R1and -R1aof formula (II) are methyl. In certain embodiments -R2and -R2aof formula (II) are independently selected from the group consisting of -H, methyl and ethyl. In certain embodiments at least one of -R2and -R2aof formula (II) is -H. In certain embodiments both -R2and -R2aof formula (II) are H. In certain embodiments -R3and -R3aof formula (II) are independently selected from the group consisting of -H, methyl, ethyl, propyl and butyl.Ascendis Pharma A / S 86 CPX75146PC09 July 2025In certain embodiments at least one of -R3and -R3aof formula (II) is methyl. In certain embodiments -R3of formula (II) is methyl and -R3aof formula (II) is -H.In certain embodiments -R3 and -R3a of formula (II) are both -H.In certain embodiments -D- is connected to -L1- through a nitrogen by forming an amide bond.In certain embodiments -L1- is of formula (II), wherein X is -C(R7R7a)-; X1 isC; -X2- is -C(R8R8a)-C(R9R9a)-; =X3 is =O; -R1 and -R1a are -H; -R2 and -R2a are -H; -R3and -R3a are methyl; -R7 is -N(R10R10a); -R7a is -H; -R8, -R8a, -R9 and -R9a are -H; and -R10 ismethyl and -R10ais -H.In certain embodiments -L1- is of formula (IIa) wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D-; and the unmarked dashed line indicates attachment to -L2-.In certain embodiments -L1- is of formula (IIa-a) wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D-; and the unmarked dashed line indicates attachment to -L2-.In certain embodiments -L1- is of formula (IIa-b) whereinAscendis Pharma A / S 87 CPX75146PC09 July 2025the dashed line marked with the asterisk indicates attachment to a nitrogen of -D-; and the unmarked dashed line indicates attachment to -L2-.The moiety of formula (IIa), (IIa-a) and (IIa-b) is connected to -D- via an amide bond formedby a nitrogen of an amine functional group and the carbonyl to the left of the dashed line markedwith the asterisk.In certain embodiments -L1- is of formula (II), wherein X is -C(R7R7a)-; X1 isC; -X2- is -C(R8R8a)-C(R9R9a)-; =X3 is =O; -R1 and -R1a are -H; -R2 and -R2a are -H; -R3and -R3aare methyl; -R7is -NR10-(C=O)-R11; -R7ais -H; -R8, -R8a, -R9and -R9aare -H; and -R10is methyl and -R11is -H.In certain embodiments -L1- is of formula (II), wherein X is -C(R7R7a)-; X1 isC; -X2- is -C(R8R8a)-C(R9R9a)-; =X3 is =O; -R1 and -R1a are -H; -R2 and -R2a are -H; -R3and -R3aare methyl; -R7is -NR10-(C=O)-R11; -R7ais -H; -R8, -R8a, -R9and -R9aare -H; and -R10is -H and -R11is -H.In certain embodiments -L1- is of formula (IIab) (IIab), wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D-; and the unmarked dashed line indicates attachment to -L2-.In certain embodiments -L1- is of formula (IIab-a) (IIab-a), wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D-; and the unmarked dashed line indicates attachment to -L2-.Ascendis Pharma A / S 88 CPX75146PC09 July 2025In certain embodiments -L1- is of formula (IIab-b) (IIab-b), wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D-; and the unmarked dashed line indicates attachment to -L2-.The moiety of formula (IIab), (IIab-a) and (IIab-b) is connected to -D- via an amide bondformed by a nitrogen of an amine functional group and the carbonyl to the left of the dashed line marked with the asterisk.In certain embodiments -L1- is selected from the group consisting of Ascendis Pharma A / S 89 CPX75146PC09 July 2025 In certain embodiments -L1- is of formula (IIab-c). In certain embodiments -L1- is of formula(IIab-ci), In certain embodiments -L1- is of formula (IIab-cii). In certain embodiments -L1- isof formula (IIab-d). In certain embodiments -L1- is of formula (IIab-di). In certainembodiments -L1- is of formula (IIab-dii). In certain embodiments -L1- is of formula (IIab-e).In certain embodiments -L1- is of formula (IIab-ei). In certain embodiments -L1- is of formula(IIab-eii). In certain embodiments -L1- is of formula (IIab-f). In certain embodiments -L1- is offormula (IIab-fi). In certain embodiments -L1- is of formula (IIab-fii). In certainembodiments -L1- is of formula (IIab-g). In certain embodiments -L1- is of formula (IIab-gi).In certain embodiments -L1- is of formula (IIab-gii).In certain embodiments -L1- is as disclosed in WO2016 / 020373A1. Accordingly, in certainembodiments the moiety -L1- is of formula (III): wherein the dashed line indicates attachment to a primary or secondary amine or hydroxyl of -D- through an amide or ester linkage, respectively;-R1, -R1a, -R2, -R2a, -R3and -R3aare independently of each other selected from the group consisting of -H, -C(R8R8aR8b), -C(=O)R8, -C≡N, -C(=NR8)R8a, -CR8(=CR8aR8b), -C≡CR8and -T; -R4, -R5and -R5aare independently of each other selected from the group consisting of -H, -C(R9R9aR9b) and -T; a1 and a2 are independently of each other 0 or 1;Ascendis Pharma A / S 90 CPX75146PC09 July 2025each -R6, -R6a, -R7, -R7a, -R8, -R8a, -R8b, -R9, -R9a, and -R9bare independently of each other selected from the group consisting of -H, halogen, -CN, -COOR10, -OR10, -C(O)R10, -C(O)N(R10R10a), -S(O)2N(R10R10a), -S(O) N(R10R10a), -S(O)2R10, -S(O)R10, -N(R10)S(O)2N(R10aR10b), -SR10, -N(R10R10a), -NO2, -OC(O)R10, -N(R10)C(O)R10a, -N(R10)S(O)2R10a, -N(R10)S(O)R10a, -N(R10)C(O)OR10a, -N(R10)C(O)N(R10aR10b),-OC(O)N(R10R10a), -T, C1-20alkyl, C2-20alkenyl, and C2-20alkynyl; wherein -T, C1-20alkyl, C2-20alkenyl, and C2-20alkynyl are optionally substituted with one or more -R11, which are the same or different and wherein C1-20 alkyl, C2-20 alkenyl, and C2-20 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R12)-, -S(O)2N(R12)-, -S(O)N(R12)-, -S(O)2-, -S(O)-, -N(R12)S(O)2N(R12a)-,-S-, -N(R12)-, -OC(OR12)(R12a)-, -N(R12)C(O)N(R12a)-, and -OC(O)N(R12)-; each -R10, -R10a, and -R10bis independently selected from the group consisting of -H, -T, C1-20 alkyl, C2-20 alkenyl, and C2-20 alkynyl; wherein -T, C1-20 alkyl, C2-20 alkenyl, and C2-20 alkynyl are optionally substituted with one or more -R11, which are the same or different and wherein C1-20alkyl, C2-20alkenyl, and C2-20alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R12)-, -S(O)2N(R12)-, -S(O)N(R12)-, -S(O)2-, -S(O)-, -N(R12)S(O)2N(R12a)-, -S-, -N(R12)-, -OC(OR12)(R12a)-, -N(R12)C(O)N(R12a)-, and -OC(O)N(R12)-; each T is independently of each other selected from the group consisting of phenyl,naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl,and 8- to 11-membered heterobicyclyl; wherein each T is independently optionallysubstituted with one or more -R11, which are the same or different; each -R11is independently of each other selected from halogen, -CN, oxo (=O), -COOR13, -OR13, -C(O)R13, -C(O)N(R13R13a), -S(O)2N(R13R13a), -S(O)N(R13R13a), -S(O)2R13, -S(O)R13, -N(R13)S(O)2N(R13aR13b), -SR13, -N(R13R13a), -NO2, -OC(O)R13, -N(R13)C(O)R13a, -N(R13)S(O)2R13a, -N(R13)S(O)R13a, -N(R13)C(O)OR13a, -N(R13)C(O)N(R13aR13b), -OC(O)N(R13R13a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different;Ascendis Pharma A / S 91 CPX75146PC09 July 2025each -R12, -R12a, -R13, -R13a, and -R13bis independently selected from the group consisting of -H, and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; optionally, one or more of the pairs -R1 / -R1a, -R2 / -R2a, -R3 / -R3a, -R6 / -R6a, and -R7 / -R7aare joined together with the atom to which they are attached to form a C3-10 cycloalkyl or a 3- to 10-membered heterocyclyl;optionally, one or more of the pairs -R1 / -R2, -R1 / -R3, -R1 / -R4, -R1 / -R5, -R1 / -R6, -R1 / -R7, -R2 / -R3, -R2 / -R4, -R2 / -R5, -R2 / -R6, -R2 / -R7, -R3 / -R4, -R3 / -R5, -R3 / -R6, -R3 / -R7, -R4 / -R5, -R4 / -R6, -R4 / -R7, -R5 / -R6, -R5 / -R7, and -R6 / -R7are joint together with the atoms to which they are attached to form a ring A; A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3-10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8- to 11-memberedheterobicyclyl; wherein -L1- is substituted with at least one -L2- and wherein -L1- is optionally furthersubstituted.The optional further substituents of -L1- of formula (III) are in certain embodiments asdescribed above.In certain embodiments -L1- of formula (III) is substituted with one moiety -L2-.In certain embodiments -L1- of formula (III) is not further substituted.In certain embodiments -L1- is as disclosed in EP1536334B1, WO2009 / 009712A1,WO2008 / 034122A1, WO2009 / 143412A2, WO2011 / 082368A2, and US8618124B2, which are herewith incorporated by reference in their entirety.In certain embodiments -L1- is as disclosed in US8946405B2 and US8754190B2, which areherewith incorporated by reference in their entirety. Accordingly, in certainembodiments -L1- is of formula (IV): Ascendis Pharma A / S 92 CPX75146PC09 July 2025wherein the dashed line indicates attachment to -D- and wherein attachment is through afunctional group of -D- selected from the group consisting of -OH, -SH and -NH2;m is 0 or 1; at least one or both of -R1and -R2is / are independently of each other selected from the group consisting of -CN, -NO2, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted alkynyl, -C(O)R3, -S(O)R3, -S(O)2R3, and -SR4, one and only one of -R1and -R2is selected from the group consisting of -H, optionally substituted alkyl, optionally substituted arylalkyl, and optionally substituted heteroarylalkyl; -R3is selected from the group consisting of -H, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR9 and -N(R9)2;-R4is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each -R5is independently selected from the group consisting of -H, optionally substituted alkyl, optionally substituted alkenylalkyl, optionally substituted alkynylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; -R9is selected from the group consisting of -H and optionally substituted alkyl; -Y- is absent and –X- is -O- or -S-; or-Y- is -N(Q)CH2- and -X- is -O-;Q is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; optionally, -R1and -R2may be joined to form a 3 to 8-membered ring; and optionally, both -R9together with the nitrogen to which they are attached form a heterocyclic ring; wherein -L1- is substituted with at least one -L2- and wherein -L1- is optionallyfurther substituted.Ascendis Pharma A / S 93 CPX75146PC09 July 2025Only in the context of formula (IV) the terms used have the following meaning: The term “alkyl” as used herein includes linear, branched or cyclic saturated hydrocarbon groups of 1 to 8 carbons, or in certain embodiments 1 to 6 or 1 to 4 carbon atoms. The term “alkoxy” includes alkyl groups bonded to oxygen, including methoxy, ethoxy, isopropoxy, cyclopropoxy, cyclobutoxy, and similar. The term “alkenyl” includes non-aromatic unsaturated hydrocarbons with carbon-carbon double bonds.The term “alkynyl” includes non-aromatic unsaturated hydrocarbons with carbon-carbon triplebonds. The term “aryl” includes aromatic hydrocarbon groups of 6 to 18 carbons, such as 6 to 10 carbons, including groups such as phenyl, naphthyl, and anthracenyl. The term “heteroaryl” includes aromatic rings comprising 3 to 15 carbons containing at least one N, O or S atom, such as 3 to 7 carbons containing at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, indenyl, and similar. In some instance, alkenyl, alkynyl, aryl or heteroaryl moieties may be coupled to the remainder of the molecule through an alkylene linkage. Under those circumstances, the substituent will be referred to as alkenylalkyl, alkynylalkyl, arylalkyl or heteroarylalkyl, indicating that an alkylene moiety is between the alkenyl, alkynyl, aryl or heteroaryl moiety and the molecule to which the alkenyl, alkynyl, aryl or heteroaryl is coupled. The term “halogen” includes bromo, fluoro, chloro and iodo. The term “heterocyclic ring” refers to a 4 to 8 membered aromatic or non-aromatic ring comprising 3 to 7 carbon atoms and at least one N, O, or S atom. Examples are piperidinyl, piperazinyl, tetrahydropyranyl, pyrrolidine, and tetrahydrofuranyl, as well as the exemplary groups provided for the term “heteroaryl” above.Ascendis Pharma A / S 94 CPX75146PC09 July 2025When a ring system is optionally substituted, suitable substituents are selected from the group consisting of alkyl, alkenyl, alkynyl, or an additional ring, each optionally further substituted. Optional substituents on any group, including the above, include halo, nitro, cyano, -OR, -SR, -NR2, -OCOR, -NRCOR, -COOR, -CONR2, -SOR, -SO2R, -SONR2, -SO2NR2, wherein each R is independently alkyl, alkenyl, alkynyl, aryl or heteroaryl, or two R groupstaken together with the atoms to which they are attached form a ring.In certain embodiments -L1- of formula (IV) is substituted with one moiety -L2-.In certain embodiments -L1- of formula (IV) is not further substituted.In certain embodiments -L1- is as disclosed in WO2013 / 036857A1, which is herewithincorporated by reference in its entirety. Accordingly, in certain embodiments -L1- is offormula (V): wherein the dashed line indicates attachment to -D- through an amine functional group ofH-D-AB2; -R1is selected from the group consisting of optionally substituted C1-C6 linear, branched, or cyclic alkyl; optionally substituted aryl; optionally substituted heteroaryl; alkoxy; and -NR52; -R2is selected from the group consisting of -H; optionally substituted C1-C6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl; -R3is selected from the group consisting of -H; optionally substituted C1-C6alkyl; optionally substituted aryl; and optionally substituted heteroaryl; -R4is selected from the group consisting of -H; optionally substituted C1-C6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl; each -R5is independently of each other selected from the group consisting of -H; optionally substituted C1-C6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl; or when taken together two -R5can be cycloalkyl or cycloheteroalkyl;Ascendis Pharma A / S 95 CPX75146PC09 July 2025wherein -L1- is substituted with at least one -L2- and wherein -L1- is optionally furthersubstituted. Only in the context of formula (V) the terms used have the following meaning: “Alkyl”, “alkenyl”, and “alkynyl” include linear, branched or cyclic hydrocarbon groups of 1- 8 carbons or 1-6 carbons or 1-4 carbons wherein alkyl is a saturated hydrocarbon, alkenyl includes one or more carbon-carbon double bonds and alkynyl includes one or more carbon- carbon triple bonds. Unless otherwise specified these contain 1-6 C. “Aryl” includes aromatic hydrocarbon groups of 6-18 carbons, such as 6-10 carbons, includinggroups such as phenyl, naphthyl, and anthracene “Heteroaryl” includes aromatic ringscomprising 3-15 carbons containing at least one N, O or S atom, such as 3-7 carbons containing at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl,oxazolyl, isoxazolyl, thiszolyl, isothiazolyl, quinolyl, indolyl, indenyl, and similar.The term “substituted” means an alkyl, alkenyl, alkynyl, aryl, or heteroaryl group comprising one or more substituent groups in place of one or more hydrogen atoms. Substituents may generally be selected from halogen including F, Cl, Br, and I; lower alkyl including linear, branched, and cyclic; lower haloalkyl including fluoroalkyl, chloroalkyl, bromoalkyl, and iodoalkyl; OH; lower alkoxy including linear, branched, and cyclic; SH; lower alkylthio including linear, branched and cyclic; amino, alkylamino, dialkylamino, silyl including alkylsilyl, alkoxysilyl, and arylsilyl; nitro; cyano; carbonyl; carboxylic acid, carboxylic ester, carboxylic amide, aminocarbonyl; aminoacyl; carbamate; urea; thiocarbamate; thiourea; ketone; sulfone; sulfonamide; aryl including phenyl, naphthyl, and anthracenyl; heteroaryl including 5-member heteroaryls including as pyrrole, imidazole, furan, thiophene, oxazole, thiazole, isoxazole, isothiazole, thiadiazole, triazole, oxadiazole, and tetrazole, 6-member heteroaryls including pyridine, pyrimidine, pyrazine, and fused heteroaryls including benzofuran, benzothiophene, benzoxazole, benzimidazole, indole, benzothiazole, benzisoxazole, and benzisothiazole.In certain embodiments -L1- of formula (V) is substituted with one moiety -L2-.In certain embodiments -L1- of formula (V) is not further substituted.Ascendis Pharma A / S 96 CPX75146PC09 July 2025In certain embodiments -L1- is as disclosed in US7585837B2, which is herewith incorporatedby reference in its entirety. Accordingly, in certain embodiments -L1- is of formula (VI): wherein the dashed line indicates attachment to -D- through an amine functional group ofH-D-AB2; R1and R2are independently selected from the group consisting of hydrogen, alkyl, alkoxy, alkoxyalkyl, aryl, alkaryl, aralkyl, halogen, nitro, -SO3H, -SO2NHR5, amino, ammonium, carboxyl, PO3H2, and OPO3H2; R3, R4, and R5are independently selected from the group consisting of hydrogen, alkyl, and aryl; wherein -L1- is substituted with at least one -L2- and wherein -L1- is optionally furthersubstituted. Suitable substituents for formulas (VI) are alkyl (such as C1-6 alkyl), alkenyl (such as C2-6 alkenyl), alkynyl (such as C2-6alkynyl), aryl (such as phenyl), heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl (such as aromatic 4 to 7 membered heterocycle) or halogen moieties. Only in the context of formula (VI) the terms used have the following meaning: The terms “alkyl”, “alkoxy”, “alkoxyalkyl”, “aryl”, “alkaryl” and “aralkyl” mean alkyl radicals of 1-8, such as 1-4 carbon atoms, e.g. methyl, ethyl, propyl, isopropyl and butyl, and aryl radicals of 6-10 carbon atoms, e.g. phenyl and naphthyl. The term “halogen” includes bromo, fluoro, chloro and iodo.In certain embodiments -L1- of formula (VI) is substituted with one moiety -L2-.In certain embodiments -L1- of formula (VI) is not further substituted.Ascendis Pharma A / S 97 CPX75146PC09 July 2025A further preferred embodiment for -L1- as is disclosed in WO2002 / 089789A1, which isherewith incorporated by reference in its entirety. Accordingly, a preferred moiety -L1- is offormula (VII): wherein the dashed line indicates attachment to -D- through an amine functional group ofH-D-AB2; L1is a bifunctional linking group, Y1and Y2are independently O, S or NR7; R2, R3, R4, R5, R6and R7are independently selected from the group consisting of hydrogen, C1-6alkyls, C3-12branched alkyls, C3-8cycloalkyls, C1-6substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, and C1-6 heteroalkoxy; Ar is a moiety which when included in formula (VII) forms a multisubstituted aromatichydrocarbon or a multi-substituted heterocyclic group; X is a chemical bond or a moiety that is actively transported into a target cell, a hydrophobic moiety, or a combination thereof, y is 0 or 1; wherein -L1- is substituted with at least one -L2- and wherein -L1- is optionally furthersubstituted. Only in the context of formula (VII) the terms used have the following meaning: The term “alkyl” shall be understood to include, e.g., straight, branched, substituted C1-12alkyls, including alkoxy, C3-8cycloalkyls or substituted cycloalkyls, etc.Ascendis Pharma A / S 98 CPX75146PC09 July 2025The term “substituted” shall be understood to include adding or replacing one or more atoms contained within a functional group or compounds with one or more different atoms. Substituted alkyls include carboxyalkyls, aminoalkyls, dialkylaminos, hydroxyalkyls and mercaptoalkyls; substituted cycloalkyls include moieties such as 4-chlorocyclohexyl; aryls include moieties such as napthyl; substituted aryls include moieties such as 3-bromo-phenyl; aralkyls include moieties such as toluyl; heteroalkyls include moieties such as ethylthiophene; substituted heteroalkyls include moieties such as 3-methoxythiophone; alkoxy includesmoieties such as methoxy; and phenoxy includes moieties such as 3-nitrophenoxy. Halo- shallbe understood to include fluoro, chloro, iodo and bromo.In certain embodiments -L1- of formula (VII) is substituted with one moiety -L2-.In certain embodiments -L1- of formula (VII) is not further substituted.In certain embodiments -L1- comprises a substructure of formula (VIII) (VIII), wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D- through an amide bond;the unmarked dashed lines indicate attachment to the remainder of -L1-; and wherein -L1- is substituted with at least one -L2- and wherein -L1- is optionally furthersubstituted.In certain embodiments -L1- of formula (VIII) is substituted with one moiety -L2-.In certain embodiments -L1- of formula (VIII) is not further substituted.In certain embodiments -L1- comprises a substructure of formula (IX)Ascendis Pharma A / S 99 CPX75146PC09 July 2025 wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D- through a carbamate bond;the unmarked dashed lines indicate attachment to the remainder of -L1-; and wherein -L1- is substituted with at least one -L2- and wherein -L1- is optionally furthersubstituted.In certain embodiments -L1- of formula (IX) is substituted with one moiety -L2-.In certain embodiments -L1- of formula (IX) is not further substituted.In certain embodiments -L1- has a structure as disclosed in WO2020 / 206358 A1. Accordingly,in certain embodiments the moiety -L1- is of formula (X): wherein the unmarked dashed line indicates attachment to -D-; the dashed line marked with the asterisk indicates attachment to -L2-; n is an integer selected from the group consisting of 0, 1, 2, 3, 4, 5 and 6; -R1and -R2are independently an electron-withdrawing group, alkyl, or -H, and wherein at least one of -R1or -R2is an electron-withdrawing group; each -R4is independently C1-C3 alkyl or the two -R4are taken together with the carbon atom to which they are attached to form a 3- to 6-membered ring; and-Y- is absent when -D- is a drug moiety connected through an amine,or -Y- is -N(R6)CH2- when -D- is a drug moiety connected through a phenol, alcohol,Ascendis Pharma A / S 100 CPX75146PC09 July 2025thiol, thiophenol, imidazole, or non-basic amine; wherein -R6is optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments n of formula (X) is an integer selected from 1, 2, 3, 4, 5 and 6. In certain embodiments n of formula (X) is an integer selected from 1, 2 and 3. In certain embodiments n of formula (X) is an integer from 0, 1, 2 and 3. In certain embodiments n of formula (X) is 1. In certain embodiments n of formula (X) is 2. In certain embodiments n of formula (X) is 3. In certain embodiments the electron-withdrawing group of -R1and -R2of formula (X) isselected from the group consisting of -CN; -NO2; optionally substituted aryl; optionallysubstituted heteroaryl; optionally substituted alkenyl; optionally substituted alkynyl; -COR3, -SOR3, or -SO2R3, wherein -R3is -H, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR8or -NR82, wherein each -R8is independently -H or optionally substituted alkyl, or both -R8groups are taken together with the nitrogen to which they are attached to form a heterocyclic ring; or -SR9, wherein -R9is optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl. In certain embodiments the electron-withdrawing group of -R1and -R2of formula (X) is -CN. In certain embodiments the electron-withdrawing group of -R1and -R2of formula (X) is -NO2. In certain embodiments the electron-withdrawing group of -R1and -R2of formula (X) is optionally substituted aryl comprising 6 to 10 carbons. In certain embodiments the electron- withdrawing group of -R1and -R2of formula (X) is optionally substituted phenyl, naphthyl, or anthracenyl. In certain embodiments the electron-withdrawing group of -R1and -R2of formula (X) is optionally substituted heteroaryl comprising 3 to 7 carbons and comprising at least one N, O, or S atom. In certain embodiments the electron-withdrawing group of -R1and -R2of formula (X) is optionally substituted pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, or indenyl. In certain embodiments theelectron-withdrawing group of -R1 and -R2 of formula (X) is optionally substituted alkenylcontaining 2 to 20 carbon atoms. In certain embodiments the electron-withdrawing group of -R1and -R2of formula (X) is optionally substituted alkynyl comprising 2 to 20 carbon atoms. In certain embodiments the electron-withdrawing group of -R1and -R2of formula (X) is -COR3, -SOR3, or -SO2R3, wherein -R3is -H, optionally substituted alkyl comprising 1 to 20Ascendis Pharma A / S 101 CPX75146PC09 July 2025carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR8or -NR82, wherein each -R8is independently -H or optionally substituted alkyl comprising 1 to 20 carbon atoms, or both -R8groups are taken together with the nitrogen to which they are attached to form a heterocyclic ring. In certain embodiments the electron-withdrawing group of -R1and -R2of formula (X)is -SR9, wherein -R9 is optionally substituted alkyl comprising 1 to 20 carbon atoms, optionallysubstituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl. In certain embodiments at least one of -R1or -R2of formula (X) is -CN, -SOR3or -SO2R3. In certain embodiments at least one of -R1and -R2of formula (X) is -CN or -SO2R3. In certain embodiments at least one of -R1and -R2of formula (X) is -CN or -SO2R3, wherein -R3is optionally substituted alkyl, optionally substituted aryl, or -NR82. In certain embodiments at least one of -R1and -R2of formula (X) is -CN, -SO2N(CH3)2, -SO2CH3, phenyl substituted with -SO2, phenyl substituted with -SO2 and -Cl, -SO2N(CH2CH2)2O, -SO2CH(CH3)2, -SO2N(CH3)(CH2CH3), or -SO2N(CH2CH2OCH3)2. In certain embodiments each -R4of formula (X) is independently C1-C3 alkyl. In certain embodiments both -R4are methyl.In certain embodiments -Y- of formula (X) is absent. In certain embodiments -Y- of formula(X) is -N(R6)CH2-.In certain embodiments -L1- is of formula (X), wherein n is 1, -R1 is -CN, -R2 is -H, and -R4is -CH3. In certain embodiments -L1- is of formula (X), wherein n is 1, -R1 is -SO2N(CH3)2, -R2is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula (X), wherein n is 1, -R1 isSO2CH3, -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula (X), wherein nis 1, -R1 is -SO2N(CH2CH2)2CHCH3, -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- isof formula (X), wherein n is 1, -R1 is phenyl substituted with -SO2, -R2 is -H, and -R4 is -CH3.In certain embodiments -L1- is of formula (X), wherein n is 1, -R1 is phenyl substitutedwith -SO2 and -Cl, -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula (X),wherein n is 1, -R1is -SO2N(CH2CH2)2O, -R2is -H, and -R4is -CH3. In certainembodiments -L1- is of formula (X), wherein n is 1, -R1 is -SO2CH(CH3)2, -R2 is -H, and -R4is -CH3. In certain embodiments -L1- is of formula (X), wherein n is 1, -R1Ascendis Pharma A / S 102 CPX75146PC09 July 2025is -SO2N(CH3)(CH2CH3), -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula(X), wherein n is 1, -R1is -SO2N(CH2CH2OCH3)2, -R2is -H, and -R4is -CH3. In certainembodiments -L1- is of formula (X), wherein n is 1, -R1 is phenyl substituted with-SO2and -CH3, -R2is -H, and -R4is -CH3.In certain embodiments -L1- is of formula (X), wherein n is 2, -R1 is -CN, -R2 is -H, and -R4is -CH3. In certain embodiments -L1- is of formula (X), wherein n is 2, -R1 is -SO2N(CH3)2, -R2is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula (X), wherein n is 2, -R1 isSO2CH3, -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula (X), wherein nis 2, -R1 is -SO2N(CH2CH2)2CHCH3, -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- isof formula (X), wherein n is 2, -R1 is phenyl substituted with -SO2, -R2 is -H, and -R4 is -CH3.In certain embodiments -L1- is of formula (X), wherein n is 2, -R1 is phenyl substitutedwith -SO2 and -Cl, -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula (X),wherein n is 2, -R1is -SO2N(CH2CH2)2O, -R2is -H, and -R4is -CH3. In certainembodiments -L1- is of formula (X), wherein n is 2, -R1 is -SO2CH(CH3)2, -R2 is -H, and -R4is -CH3. In certain embodiments -L1- is of formula (X), wherein n is 2, -R1is -SO2N(CH3)(CH2CH3), -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula(X), wherein n is 2, -R1is -SO2N(CH2CH2OCH3)2, -R2is -H, and -R4is -CH3. In certainembodiments -L1- is of formula (X), wherein n is 2, -R1 is phenyl substituted with -SO2and -CH3, -R2is -H, and -R4is -CH3.In certain embodiments -L1- is of formula (X), wherein n is 3, -R1 is -CN, -R2 is -H, and -R4is -CH3. In certain embodiments -L1- is of formula (X), wherein n is 3, -R1 is -SO2N(CH3)2, -R2is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula (X), wherein n is 3, -R1 isSO2CH3, -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula (X), wherein nis 3, -R1 is -SO2N(CH2CH2)2CHCH3, -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- isof formula (X), wherein n is 3, -R1 is phenyl substituted with -SO2, -R2 is -H, and -R4 is -CH3.In certain embodiments -L1- is of formula (X), wherein n is 3, -R1 is phenyl substitutedwith -SO2 and -Cl, -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula (X),wherein n is 3, -R1is -SO2N(CH2CH2)2O, -R2is -H, and -R4is -CH3. In certainembodiments -L1- is of formula (X), wherein n is 3, -R1 is -SO2CH(CH3)2, -R2 is -H, and -R4is -CH3. In certain embodiments -L1- is of formula (X), wherein n is 3, -R1is -SO2N(CH3)(CH2CH3), -R2 is -H, and -R4 is -CH3. In certain embodiments -L1- is of formula(X), wherein n is 3, -R1is -SO2N(CH2CH2OCH3)2, -R2is -H, and -R4is -CH3. In certainAscendis Pharma A / S 103 CPX75146PC09 July 2025embodiments -L1- is of formula (X), wherein n is 3, -R1 is phenyl substituted with -SO2and -CH3, -R2is -H, and -R4is -CH3. Only in the context of formula (X) the terms used have the following meaning: The term "alkyl" refers to linear, branched, or cyclic saturated hydrocarbon groups of 1 to 20, 1 to 12, 1 to 8, 1 to 6, or 1 to 4 carbon atoms. In certain embodiments an alkyl is linear or branched. Examples of linear or branched alkyl groups include methyl, ethyl, n-propyl,isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n- octyl, n-nonyl,and n-decyl. In certain embodiments an alkyl is cyclic. Examples of cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentadienyl, and cyclohexyl. The term "alkoxy" refers to alkyl groups bonded to oxygen, including methoxy, ethoxy, isopropoxy, cyclopropoxy, and cyclobutoxy. The term "alkenyl" refers to non-aromatic unsaturated hydrocarbons with carbon-carbondouble bonds and 2 to 20, 2 to 12, 2 to 8, 2 to 6, or 2 to 4 carbon atoms.The term "alkynyl" refers to non-aromatic unsaturated hydrocarbons with carbon-carbon triple bonds and 2 to 20, 2 to 12, 2 to 8, 2 to 6, or 2 to 4 carbon atoms. The term "aryl" refers to aromatic hydrocarbon groups of 6 to 18 carbons, preferably 6 to 10 carbons, including groups such as phenyl, naphthyl, and anthracenyl. The term "heteroaryl" refers to aromatic rings comprising 3 to 15 carbons comprising at least one N, O or S atom, preferably 3 to 7 carbons comprising at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, and indenyl. In certain embodiments alkenyl, alkynyl, aryl or heteroaryl moieties may be coupled to the remainder of the molecule through an alkyl linkage. Under those circumstances, the substituent will be referred to as alkenylalkyl, alkynylalkyl, arylalkyl or heteroarylalkyl, indicating that an alkylene moiety is between the alkenyl, alkynyl, aryl or heteroaryl moiety and the molecule to which the alkenyl, alkynyl, aryl or heteroaryl is coupled.Ascendis Pharma A / S 104 CPX75146PC09 July 2025The term "halogen" or "halo" refers to bromo, fluoro, chloro and iodo.The term "heterocyclic ring" or "heterocyclyl" refers to a 3- to 15-membered aromatic or non-aromatic ring comprising at least one N, O, or S atom. Examples include piperidinyl, piperazinyl, tetrahydropyranyl, pyrrolidine, and tetrahydrofuranyl, as well as the exemplary groups provided for the term "heteroaryl" above. In certain embodiments a heterocyclic ring or heterocyclyl is non-aromatic. In certain embodiments a heterocyclic ring or heterocyclyl is aromatic. The term "optionally substituted" refers to a group may be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4 or 5) of the substituents which may be the same or different. Examples of substituents include alkyl, alkenyl, alkynyl, halogen, -CN, -ORaa, -SRaa, -NRaaRbb, -NO2, -C=NH(ORaa), -C(O)Raa, -OC(O)Raa, -C(O)ORaa, -C(O)NRaaRbb, -OC(O)NRaaRbb, -NRaaC(O)Rbb, -NRaaC(O)ORbb, -S(O)Raa, -S(O)2Raa, -NRaaS(O)Rbb, -C(O)NRaaS(O)Rbb, -NRaaS(O)2Rbb, -C(O)NRaaS(O)2Rbb, -S(O)NRaaRbb, -S(O)2NRaaRbb, -P(O)(ORaa)(ORbb), heterocyclyl, heteroaryl, or aryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, and aryl are each independently optionally substituted by -Rcc, wherein -Raaand -Rbbare each independently -H, alkyl, alkenyl, alkynyl, heterocyclyl, heteroaryl, or aryl, or -Raaand -Rbbare taken together with the nitrogen atom to which they attach to form a heterocyclyl, which is optionally substituted by alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, or -CN, and wherein: each -Rccis independently alkyl, alkenyl, alkynyl, halogen, heterocyclyl, heteroaryl, aryl, -CN, or -NO2.In certain embodiments -L1- has a structure as disclosed in formula I of WO2021 / 242756 A1.Accordingly, in certain embodiments the moiety -L1- is of formula (XIIa): wherein the unmarked dashed line indicates attachment to -D-; the dashed line marked with the asterisk indicates attachment to -L2-; -R2, -R4and -R8are independently selected from the group consisting of -H or C1-4 alkyl;Ascendis Pharma A / S 105 CPX75146PC09 July 2025-R3is C1-4 alkyl or -R3and -R4together with the atoms to which they are attached form a 5- or 6-membered heterocyclic ring;-R5is -NH2; with the proviso that when -R4and -R3together with the atoms to which they are attached from a 5- or 6-membered heterocyclic ring -R2 is not -H; andwherein the -L1- of formula (XIIa) is optionally substituted.In certain embodiments both -R4and -R8of formula (XIIa) are -H. In certain embodiments -R3is methyl. In certain embodiments -R3is -H. In certain embodiments -R2is -H.In certain embodiments -L1- is of formula (XIIa-i) (XIIa-i), the unmarked dashed line indicates attachment to -D-; and the dashed line marked with the asterisk indicates attachment to -L2-.In certain embodiments -L1- is of formula (XIIa-ii) ii), the unmarked dashed line indicates attachment to -D-; and the dashed line marked with the asterisk indicates attachment to -L2-.In certain embodiments -L1- is of formula (XIIa-iii) (XIIa-iii), the unmarked dashed line indicates attachment to -D-; and the dashed line marked with the asterisk indicates attachment to -L2-.Ascendis Pharma A / S 106 CPX75146PC09 July 2025In certain embodiments -L1- has a structure as disclosed in formula II of WO2022 / 096636 A1.Accordingly, in certain embodiments the moiety -L1- is of formula (XIIb): (XIIb), wherein the unmarked dashed line indicates attachment to -D-; and the dashed line marked with the asterisk indicates attachment to -L2-.In certain embodiments -L2- has a molecular weight of at least 3 kDa, of at least 3.5 kDa, of atleast 4 kDa, of at least 4.5 kDa or of at least 5 kDa. In certain embodiments the molecularweight of -L2- is less than 100 kDa, less than 80, less than 60 kDa, less than 40 kDa, less than30 kDa or less than 20 kDa. In certain embodiments the molecular weight of -L2- ranges from1 kDa to 80 kDa. In certain embodiments the molecular weight of -L2- ranges from 2 kDa to60 kDa. In certain embodiments the molecular weight of -L2- ranges from 2.5 kDa to 50 kDa.In certain embodiments the molecular weight of -L2- ranges from 3 kDa to 40 kDa. In certainembodiments the molecular weight of -L2- ranges from 4 kDa to 30 kDa. In certainembodiments the molecular weight of -L2- ranges from 4 kDa to 20 kDa. In certainembodiments the molecular weight of -L2- ranges from 4 kDa to 15 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 2 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 2.5 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 3 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 3.5 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 4 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 5 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 6 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 7 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 8 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 9 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 10 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 11 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 12 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 13 kDa. In certainAscendis Pharma A / S 107 CPX75146PC09 July 2025embodiments the molecular weight of -L2- has a molecular weight of about 14 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 15 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 16 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 17 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 18 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 19 kDa. In certainembodiments the molecular weight of -L2- has a molecular weight of about 20 kDa.In certain embodiments the one or more polymer moiety of -L2- has a Flory radius of at least1.2 nm, of at least 1.5 nm, of at least 2 nm, of at least 2.5 nm, of at least 3 nm, of at least 3.5nm, of at least 4 nm, of at least 4.5 nm or of at least 5 nm. In certain embodiments the one ormore polymer moiety of -L2- has a Flory radius of no more than 200 nm, of no more than 175nm, of no more than 150 nm, of no more than 125 nm, of no more than 100 nm, of no morethan 75 nm, of no more than 50 nm, of no more than 45 nm, of no more than 40 nm, of no morethan 35 nm or of no more than 30 nm. In certain embodiments the one or more polymer moietyof -L2- has a Flory radius of about 1.2 nm, of about 1.5 nm, of about 2 nm, of about 2.5 nm, ofabout 3 nm, of about 3.5 nm, of about 4 nm, of about 4.5 nm, of about 5 nm, of about 5.5 nm,of about 6 nm. In certain embodiments the one or more polymer moiety of -L2-has a Floryradius of about 6.5 nm, of about 7 nm, of about 7.5 nm, of about 8.5 nm, of about 9 nm, ofabout 9.5 nm or of about 10 nm. It is understood that if -L2- comprises one polymer moiety theFlory radius provided above applies to this one polymer moiety and if -L2- comprises morethan one polymer moiety the Flory radius provided above refers to the Flory radius of all polymer moieties together.In certain embodiments -L2- comprises a polymeric moiety.In certain embodiments -L2- is a spacer moiety of formula (B) wherein the unmarked dashed line indicates attachment to -L1-; the dashed line marked with the asterisk indicates attachment to -AB1; -POL- is a polymeric moiety; andAscendis Pharma A / S 108 CPX75146PC09 July 2025-LD- and -LE- are independently absent or selected from the group consistingof -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry1)-, -S(O)2N(Ry1)-, -S(O)N(Ry1)-, -S(O)2-, -S(O)-, -N(Ry1)S(O)2N(Ry1a)-, -S-, -N(Ry1)-, -OC(ORy1)(Ry1a)-, -N(Ry1)C(O)N(Ry1a)-, -OC(O)N(Ry1)-, C1-50alkyl, C2-50alkenyl, and C2-50alkynyl; wherein -T-, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more -Ry2, which are the same or different and wherein C1-50alkyl, C2-50alkenyl, and C2-50alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry3)-, -S(O)2N(Ry3)-, -S(O)N(Ry3)-, -S(O)2-, -S(O)-, -N(Ry3)S(O)2N(Ry3a)-, -S-, -N(Ry3)-, -OC(ORy3)(Ry3a)-, -N(Ry3)C(O)N(Ry3a)-, and -OC(O)N(Ry3)-; -Ry1and -Ry1aare independently of each other selected from the group consisting of -H, -T, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T, C1-50 alkyl, C2-50 alkenyl, and C2-50alkynyl are optionally substituted with one or more -Ry2, which are the same or different, and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry4)-, -S(O)2N(Ry4)-, -S(O)N(Ry4)-, -S(O)2-, -S(O)-, -N(Ry4)S(O)2N(Ry4a)-, -S-, -N(Ry4)-, -OC(ORy4)(Ry4a)-, -N(Ry4)C(O)N(Ry4a)-, and -OC(O)N(Ry4)-; each T is independently selected from the group consisting of phenyl, naphthyl, indenyl,indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-memberedheterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-memberedheteropolycyclyl; wherein each T is independently optionally substituted with one or more -Ry2, which are the same or different; each -Ry2is independently selected from the group consisting of halogen, -CN, oxo (=O), -COORy5, -ORy5, -C(O)Ry5, -C(O)N(Ry5Ry5a), -S(O)2N(Ry5Ry5a), -S(O)N(Ry5Ry5a), -S(O)2Ry5, -S(O)Ry5, -N(Ry5)S(O)2N(Ry5aRy5b), -SRy5, -N(Ry5Ry5a), -NO2, -OC(O)Ry5, -N(Ry5)C(O)Ry5a, -N(Ry5)S(O)2Ry5a, -N(Ry5)S(O)Ry5a, -N(Ry5)C(O)ORy5a, -N(Ry5)C(O)N(Ry5aRy5b), -OC(O)N(Ry5Ry5a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; andeach -Ry3, -Ry3a, -Ry4, -Ry4a, -Ry5, -Ry5a and -Ry5b is independently selected from the groupconsisting of -H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different.Ascendis Pharma A / S 109 CPX75146PC09 July 2025In certain embodiments -LD- and -LE- are independently selected from the group consistingof -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry1)-, -S(O)2N(Ry1)-, -S(O)N(Ry1)-, -S(O)2-,-S(O)-, -N(Ry1)S(O)2N(Ry1a)-, -S-, -N(Ry1)-, -OC(ORy1)(Ry1a)-, -N(Ry1)C(O)N(Ry1a)-, -OC(O)N(Ry1)-, C1-50alkyl, C2-50alkenyl, and C2-50alkynyl; wherein -T-, C1-20alkyl, C2-20alkenyl, and C2-20 alkynyl are optionally substituted with one or more -Ry2, which are the same or different and wherein C1-20alkyl, C2-20alkenyl, and C2-20alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry3)-, -S(O)2N(Ry3)-, -S(O)N(Ry3)-, -S(O)2-, -S(O)-, -N(Ry3)S(O)2N(Ry3a)-, -S-, -N(Ry3)-, -OC(ORy3)(Ry3a)-, -N(Ry3)C(O)N(Ry3a)-, and -OC(O)N(Ry3)-; -Ry1and -Ry1aare independently of each other selected from the group consisting of -H, -T, C1-10 alkyl, C2-10 alkenyl, and C2-10 alkynyl; wherein -T, C1-10 alkyl, C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more -Ry2, which are the same or different, and wherein C1-10alkyl, C2-10alkenyl, and C2-10alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry4)-, -S(O)2N(Ry4)-, -S(O)N(Ry4)-, -S(O)2-, -S(O)-, -N(Ry4)S(O)2N(Ry4a)-, -S-, -N(Ry4)-, -OC(ORy4)(Ry4a)-, -N(Ry4)C(O)N(Ry4a)-, and -OC(O)N(Ry4)-; each T is independently selected from the group consisting of phenyl, naphthyl, indenyl,indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-memberedheterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl;wherein each T is independently optionally substituted with one or more -Ry2, which are the same or different; -Ry2is selected from the group consisting of halogen, -CN, oxo (=O), -COORy5, -ORy5, -C(O)Ry5, -C(O)N(Ry5Ry5a), -S(O)2N(Ry5Ry5a), -S(O)N(Ry5Ry5a), -S(O)2Ry5, -S(O)Ry5, -N(Ry5)S(O)2N(Ry5aRy5b), -SRy5, -N(Ry5Ry5a), -NO2, -OC(O)Ry5, -N(Ry5) C(O)Ry5a, -N(Ry5)S(O)2Ry5a, -N(Ry5)S(O)Ry5a, -N(Ry5)C(O)ORy5a, -N(Ry5)C(O)N(Ry5aRy5b), -OC(O)N(Ry5Ry5a), and C1-6alkyl; wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different; and each -Ry3, -Ry3a, -Ry4, -Ry4a, -Ry5, -Ry5aand -Ry5bis independently of each other selected from the group consisting of -H, and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different.In certain embodiments -LD- and -LE- are independently selected from the group consistingof -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry1)-, -S(O)2N(Ry1)-, -S(O)N(Ry1)-, -S(O)2-, -S(O)-, -N(Ry1)S(O)2N(Ry1a)-, -S-, -N(Ry1)-, -OC(ORy1)(Ry1a)-, -N(Ry1)C(O)N(Ry1a)-, -OC(O)N(Ry1)-,Ascendis Pharma A / S 110 CPX75146PC09 July 2025C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T-, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more -Ry2, which are the same or different and wherein C1-50alkyl, C2-50alkenyl, and C2-50alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry3)-, -S(O)2N(Ry3)-, -S(O)N(Ry3)-, -S(O)2-, -S(O)-, -N(Ry3)S(O)2N(Ry3a)-, -S-, -N(Ry3)-, -OC(ORy3)(Ry3a)-, -N(Ry3)C(O)N(Ry3a)-, and -OC(O)N(Ry3)-;-Ry1 and -Ry1a are independently selected from the group consisting of -H, -T, C1-10 alkyl, C2-10alkenyl, and C2-10 alkynyl; each T is independently selected from the group consisting of phenyl, naphthyl, indenyl,indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-memberedheterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl;each -Ry2is independently selected from the group consisting of halogen, and C1-6 alkyl; and each -Ry3, -Ry3a, -Ry4, -Ry4a, -Ry5, -Ry5aand -Ry5bis independently of each other selected from the group consisting of -H, and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different.In certain embodiments -LD- and -LE- are independently a C1-20 alkyl chain, which is optionallyinterrupted by one or more groups independently selected from -C(O)-, -N(Ry1)-,-O-, -S-, -T- and -C(O)N(Ry1)-; and which C1-20 alkyl chain is optionally substituted with oneor more groups independently selected from halogen, -OH, -T and -N(Ry1Ry1a); wherein -Ry1and -Ry1a are independently selected from the group consisting of H and C1-4 alkyl and whereinT is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl, which is optionallysubstituted with one or more oxo (=O) or halogen.In certain embodiments -LD- and -LE- have independently of each other a molecular weight inthe range of from 14 g / mol to 750 g / mol.In certain embodiments -LD- and -LE- independently comprise a moiety selected fromAscendis Pharma A / S 111 CPX75146PC09 July 2025,, , ; wherein -R and -Raare independently of each other selected from the group consisting of -H, methyl,ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-Ascendis Pharma A / S 112 CPX75146PC09 July 2025dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl and 3,3-dimethylpropyl.In certain embodiments -LD- and -LE- have independently a chain length of 1 to 20 atoms. Incertain embodiments -LD- and -LE- have independently a chain length of 2 to 10 atoms.In certain embodiments -LD- is absent. In certain embodiments -LD- is -N(Ry1)-, wherein -Ry1is -H, methyl, ethyl, propyl or isopropyl. In certain embodiments -LD- is -NH-. In certainembodiments -LD- is -C(O)-.In certain embodiments -LE- is absent. In certain embodiments -LE- is of formula (B-a) wherein the dashed line marked with the asterisk indicates attachment to -POL-; the unmarked dashed line indicates attachment to -L1-; d1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; d2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; d3 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and -Z1- and -Z2- are independently selected from the group consisting of Ascendis Pharma A / S 113 CPX75146PC09 July 2025 wherein -R and -Raare independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,Ascendis Pharma A / S 114 CPX75146PC09 July 20252-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2- dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl. In certain embodiments d1 of formula (B-a) is 0. In certain embodiments d1 of formula (B-a) is 1. In certain embodiments d1 of formula (B-a) is 2. In certain embodiments d1 of formula (B-a) is 3. In certain embodiments d1 of formula (B-a) is 4. In certain embodiments d1 of formula (B-a) is 5. In certain embodiments d1 of formula (B-a) is 6. In certain embodiments d1 of formula (B-a) is 7. In certain embodiments d1 of formula (B-a) is 8. In certain embodiments d1 of formula (B-a) is 9. In certain embodiments d1 of formula (B-a) is 10. In certain embodiments d1 of formula (B-a) is 11. In certain embodiments d1 of formula (B-a) is 12. In certain embodiments d1 of formula (B-a) is 13. In certain embodiments d1 of formula (B-a) is 14. In certain embodiments d1 of formula (B-a) is 15. In certain embodiments d1 of formula (B-a) is 16. In certain embodiments d1 of formula (B-a) is 17. In certain embodiments d1 of formula (B-a) is 18. In certain embodiments d1 of formula (B-a) is 19. In certain embodiments d1 of formula (B-a) is 20. In certain embodiments d2 of formula (B-a) is 0. In certain embodiments d2 of formula (B-a) is 1. In certain embodiments d2 of formula (B-a) is 2. In certain embodiments d2 of formula (B-a) is 3. In certain embodiments d2 of formula (B-a) is 4. In certain embodiments d2 of formula (B-a) is 5. In certain embodiments d2 of formula (B-a) is 6. In certain embodiments d2 of formula (B-a) is 7. In certain embodiments d2 of formula (B-a) is 8. In certain embodiments d2 of formula (B-a) is 9. In certain embodiments d2 of formula (B-a) is 10. In certain embodiments d2 of formula (B-a) is 11. In certain embodiments d2 of formula (B-a) is 12. In certain embodiments d2 of formula (B-a) is 13. In certain embodiments d2 of formula (B-a) is 14. In certain embodiments d2 of formula (B-a) is 15. In certain embodiments d2 of formula (B-a) is 16. In certain embodiments d2 of formula (B-a) is 17. In certain embodiments d2 of formula (B-a) is 18. In certain embodiments d2 of formula (B-a) is 19. In certain embodiments d2 of formula (B-a) is 20. In certain embodiments d3 of formula (B-a) is 1. In certain embodiments d3 of formula (B-a) is 2. In certain embodiments d3 of formula (B-a) is 3. In certain embodiments d3 of formula(B-a) is 4. In certain embodiments d3 of formula (B-a) is 5. In certain embodiments d3 offormula (B-a) is 6. In certain embodiments d3 of formula (B-a) is 7. In certain embodiments d3 of formula (B-a) is 8. In certain embodiments d3 of formula (B-a) is 9. In certainAscendis Pharma A / S 115 CPX75146PC09 July 2025embodiments d3 of formula (B-a) is 10. In certain embodiments d3 of formula (B-a) is 11. In certain embodiments d3 of formula (B-a) is 12. In certain embodiments d3 of formula (B-a) is 13. In certain embodiments d3 of formula (B-a) is 14. In certain embodiments d3 of formula (B-a) is 15. In certain embodiments d3 of formula (B-a) is 16. In certain embodiments d3 of formula (B-a) is 17. In certain embodiments d3 of formula (B-a) is 18. In certain embodiments d3 of formula (B-a) is 19. In certain embodiments d3 of formula (B-a) is 20.In certain embodiments -Z1- is of formula (e1). In certain embodiments -Z1- is of formula (e2).In certain embodiments -Z1- is of formula (e3). In certain embodiments -Z1- is of formula (e4).In certain embodiments -Z1- is of formula (e5). In certain embodiments -Z1- is of formula (e6).In certain embodiments -Z1- is of formula (e7). In certain embodiments -Z1- is of formula (e8).In certain embodiments -Z1- is of formula (e9). In certain embodiments -Z1- is of formula (e10).In certain embodiments -Z1- is of formula (e11). In certain embodiments -Z1- is of formula(e12). In certain embodiments -Z1- is of formula (e13). In certain embodiments -Z1- is offormula (e14). In certain embodiments -Z1- is of formula (e15). In certain embodiments -Z1- isof formula (e16). In certain embodiments -Z1- is of formula (e17). In certainembodiments -Z1- is of formula (e18). In certain embodiments -Z1- is of formula (e19). Incertain embodiments -Z1- is of formula (e20). In certain embodiments -Z1- is of formula (e21).In certain embodiments -Z1- is of formula (e22).In certain embodiments -Z2- is of formula (e1). In certain embodiments -Z2- is of formula (e2).In certain embodiments -Z2- is of formula (e3). In certain embodiments -Z2- is of formula (e4).In certain embodiments -Z2- is of formula (e5). In certain embodiments -Z2- is of formula (e6).In certain embodiments -Z2- is of formula (e7). In certain embodiments -Z2- is of formula (e8).In certain embodiments -Z2- is of formula (e9). In certain embodiments -Z2- is of formula (e10).In certain embodiments -Z2- is of formula (e11). In certain embodiments -Z2- is of formula(e12). In certain embodiments -Z2- is of formula (e13). In certain embodiments -Z2- is offormula (e14). In certain embodiments -Z2- is of formula (e15). In certain embodiments -Z2- isof formula (e16). In certain embodiments -Z2- is of formula (e17). In certainembodiments -Z2- is of formula (e18). In certain embodiments -Z2- is of formula (e19). Incertain embodiments -Z2- is of formula (e20). In certain embodiments -Z2- is of formula (e21).In certain embodiments -Z2- is of formula (e22).In certain embodiments -LE- is of formula (B-b)Ascendis Pharma A / S 116 CPX75146PC09 July 2025 wherein the dashed line marked with the asterisk indicates attachment to -POL-; the unmarked dashed line indicates attachment to -L1-; d1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; d2 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; d3 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20; and -R is -H, methyl, ethyl, propyl or isopropyl. In certain embodiments d1 of formula (B-b) is 0, 1, 2, 3, 4, 5 or 6. In certain embodiments d1of formula (B-b) is 0. In certain embodiments d1 of formula (B-b) is 1. In certain embodimentsd1 of formula (B-b) is 2. In certain embodiments d1 of formula (B-b) is 3. In certain embodiments d1 of formula (B-b) is 4. In certain embodiments d1 of formula (B-b) is 5. In certain embodiments d1 of formula (B-b) is 6. In certain embodiments d2 of formula (B-b) is 0, 1, 2, 3, 4, 5 or 6. In certain embodiments d2 of formula (B-b) is 0. In certain embodiments d2 of formula (B-b) is 1. In certain embodiments d2 of formula (B-b) is 2. In certain embodiments d2 of formula (B-b) is 3. In certain embodiments d2 of formula (B-b) is 4. In certain embodiments d2 of formula (B-b) is 5. In certain embodiments d2 of formula (B-b) is 6. In certain embodiments d3 of formula (B-b) is 0, 1, 2, 3, 4, 5 or 6. In certain embodiments d3 of formula (B-b) is 0. In certain embodiments d3 of formula (B-b) is 1. In certain embodiments d3 of formula (B-b) is 2. In certain embodiments d3 of formula (B-b) is 3. In certain embodiments d3 of formula (B-b) is 4. In certain embodiments d3 of formula (B-b) is 5. In certain embodiments d3 of formula (B-b) is 6. In certain embodiments -R of formula (B-b) is -H. In certain embodiments -R of formula (B- b) is of methyl.Ascendis Pharma A / S 117 CPX75146PC09 July 2025In certain embodiments -LE- is of formula (B-b), in which d1 is 2, d2 is 2, d3 is 5 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 2, d2 is 2, d3 is 5 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 2, d2 is 3, d3 is 5 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 3, d2 is 3, d3 is 5 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 2, d2 is 2, d3 is 6 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 2, d2 is 2, d3 is 6 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 2, d2 is 3, d3 is 6 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 3, d2 is 3, d3 is 6 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 2, d2 is 2, d3 is 4 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 2, d2 is 2, d3 is 4 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 2, d2 is 3, d3 is 4 and -R is -H.In certain embodiments -LE- is of formula (B-b), in which d1 is 3, d2 is 3, d3 is 4 and -R is -H.In certain embodiments -POL- of formula (B) is a polymeric moiety with a molecular weightof at least 3 kDa, at least 3.5 kDa, at least 4 kDa, at least 4.5 kDa or at least 5 kDa. In certainembodiments the molecular weight of -POL- of formula (B) is less than 100 kDa. In certainembodiments the molecular weight of -POL- of formula (B) is less than 80 kDa. In certainembodiments the molecular weight of -POL- of formula (B) is less than 60 kDa. In certainembodiments the molecular weight of -POL- of formula (B) is less than 40 kDa. In certainembodiments the molecular weight of -POL- of formula (B) is less than 30 kDa. In certainembodiments the molecular weight of -POL- of formula (B) is less than 20 kDa. In certainembodiments the molecular weight of -POL- of formula (B) ranges from 1 kDa to 80 kDa. Incertain embodiments the molecular weight of -POL- of formula (B) ranges from 2 kDa to 60kDa. In certain embodiments the molecular weight of -POL- of formula (B) ranges from 2.5kDa to 50 kDa. In certain embodiments the molecular weight of -POL- of formula (B) rangesfrom 3 kDa to 40 kDa. In certain embodiments the molecular weight of -POL- of formula (B)ranges from 4 kDa to 30 kDa. In certain embodiments the molecular weight of -POL- offormula (B) ranges from 4 kDa to 20 kDa. In certain embodiments the molecular weightof -POL- of formula (B) ranges from 4 kDa to 15 kDa. In certain embodiments the molecularweight of -POL- of formula (B) has a molecular weight of about 2 kDa. In certain embodimentsthe molecular weight of -POL- of formula (B) has a molecular weight of about 2.5 kDa. Incertain embodiments the molecular weight of -POL- of formula (B) has a molecular weight ofabout 3 kDa. In certain embodiments the molecular weight of -POL- of formula (B) has amolecular weight of about 3.5 kDa. In certain embodiments the molecular weight of -POL- ofAscendis Pharma A / S 118 CPX75146PC09 July 2025formula (B) has a molecular weight of about 4 kDa. In certain embodiments the molecularweight of -POL- of formula (B) has a molecular weight of about 5 kDa. In certain embodimentsthe molecular weight of -POL- of formula (B) has a molecular weight of about 6 kDa. In certainembodiments the molecular weight of -POL- of formula (B) has a molecular weight of about 7kDa. In certain embodiments the molecular weight of -POL- of formula (B) has a molecularweight of about 8 kDa. In certain embodiments the molecular weight of -POL- of formula (B)has a molecular weight of about 9 kDa. In certain embodiments the molecular weightof -POL- of formula (B) has a molecular weight of about 10 kDa. In certain embodiments themolecular weight of -POL- of formula (B) has a molecular weight of about 11 kDa. In certainembodiments the molecular weight of -POL- of formula (B) has a molecular weight of about12 kDa. In certain embodiments the molecular weight of -POL- of formula (B) has a molecularweight of about 13 kDa. In certain embodiments the molecular weight of -POL- of formula (B)has a molecular weight of about 14 kDa. In certain embodiments the molecular weightof -POL- of formula (B) has a molecular weight of about 15 kDa. In certain embodiments themolecular weight of -POL- of formula (B) has a molecular weight of about 16 kDa. In certainembodiments the molecular weight of -POL- of formula (B) has a molecular weight of about17 kDa. In certain embodiments the molecular weight of -POL- of formula (B) has a molecularweight of about 18 kDa. In certain embodiments the molecular weight of -POL- of formula (B)has a molecular weight of about 19 kDa In certain embodiments the molecular weightof -POL- of formula (B) has a molecular weight of about 20 kDa.Applicant surprisingly found that the presence of suitable distance between -AB1 and -AB2,such as the distance provided by a moiety -POL-, allows for the binding of two different albumin molecules. This is advantageous, because the ability to bind to two different albumins increases the likelihood that the compound of formula (Ia) or (Ib) is bound to at least one albumin and thus increases circulation half-life.In certain embodiments -POL- comprises a polymer selected from the group consisting ofpoly(2-methacryloyl-oxyethyl phosphoyl cholins), poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(glycolic acids),Ascendis Pharma A / S 119 CPX75146PC09 July 2025poly(hydroxyethyl acrylates), poly(hydroxyethyl-oxazolines), poly(hydroxymethacrylates), poly(hydroxypropylmethacrylamides), poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines), poly(iminocarbonates), poly(lactic acids), poly(lactic-co- glycolic acids), poly(methacrylamides), poly(methacrylates), poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters), poly(oxazolines), poly(propylene glycols), poly(siloxanes), poly(urethanes), poly(vinyl alcohols), poly(vinyl amines), poly(vinylmethylethers), poly(vinylpyrrolidones), silicones, celluloses, carbomethyl celluloses, hydroxypropyl methylcelluloses, chitins, chitosans, dextrans, dextrins, gelatins,hyaluronic acids and derivatives, functionalized hyaluronic acids, alginate, mannans, pectins,rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches and other carbohydrate-based polymers, xylans and copolymers thereof.In certain embodiments -POL- of formula (B) is a PEG-based polymer.In certain embodiments -POL- of formula (B) is of formula (XII-i) wherein y is an integer ranging from 2 to 1000. In certain embodiments y of formula (XII-i) is an integer ranging from 68 to 1000. In certainembodiments y of formula (XII-i) is an integer ranging from 79 to 800. In certain embodimentsy of formula (XII-i) is an integer ranging from 90 to 600. In certain embodiments y of formula(XII-i) is an integer ranging from 102 to 500. In certain embodiments y of formula (XII-i) isan integer ranging from 113 to 450. In certain embodiments y of formula (XII-i) is selected such that the molecular weightof -POL- is about 3 kDa. In certain embodiments y of formula (XII-i) is selected such that themolecular weight of -POL- is about 3.5 kDa. In certain embodiments y of formula (XII-i) isselected such that the molecular weight of -POL- is about 4 kDa. In certain embodiments y offormula (XII-i) is selected such that the molecular weight of -POL- is about 4.5 kDa. In certainembodiments y of formula (XII-i) is selected such that the molecular weight of -POL- is about5 kDa. In certain embodiments y of formula (XII-i) is selected such that the molecular weightof -POL- is about 6 kDa. In certain embodiments y of formula (XII-i) is selected such that theAscendis Pharma A / S 120 CPX75146PC09 July 2025molecular weight of -POL- is about 7 kDa. In certain embodiments y of formula (XII-i) isselected such that the molecular weight of -POL- is about 8 kDa. In certain embodiments y offormula (XII-i) is selected such that the molecular weight of -POL- is about 9 kDa. In certainembodiments y of formula (XII-i) is selected such that the molecular weight of -POL- is about10 kDa. In certain embodiments y of formula (XII-i) is selected such that the molecular weightof -POL- is about 11 kDa. In certain embodiments y of formula (XII-i) is selected such that themolecular weight of -POL- is about 12 kDa. In certain embodiments y of formula (XII-i) isselected such that the molecular weight of -POL- is about 13 kDa. In certain embodiments y offormula (XII-i) is selected such that the molecular weight of -POL- is about 14 kDa. In certainembodiments y of formula (XII-i) is selected such that the molecular weight of -POL- is about15 kDa. In certain embodiments y of formula (XII-i) is selected such that the molecular weightof -POL- is about 20 kDa. In certain embodiments y of formula (XII-i) is selected such that themolecular weight of -POL- is about 25 kDa. In certain embodiments y of formula (XII-i) isselected such that the molecular weight of -POL- is about 30 kDa. In certain embodiments y offormula (XII-i) is selected such that the molecular weight of -POL- is about 40 kDa.In certain embodiments -L2- is of formula (XII-ii) wherein the dashed line marked with the asterisk indicates attachment to -L1-; the unmarked dashed line indicates attachment to -AB1; a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15; b is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15; c is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15; x ranges from 2 to 1000; -R1and -R2are independent of each other selected from the group consisting of -H and C1-6 alkyl.In certain embodiments x of formula (XII-ii) is about 68. In certain embodiments x of formula(XII-ii) is about 79. In certain embodiments x of formula (XII-ii) is about 90. In certain embodiments x of formula (XII-ii) is about 102. In certain embodiments x of formula (XII-ii)Ascendis Pharma A / S 121 CPX75146PC09 July 2025is about 113. In certain embodiments x of formula (XII-ii) is about 136. In certain embodiments x of formula (XII-ii) is about 160. In certain embodiments x of formula (XII-ii) is about 182. In certain embodiments x of formula (XII-ii) is about 204. In certain embodiments x of formula (XII-ii) is about 227. In certain embodiments x of formula (XII-ii) is about 250. In certain embodiments x of formula (XII-ii) is about 340. In certain embodiments x of formula (XII-ii) is about 455. In certain embodiments x of formula (XII-ii) is about 910. In certain embodiments x of formula (XII-ii) ranges from 23 to 910, from 45 to 600, from 65to 500, from 79 to 450, from 90 to 350 or from 100 to 280.In certain embodiments a of formula (XII-ii) is 1. In certain embodiments a of formula (XII-ii) is 2. In certain embodiments a of formula (XII-ii) is 3. In certain embodiments a of formula (XII-ii) is 4. In certain embodiments a of formula (XII-ii) is 5. In certain embodiments a of formula (XII-ii) is 6. In certain embodiments a of formula (XII-ii) is 7. In certain embodiments a of formula (XII-ii) is 8. In certain embodiments a of formula (XII-ii) is 9. In certain embodiments a of formula (XII-ii) is 10. In certain embodiments a of formula (XII-ii) is 11. Incertain embodiments a of formula (XII-ii) is 12. In certain embodiments a of formula (XII-ii)is 13. In certain embodiments a of formula (XII-ii) is 14. In certain embodiments a of formula (XII-ii) is 15. In certain embodiments b of formula (XII-ii) is 1. In certain embodiments b of formula (XII- ii) is 2. In certain embodiments b of formula (XII-ii) is 3. In certain embodiments b of formula (XII-ii) is 4. In certain embodiments b of formula (XII-ii) is 5. In certain embodiments b of formula (XII-ii) is 6. In certain embodiments b of formula (XII-ii) is 7. In certain embodiments b of formula (XII-ii) is 8. In certain embodiments b of formula (XII-ii) is 9. In certain embodiments b of formula (XII-ii) is 10. In certain embodiments b of formula (XII-ii) is 11. Incertain embodiments b of formula (XII-ii) is 12. In certain embodiments b of formula (XII-ii)is 13. In certain embodiments b of formula (XII-ii) is 14. In certain embodiments b of formula (XII-ii) is 15. In certain embodiments c of formula (XII-ii) is 1. In certain embodiments c of formula (XII-ii) is 2. In certain embodiments c of formula (XII-ii) is 3. In certain embodiments c of formula (XII-ii) is 4. In certain embodiments c of formula (XII-ii) is 5. In certain embodiments c of formula (XII-ii) is 6. In certain embodiments c of formula (XII-ii) is 7. In certain embodimentsAscendis Pharma A / S 122 CPX75146PC09 July 2025c of formula (XII-ii) is 8. In certain embodiments c of formula (XII-ii) is 9. In certain embodiments c of formula (XII-ii) is 10. In certain embodiments c of formula (XII-ii) is 11. In certain embodiments c of formula (XII-ii) is 12. In certain embodiments c of formula (XII-ii) is 13. In certain embodiments c of formula (XII-ii) is 14. In certain embodiments c of formula (XII-ii) is 15. In certain embodiments -R1of formula (XII-ii) is -H. In certain embodiments -R1of formula (XII-ii) is methyl. In certain embodiments -R1of formula (XII-ii) is ethyl. In certain embodiments -R1of formula (XII-ii) is propyl. In certain embodiments -R1of formula (XII-ii) is isopropyl.In certain embodiments -R2 of formula (XII-ii) is -H. In certain embodiments -R2 of formula(XII-ii) is methyl. In certain embodiments -R2of formula (XII-ii) is ethyl. In certain embodiments -R2of formula (XII-ii) is propyl. In certain embodiments -R2of formula (XII-ii) is isopropyl. In certain embodiments a of formula (XII-ii) is 5, b of formula (XII-ii) is 2, c of formula (XII- ii) is 2, and both -R1and -R2of formula (XII-ii) are -H. In certain embodiments a of formula (XII-ii) is 5, b of formula (XII-ii) is 2, c of formula (XII-ii) is 2, and both -R1and -R2of formula(XII-ii) are -H and x of formula (XII-ii) ranges from 79 to 340. In certain embodiments a offormula (XII-ii) is 5, b of formula (XII-ii) is 2, c of formula (XII-ii) is 2, and both -R1and -R2of formula (XII-ii) are -H and x of formula (XII-ii) is about 113. In certain embodiments the compound is of formula (XIII) a is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24; n is an integer ranging from 2 to 1000; the dashed line indicates attachment to a moietyAscendis Pharma A / S 123 CPX75146PC09 July 2025 , wherein the unmarked dashed line indicates attachment to the dashed line in formula (XIII); the dashed line marked with the asterisk indicates attachment to -D-; and e1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14.In certain embodiments n of formula (XIII) ranges from 68 to 900. In certain embodiments nof formula (XIII) ranges from 79 to 680. In certain embodiments n of formula (XIII) rangesfrom 90 to 450. In certain embodiments n of formula (XIII) ranges from 90 to 400. In certainembodiments n of formula (XIII) ranges from 90 to 300. In certain embodiments n of formula(XIII) is about 115. In certain embodiments n of formula (XIII) is about 160. In certainembodiments n of formula (XIII) is about 230. In certain embodiments n of formula (XIII) isabout 300. In certain embodiments n of formula (XIII) is about 350. In certain embodiments n of formula (XIII) is about 400. In certain embodiments n of formula (XIII) is about 450. In certain embodiments n of formula (XIII) is 14. In certain embodiments n of formula (XIII) is 15. In certain embodiments n of formula (XIII) is 16. In certain embodiments n of formula (XIII) is 17. In certain embodiments n of formula (XIII) is 18. In certain embodiments n of formula (XIII) is 19. In certain embodiments n of formula (XIII) is 20. In certain embodimentsn of formula (XIII) is 21. In certain embodiments n of formula (XIII) is 22. In certainembodiments n of formula (XIII) is 23. In certain embodiments n of formula (XIII) is 24. In certain embodiments e1 of formula (XIII) is 1. In certain embodiments e1 of formula (XIII) is 2. In certain embodiments e1 of formula (XIII) is 3. In certain embodiments e1 of formula (XIII) is 4. In certain embodiments e1 of formula (XIII) is 5. In certain embodiments e1 of formula (XIII) is 6. In certain embodiments e1 of formula (XIII) is 7. In certain embodiments e1 of formula (XIII) is 8. In certain embodiments e1 of formula (XIII) is 9. In certain embodiments e1 of formula (XIII) is 10. In certain embodiments e1 of formula (XIII) is 11. InAscendis Pharma A / S 124 CPX75146PC09 July 2025certain embodiments e1 of formula (XIII) is 12. In certain embodiments e1 of formula (XIII) is 13. In certain embodiments e1 of formula (XIII) is 14.In certain embodiments -D- or -D-AB2 of formula (XIII) is a GLP-1 receptor agonist. In certainembodiments -D- or -D-AB2 is a dual GLP-1 receptor agonist. In certainembodiments -D- or -D-AB2 is a triple GLP-1 receptor agonist. Embodiments for the GLP-1receptor agonist, the dual GLP-1 receptor agonist and the triple GLP-1 receptor agonist are as described elsewhere herein. In certain embodiments the compound is of formula (XIII), wherein a is 18, e1 is 5, n is approx. 108 and the dashed line marked with the asterisk indicates attachment to the N-terminal amine functional group of semaglutide. In certain embodiments the compound is of formula (XIII), wherein a is 16, e1 is 5, n is approx. 108 and the dashed line marked with the asterisk indicates attachment to the N-terminal amine functional group of semaglutide.In certain embodiments the molecular weight of the moiety AB1-L2-L1- ranges from 1 kDa to30 kDa. In certain embodiments the molecular weight of the moiety AB1-L2-L1- ranges from2 kDa to 20 kDa. In certain embodiments the molecular weight of the moiety AB1-L2-L1- rangesfrom 3 kDa to 15 kDa. In certain embodiments the molecular weight of the moietyAB1-L2-L1- ranges from 4 kDa to 12 kDa.In another aspect the present invention relates to a pharmaceutical composition comprising atleast one compound of the present invention or a pharmaceutically acceptable salt thereof andat least one excipient. In certain embodiments the pharmaceutical composition comprises the at least one compoundof the present invention or a pharmaceutically acceptable salt thereof in a concentration of atleast 0.1 mg / ml, based on the molecular weight of -D-AB2.In certain embodiments the pharmaceutical composition has a pH ranging from pH 3 to pH 9.Ascendis Pharma A / S 125 CPX75146PC09 July 2025In certain embodiments such pharmaceutical composition is injectable through a 25 or highergauge (G) needle. In certain embodiments such pharmaceutical composition is injectablethrough a 25 G needle. In certain embodiments such pharmaceutical composition is injectablethrough a 26 G needle. In certain embodiments such pharmaceutical composition is injectablethrough a 27 G needle. In certain embodiments such pharmaceutical composition is injectablethrough a 28 G needle. In certain embodiments such pharmaceutical composition is injectablethrough a 29 G needle. In certain embodiments such pharmaceutical composition is injectablethrough a 30 G needle. In certain embodiments such pharmaceutical composition is injectablethrough a 31 G needle. In certain embodiments such pharmaceutical composition is injectablethrough a 32 G needle.In another aspect the present invention relates to a compound of the present invention or apharmaceutically acceptable salt thereof or a pharmaceutical composition of the presentinvention for use as a medicament. In certain embodiments the medicament is administeredevery 2, every 3, every 4, every 5, every 6, every 7 or every 8 weeks. In certain embodiments such medicament comprises at least one additional drug. In certain embodiments suchmedicament is for a co-treatment with at least one additional drug.The present invention also relates to a compound or its pharmaceutically acceptable salt thereofor a pharmaceutical composition of the present invention for use in the manufacture of a medicament. In certain embodiments the medicament is administered every 2, every 3, every 4, every 5, every 6, every 7 or every 8 weeks. In certain embodiments such medicament comprises at least one additional drug. In certain embodiments such medicament is for a co- treatment with at least one additional drug. Such medicament may be used in the treatment or prevention of a disease that can be treated or prevented with H-D-AB2.Another aspect of the present invention relates to a compound of the present invention or apharmaceutically acceptable salt thereof or a pharmaceutical composition comprising saidcompound of the present invention for use in a method of treating or preventing a disease thatcan be treated or prevented with H-D-AB2or its pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutically active compounds.Ascendis Pharma A / S 126 CPX75146PC09 July 2025In another aspect the present invention relates to a method of treating a patient having a disease that can be treated or prevented with H-D-AB2, wherein the method comprises the step ofadministering a pharmaceutically acceptable amount of a compound or a pharmaceuticallyacceptable salt thereof or a pharmaceutical composition of the present invention to a patient in need thereof, optionally in combination with one or more additional therapeutically active compounds. Administration of a compound, a pharmaceutically acceptable salt thereof or a pharmaceuticalcomposition of the present invention may be via external application, injection or infusion,including intraarticular, periarticular, intradermal, subcutaneous, intramuscular, intravenous, intraosseous, intraperitoneal, intrathecal, intracapsular, intraorbital, intravitreal, intratympanic, intravesical, intracardiac, transtracheal, subcuticular, subcapsular, subarachnoid, intraspinal, intraventricular, intrasternal injection and infusion; direct delivery to the brain via implanted device allowing delivery of the invention or the like to brain tissue or brain fluids (e.g., Ommaya Reservoir), direct intracerebroventricular injection or infusion, injection or infusion into brain or brain associated regions, injection into the subchoroidal space, retro-orbital injection and ocular instillation. In certain embodiments the medicament is for subcutaneous injection, which may be done with a pen injector or via a syringe.A compound, in which -D- or -D-AB2 is a GLP-1 receptor agonist moiety or itspharmaceutically acceptable salt thereof or a pharmaceutical composition comprising such compound may be used in the treatment or prevention of a disease selected from the group consisting of (i) all forms of diabetes, (ii) obesity, (iii) non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), (iv) cardiovascular disease, (v) neurodegenerative disorders, (vi) chronic kidney disease (CKD), (vii) diabetic kidney disease (DKD), (viii) peripheral arterial disease (PAD), and / or (ix) heart failure (HF). Exemplary cardiovascular diseases may be selected from the group consisting of syndrome X, atherosclerosis, myocardial infarction, coronary heart disease, reperfusion injury, stroke,cerebral ischemia, an early cardiac or early cardiovascular disease, left ventricular hypertrophy,coronary artery disease, hypertension, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise intolerance, acute and / or chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, angina pectoris, cardiac bypass and / or stent reocclusion, intermittent claudication (atheroschlerosis oblitterens), diastolic dysfunction,Ascendis Pharma A / S 127 CPX75146PC09 July 2025and / or systolic dysfunction; and reduction of blood pressure, such as reduction of systolic blood pressure.A compound, in which -D- or -D-AB2 is a GLP-1 receptor agonist moiety or itspharmaceutically acceptable salt thereof or a pharmaceutical composition comprising such compound may be used in the treatment or prevention of a disease selected from the group consisting of dyslipidemia and / or diseases where one or more of the following clinical outcomes are the treatment goal: lowering total serum lipids; increasing HDL; lowering small,dense LDL; lowering VLDL; lowering triglycerides; lowering cholesterol; lowering plasmalevels of lipoprotein a (Lp(a)) in a human; inhibiting generation of apolipoprotein A (apo(A)). Exemplary neurodegenerative disorders may be selected from the group consisting of Alzheimer´s disease and Parkinson´s disease. Exemplary forms of HF may be selected from the group consisting of heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF).A compound, in which -D- or -D-AB2 is a GLP-1 receptor agonist moiety or itspharmaceutically acceptable salt thereof or a pharmaceutical composition comprising such compound may be used for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).A compound, in which -D- or -D-AB2 is a GLP-1 receptor agonist moiety or itspharmaceutically acceptable salt thereof or a pharmaceutical composition comprising suchcompound may in certain embodiments be used for the treatment of a disease selected from thegroup consisting of obesity and eating disorders, where one or more of the following clinical outcomes are the treatment goal: decreasing food intake, increasing energy expenditure, reducing body weight, suppressing appetite, inducing satiety.A compound, in which -D- or -D-AB2 is a GLP-1 receptor agonist moiety or itspharmaceutically acceptable salt thereof or a pharmaceutical composition comprising suchcompound may also be combined with one or more additional drugs, such as drugs selectedfrom cardiovascular agents, antidiabetic agents, and / or anti-obesity agents. Examples of theseAscendis Pharma A / S 128 CPX75146PC09 July 2025pharmacologically active substances are: inotropes, beta adrenergic receptor blockers, HMG-CoA reductase inhibitors, angiotensin II receptor antagonists, angiotensin converting enzymeinhibitors, calcium channel blockers, endothelin antagonists, renin inhibitors, diuretics,aldosterone receptor blockers, endothelin receptor blockers, aldosterone synthase inhibitors,CETP inhibitor, relaxin, PCSK9 inhibitors, BNP and NEP inhibitors, GLP-1 analogues,insulin, sulphonylureas, biguanides, meglitinides, glucosidase inhibitors, glucagon antagonists,DPP-IV inhibitors, SGLT2 inhibitors. The treatment with the compound or pharmaceuticallyits pharmaceutically acceptable salt or the pharmaceutical composition of the present invention may also be combined with heart surgery.A compound, in which -D- or -D-AB2 is a GLP-1 receptor agonist, or its pharmaceuticallyacceptable salt thereof or a pharmaceutical composition of the present invention may also beadministered in combination with a growth hormone, such as a human growth hormone. Such human growth hormone may be in the form of an unmodified drug, such as the human growth hormone of SEQ ID NO:58, or as a conjugate or complex comprising human growth hormone.Suitably, the compound, in which - D-AB2 is a GLP-1 receptor agonist, is administered to apatient in a co-treatment with lonapegsomatropin, which has the following structure: , wherein D is a human growth hormone polypeptide of SEQ ID NO:58 connected to the rest of the molecule through an amine functional group provided by a lysine side chain; and each p1, p2, p3, p4 is independently an integer ranging from 210 to 240. SEQ ID NO:58 has the following sequence:Ascendis Pharma A / S 129 CPX75146PC09 July 2025FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIP TPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDL EEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKV ETFLRIVQCRSVEGSCGFFurther growth hormone compounds for the cotreatment with a compound as disclosed herein,in which -D- or -D-AB2 is a GLP-1 receptor agonist, are somapacitan and somatrogon.In such co-treatment the compound, in which -D-AB2is a GLP-1 receptor agonist, may be administered prior to, at the same time or after administration of the unmodified human growth hormone, the conjugate or complex comprising human growth hormone.A compound or its pharmaceutically acceptable salt thereof or a pharmaceutical compositionof the present invention may be administered, such as via subcutaneous administration, once a week, every two weeks, every three weeks or once a month.In certain embodiments a compound or its pharmaceutically acceptable salt thereof or apharmaceutical composition of the present invention may be administered once a week, every two weeks, every three weeks or once a month.In another aspect the present invention relates to a prefilled container comprising one or moreof the compounds of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising one or more of the compounds of formula (Ia) or (Ib)a or a pharmaceutically acceptable salt thereof s described herein. The container may forexample be a syringe, a vial, a bottle, a pouch, a carpule or an ampoule. Suitable materials forsuch a container are, for example, glass or plastic. Such a container may be sealable by asuitable closure system. For example, a vial may be closed with a screw cap; a stopper of cork,plastic or rubber; a flip-top or a snap cap. A prefilled syringe typically has two openings thatare suitably sealed to prevent leakage of the content, such as, for example, by a plunger orplunger stopper at one end and by, for example, a cap at the other end.As used herein, the term “prefilled container” refers to a container, such as a syringe, vial,bottle, pouch, carpule or ampoule, which has a partially or fully enclosed space that can beAscendis Pharma A / S 130 CPX75146PC09 July 2025sealed or is sealed and that can be used to contain, store and / or transport a drug or pharmaceutical composition. Another aspect is a kit of parts comprising at least one compound or a pharmaceuticallyacceptable salt thereof, at least one pharmaceutical composition or at least one prefilledcontainer as described herein and optionally instructions for use in a packaging, such as a boxor pouch. In another aspect the present invention relates to a kit comprising the pharmaceuticalcomposition as described herein and instructions for use. In some embodiments the instructionsfor use comprise the package insert of a drug. In another aspect the present invention relates to a kit comprising the pharmaceuticalcomposition as described herein and an injection device.The invention is further described by the following non-limiting items.1. A compound or a pharmaceutically acceptable salt thereof of formula (Ia) or (Ib) wherein each -D- is independently a drug moiety;each -AB1and -AB2is independently an albumin-binding moiety; each -L1- is independently a linker moiety covalently and reversibly connected to -D-;each -L2- is independently a spacer moiety;x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25; and y is an integer selected from the group consisting of 2, 3, 4 and 5.2. The compound of item 1, wherein the compound is of formula (Ia).3. The compound of item 1 or 2, wherein x of formula (Ia) is 1.4. The compound of item 1 or 2, wherein x of formula (Ia) is 2.5. The compound of item 1 or 2, wherein x of formula (Ia) is 3.6. The compound of item 1 or 2, wherein x of formula (Ia) is 4.7. The compound of item 1, wherein the compound is of formula (Ib).Ascendis Pharma A / S 131 CPX75146PC09 July 20258. The compound of item 1 or 7, wherein y of formula (Ib) is 2.9. The compound of item 1 or 7, wherein y of formula (Ib) is 3.10. The compound of item 1 or 7, wherein y of formula (Ib) is 4.11. The compound of any one of items 1 to 10, wherein -L1- is of formula (II).12. The compound of item 11, wherein -R1 and R1a of formula (II) are both -H.13. The compound of item 11, wherein -R1 of formula (II) is -H and R1a of formula (II) ismethyl.14. The compound of item 11, wherein -R1 and R1a of formula (II) are both methyl.15. The compound of any one of items 11 to 14, wherein -R2 and R2a of formula (II) areboth -H.16. The compound of any one of items 11 to 14, wherein -R2 of formula (II) is -H and R2aof formula (II) is methyl.17. The compound of any one of items 11 to 14, wherein -R2 and R2a of formula (II) areboth methyl.18. The compound of any one of items 11 to 17, wherein -R3 and R3a of formula (II) areboth -H.19. The compound of any one of items 11 to 17, wherein -R3 of formula (II) is -H and R3aof formula (II) is methyl.20. The compound of any one of items 11 to 17, wherein -R3 and R3a of formula (II) areboth methyl.21. The compound of any one of items 11 to 20, wherein -R4 of formula (II) is -H.22. The compound of any one of items 11 to 20, wherein -R4 of formula (II) is methyl.23. The compound of any one of items 11 to 22, wherein -R4a of formula (II) is -H.24. The compound of any one of items 11 to 22, wherein -R4a of formula (II) is methyl.25. The compound of any one of items 11 to 24, wherein -R5 and-R5a of formula (II) areboth -H.26. The compound of any one of items 11 to 24, wherein -R5 and-R5a of formula (II) areboth methyl.27. The compound of any one of items 11 to 24, wherein -R5 of formula (II) is -H and-R5aof formula (II) is methyl.28. The compound of any one of items 11 to 27, wherein -R6 of formula (II) is -H.29. The compound of any one of items 11 to 27, wherein -R6 of formula (II) is methyl.30. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -C(R7R7a)-.31. The compound of any one of items 11 to 30, wherein -R7 of formula (II) is -N(R10R10a).Ascendis Pharma A / S 132 CPX75146PC09 July 202532. The compound of any one of items 11 to 30, wherein -R7 of formula (II) is -NR10-(C=O)-R11.33. The compound of item 31 or 32, wherein -R10 of formula (II) is -H.34. The compound of item 31 or 32, wherein -R10 of formula (II) is methyl.35. The compound of item 31, wherein -R10a of formula (II) is -H.36. The compound of item 31, wherein -R10a of formula (II) is methyl.37. The compound of item 32, wherein -R11 of formula (II) is -H.38. The compound of item 32, wherein -R11 of formula (II) is methyl.39. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -C(R4R4a)-.40. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -C(R4R4a)-C(R5R5a)-.41. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -C(R5R5a)-C(R4R4a)-.42. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -N(R4)-.43. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -C(R4R4a)-N(R6)-.44. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -N(R6)-C(R4R4a)-.45. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -C(R4R4a)-O-.46. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -O-C(R4R4a)-.47. The compound of any one of items 11 to 29, wherein -X- of formula (II) is -O-.48. The compound of any one of items 11 to 47, wherein X1 of formula (II) is C.49. The compound of any one of items 11 to 47, wherein X1 of formula (II) is S(O).50. The compound of any one of items 11 to 49, wherein =X3 of formula (II) is =O.51. The compound of any one of items 11 to 49, wherein =X3 of formula (II) is =S.52. The compound of any one of items 11 to 49, wherein =X3 of formula (II) is =N-CN.53. The compound of any one of items 11 to 52, wherein -R1 of formula (II) is -H, whichis substituted with -L2-.54. The compound of any one of items 11 to 52, wherein -R1a of formula (II) is -H, whichis substituted with -L2-.55. The compound of any one of items 11 to 52, wherein -R2 of formula (II) is -H, whichis substituted with -L2-.Ascendis Pharma A / S 133 CPX75146PC09 July 202556. The compound of any one of items 11 to 52, wherein -R2a of formula (II) is -H, whichis substituted with -L2-.57. The compound of any one of items 11 to 52, wherein -R3 of formula (II) is -H, whichis substituted with -L2-.58. The compound of any one of items 11 to 52, wherein -R3a of formula (II) is -H, whichis substituted with -L2-.59. The compound of any one of items 39 to 46 or 48 to 52, wherein -R4 of formula (II)is -H, which is substituted with -L2-.60. The compound of any one of items 39 to 41, 43 to 46 or 48 to 52, wherein -R4a offormula (II) is -H, which is substituted with -L2-.61. The compound of item 40 or 41 or 48 to 52, wherein -R5 of formula (II) is -H, which issubstituted with -L2-.62. The compound of item 40 or 41 or 48 to 52, wherein -R5a of formula (II) is -H, whichis substituted with -L2-.63. The compound of any one of items 43, 44 or 48 to 52, wherein -R6 of formula (II) is -H,which is substituted with -L2-.64. The compound of any one of items 1 to 10, wherein -L1- is formula (IIa).65. The compound of any one of items 1 to 10, wherein -L1- is formula (IIa-a).66. The compound of any one of items 1 to 10, wherein -L1- is formula (IIa-b).67. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab).68. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-a).69. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-b).70. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-c).71. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-ci).72. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-cii).73. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-d).74. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-di).75. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-dii).76. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-e).77. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-ei).78. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-eii).79. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-f).80. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-fi).81. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-fii).Ascendis Pharma A / S 134 CPX75146PC09 July 202582. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-g).83. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-gi).84. The compound of any one of items 1 to 10, wherein -L1- is formula (IIab-gii).85. The compound of any one of items 1 to 10, wherein -L1- is of formula (III).86. The compound of any one of items 1 to 10, wherein -L1- is of formula (IV).87. The compound of any one of items 1 to 10, wherein -L1- is of formula (V).88. The compound of any one of items 1 to 10, wherein -L1- is of formula (VI) or of formula(VII).89. The compound of any one of items 1 to 10, wherein -L1- is of formula (VIII).90. The compound of any one of items 1 to 10, wherein -L1- is of formula (IX).91. The compound of any one of items 1 to 10, wherein -L1- is of formula (X).92. The compound of any one of items 1 to 10, wherein -L1- is of formula (XIIa).93. The compound of item 92, wherein both -R4 and -R8 of formula (XIIa) are -H.94. The compound of item 92, wherein both -R4 and -R8 of formula (XIIa) are methyl.95. The compound of item 92, wherein -R4 is -H and -R8 of formula (XIIa) is -H.96. The compound of any one of items 92 to 95, wherein -R3 of formula (XIIa) is -H.97. The compound of any one of items 95 to 95, wherein -R3 of formula (XIIa) is methyl.98. The compound of item 92, wherein -R3 and -R4 of formula (XIIa) together with theatoms to which they are attached form a 5- or 6-membered heterocyclic ring.99. The compound of any one of items 92 to 98, wherein -R2 of formula (XIIa) is -H.100. The compound of any one of items 1 to 10, wherein -L1- is of formula (XIIa-i).101. The compound of any one of items 1 to 10, wherein -L1- is of formula (XIIa-ii).102. The compound of any one of items 1 to 10, wherein -L1- is of formula (XIIa-iii).103. The compound of any one of items 1 to 10, wherein -L1- is of formula (XIIb).104. The compound of any one of items 1 to 104, wherein -L2- comprises a polymericmoiety.105. The compound of any one of items 1 to 104, wherein -L2- is a spacer moiety of formula(B) wherein the unmarked dashed line indicates attachment to -L1-; the dashed line marked with the asterisk indicates attachment to -AB1; -POL- is a polymeric moiety; andAscendis Pharma A / S 135 CPX75146PC09 July 2025-LD- and -LE- are independently absent or selected from the group consistingof -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry1)-, -S(O)2N(Ry1)-, -S(O)N(Ry1)-, -S(O)2-, -S(O)-, -N(Ry1)S(O)2N(Ry1a)-, -S-, -N(Ry1)-, -OC(ORy1)(Ry1a)-, -N(Ry1)C(O)N(Ry1a)-, -OC(O)N(Ry1)-, C1-50alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T-, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more -Ry2, which are the same or different and wherein C1-50alkyl, C2-50alkenyl, and C2-50alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry3)-, -S(O)2N(Ry3)-, -S(O)N(Ry3)-, -S(O)2-, -S(O)-, -N(Ry3)S(O)2N(Ry3a)-, -S-, -N(Ry3)-, -OC(ORy3)(Ry3a)-, -N(Ry3)C(O)N(Ry3a)-, and -OC(O)N(Ry3)-; -Ry1and -Ry1aare independently of each other selected from the group consisting of -H, -T, C1-50alkyl, C2-50alkenyl, and C2-50alkynyl; wherein -T, C1-50alkyl, C2-50alkenyl, and C2-50 alkynyl are optionally substituted with one or more -Ry2, which are the same or different, and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry4)-, -S(O)2N(Ry4)-, -S(O)N(Ry4)-, -S(O)2-, -S(O)-, -N(Ry4)S(O)2N(Ry4a)-, -S-, -N(Ry4)-, -OC(ORy4)(Ry4a)-, -N(Ry4)C(O)N(Ry4a)-, and -OC(O)N(Ry4)-; each T is independently selected from the group consisting of phenyl, naphthyl,indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more -Ry2, which are the same or different; each -Ry2is independently selected from the group consisting of halogen, -CN, oxo (=O), -COORy5, -ORy5, -C(O)Ry5, -C(O)N(Ry5Ry5a), -S(O)2N(Ry5Ry5a), -S(O)N(Ry5Ry5a), -S(O)2Ry5, -S(O)Ry5, -N(Ry5)S(O)2N(Ry5aRy5b), -SRy5, -N(Ry5Ry5a), -NO2, -OC(O)Ry5, -N(Ry5)C(O)Ry5a, -N(Ry5)S(O)2Ry5a, -N(Ry5)S(O)Ry5a, -N(Ry5)C(O)ORy5a, -N(Ry5)C(O)N(Ry5aRy5b), -OC(O)N(Ry5Ry5a), and C1-6alkyl; wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different; and each -Ry3, -Ry3a, -Ry4, -Ry4a, -Ry5, -Ry5aand -Ry5bis independently selected from the group consisting of -H, and C1-6alkyl, wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different.Ascendis Pharma A / S 136 CPX75146PC09 July 2025106. The compound of item 105, wherein -LD- and -LE- of formula (B) are independentlyselected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry1)- , -S(O)2N(Ry1)-, -S(O)N(Ry1)-, -S(O)2-, -S(O)-, -N(Ry1)S(O)2N(Ry1a)-, -S-, -N(Ry1)-, -OC(ORy1)(Ry1a)-, -N(Ry1)C(O)N(Ry1a)-, -OC(O)N(Ry1)-, C1-50 alkyl, C2-50 alkenyl, and C2-50alkynyl; wherein -T-, C1-20alkyl, C2-20alkenyl, and C2-20alkynyl are optionally substituted with one or more -Ry2, which are the same or different and wherein C1-20 alkyl, C2-20 alkenyl, and C2-20 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry3)-, -S(O)2N(Ry3)-, -S(O)N(Ry3)-, -S(O)2-, -S(O)-, -N(Ry3)S(O)2N(Ry3a)-, -S-, -N(Ry3)-, -OC(ORy3)(Ry3a)-, -N(Ry3)C(O)N(Ry3a)-, and -OC(O)N(Ry3)-; -Ry1and -Ry1aare independently of each other selected from the group consisting of -H, -T, C1-10 alkyl, C2-10 alkenyl, and C2-10 alkynyl; wherein -T, C1-10 alkyl, C2-10 alkenyl, and C2-10 alkynyl are optionally substituted with one or more -Ry2, which are the same or different, and wherein C1-10 alkyl, C2-10 alkenyl, and C2-10 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry4)-, -S(O)2N(Ry4)-, -S(O)N(Ry4)-, -S(O)2-, -S(O)-, -N(Ry4)S(O)2N(Ry4a)-, -S-, -N(Ry4)-, -OC(ORy4)(Ry4a)-, -N(Ry4)C(O)N(Ry4a)-, and -OC(O)N(Ry4)-; each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more -Ry2, which are the same or different; -Ry2is selected from the group consisting of halogen, -CN, oxo (=O), -COORy5, -ORy5, -C(O)Ry5, -C(O)N(Ry5Ry5a), -S(O)2N(Ry5Ry5a), -S(O)N(Ry5Ry5a), -S(O)2Ry5, -S(O)Ry5, -N(Ry5)S(O)2N(Ry5aRy5b), -SRy5, -N(Ry5Ry5a), -NO2, -OC(O)Ry5, -N(Ry5)C(O)Ry5a, -N(Ry5)S(O)2Ry5a, -N(Ry5)S(O)Ry5a, -N(Ry5)C(O) ORy5a, -N(Ry5)C(O)N(Ry5aRy5b), -OC(O)N(Ry5Ry5a), and C1-6alkyl; wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different; and each -Ry3, -Ry3a, -Ry4, -Ry4a, -Ry5, -Ry5aand -Ry5bis independently of each other selected from the group consisting of -H, and C1-6alkyl; wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different.Ascendis Pharma A / S 137 CPX75146PC09 July 2025107. The compound of item 105 or 106, wherein -LD- and -LE- of formula (B) areindependently selected from the group consisting of-T-, -C(O)O-, -O-, -C(O)-, - C(O)N(Ry1)-, -S(O)2N(Ry1)-, -S(O)N(Ry1)-, -S(O)2-, -S(O)-, -N(Ry1)S(O)2N(Ry1a)-, -S-, -N(Ry1)-, -OC(ORy1)(Ry1a)-, -N(Ry1)C(O)N(Ry1a)-, -OC(O)N(Ry1)-, C1-50 alkyl, C2-50 alkenyl, and C2-50alkynyl; wherein -T-, C1-50alkyl, C2-50alkenyl, and C2-50alkynyl are optionally substituted with one or more -Ry2, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry3)-, -S(O)2N(Ry3)-, -S(O)N(Ry3)-, -S(O)2-, -S(O)-, -N(Ry3)S(O)2N(Ry3a)-, -S-, -N(Ry3)-, -OC(ORy3)(Ry3a)-, -N(Ry3)C(O)N(Ry3a)-, and -OC(O)N(Ry3)-; -Ry1and -Ry1aare independently selected from the group consisting of -H, -T, C1-10alkyl, C2-10 alkenyl, and C2-10 alkynyl; each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; each -Ry2is independently selected from the group consisting of halogen, and C1-6alkyl; and each -Ry3, -Ry3a, -Ry4, -Ry4a, -Ry5, -Ry5aand -Ry5bis independently of each other selected from the group consisting of -H, and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different.108. The compound of any one of items 105 to 107, wherein LD- and -LE- of formula (B) areindependently a C1-20 alkyl chain, which is optionally interrupted by one or more groups independently selected from -C(O)-, -N(Ry1)-, -O-, -S-, -T- and -C(O)N(Ry1)-; and which C1-20 alkyl chain is optionallysubstituted with one or more groups independently selected from halogen, -OH, -Tand -N(Ry1Ry1a); wherein -Ry1and -Ry1aare independently selected from the group consisting of H and C1-4alkyl and wherein T is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-memberedheterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl,and 8- to 30-membered heteropolycyclyl, which is optionally substituted with one ormore oxo (=O) or halogen.Ascendis Pharma A / S 138 CPX75146PC09 July 2025109. The compound of any one of items 105 to 108, wherein -LD- and -LE- of formula (B)have independently of each other a molecular weight in the range of from 14 g / mol to 750 g / mol.110. The compound of any one of items 105 to 109, wherein -LD- and -LE- of formula (B)independently comprise one or more moiety selected from the group consisting of , , , Ascendis Pharma A / S 139 CPX75146PC09 July 2025 wherein -R and -Raare independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2- dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl.111. The compound of any one of items 105 to 110, wherein -LD- and -LE- of formula (B)have independently a chain length of 1 to 20 atoms.112. The compound of any one of items 105 to 111, wherein -LD- and -LE- of formula (B)have independently a chain length of 2 to 10 atoms.113. The compound of item 105, wherein -LD- of formula (B) is absent.114. The compound of item 105, wherein -LD- of formula (B) is -N(Ry1)-, wherein -Ry1 is -H,methyl, ethyl, propyl or isopropyl.115. The compound of item 114, wherein -LD- of formula (B) is -NH-.116. The compound of item 114, wherein -LD- of formula (B) is -C(O)-.117. The compound of any one of items 105 or 113 to 116, wherein -LE- of formula (B) isabsent.118. The compound of any one of items 105 or 113 to 116, wherein -LE- of formula (B) isof formula (B-a).119. The compound of item 118, wherein d1 of formula (B-a) is 0.120. The compound of item 118, wherein d1 of formula (B-a) is 1.121. The compound of item 118, wherein d1 of formula (B-a) is 2.Ascendis Pharma A / S 140 CPX75146PC09 July 2025122. The compound of item 118, wherein d1 of formula (B-a) is 3.123. The compound of item 118, wherein d1 of formula (B-a) is 4.124. The compound of item 118, wherein d1 of formula (B-a) is 5.125. The compound of item 118, wherein d1 of formula (B-a) is 6.126. The compound of item 118, wherein d1 of formula (B-a) is 7.127. The compound of item 118, wherein d1 of formula (B-a) is 8.128. The compound of item 118, wherein d1 is 9.129. The compound of item 118, wherein d1 of formula (B-a) is 10.130. The compound of item 118, wherein d1 of formula (B-a) is 11.131. The compound of item 118, wherein d1 of formula (B-a) is 12.132. The compound of item 118, wherein d1 of formula (B-a) is 13.133. The compound of item 118, wherein d1 of formula (B-a) is 14.134. The compound of item 118, wherein d1 of formula (B-a) is 15.135. The compound of item 118, wherein d1 of formula (B-a) is 16.136. The compound of item 118, wherein d1 of formula (B-a) is 17.137. The compound of item 118, wherein d1 of formula (B-a) is 18.138. The compound of item 118, wherein d1 of formula (B-a) is 19.139. The compound of item 118, wherein d1 of formula (B-a) is 20.140. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 0.141. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 1.142. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 2.143. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 3.144. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 4.145. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 5.146. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 6.147. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 7.148. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 8.149. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 9.150. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 10.151. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 11.152. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 12.153. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 13.154. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 14.155. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 15.Ascendis Pharma A / S 141 CPX75146PC09 July 2025156. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 16.157. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 17.158. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 18.159. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 19.160. The compound of any one of items 118 to 139, wherein d2 of formula (B-a) is 20.161. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 0.162. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 1.163. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 2.164. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 3.165. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 4.166. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 5.167. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 6.168. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 7.169. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 8.170. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 9.171. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 10.172. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 11.173. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 12.174. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 13.175. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 14.176. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 15.177. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 16.178. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 17.179. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 18.180. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 19.181. The compound of any one of items 118 to 160, wherein d3 of formula (B-a) is 20.182. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e1).183. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e2).184. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e3).185. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e4).Ascendis Pharma A / S 142 CPX75146PC09 July 2025186. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e5).187. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e6).188. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e7).189. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e8).190. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e9).191. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e10).192. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e11).193. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e12).194. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e13).195. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e14).196. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e15).197. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e16).198. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e17).199. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e18)200. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e19).201. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e20).202. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e21).Ascendis Pharma A / S 143 CPX75146PC09 July 2025203. The compound of any one of items 118 to 181, wherein -Z1- of formula (B-a) is offormula (e22).204. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e1).205. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e2).206. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e3).207. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e4).208. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e5).209. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e6).210. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e7).211. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e8).212. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e9).213. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e10).214. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e11).215. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e12).216. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e13).217. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e14).218. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e15).219. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e16).Ascendis Pharma A / S 144 CPX75146PC09 July 2025220. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e17).221. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e18)222. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e19).223. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e20).224. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e21).225. The compound of any one of items 118 to 203, wherein -Z2- of formula (B-a) is offormula (e22).226. The compound of any one of items 105 or 113 to 116, wherein -LE- of formula (B) isis of formula (B-b).227. The compound of item 226, wherein d1 of formula (B-b) is 0.228. The compound of item 226, wherein d1 of formula (B-b) is 1.229. The compound of item 226, wherein d1 of formula (B-b) is 2.230. The compound of item 226, wherein d1 of formula (B-b) is 3.231. The compound of item 226, wherein d1 of formula (B-b) is 4.232. The compound of item 226, wherein d1 of formula (B-b) is 5.233. The compound of item 226, wherein d1 of formula (B-b) is 6.234. The compound of item 226, wherein d1 of formula (B-b) is 7.235. The compound of item 226, wherein d1 of formula (B-b) is 8.236. The compound of item 226, wherein d1 of formula (B-b) is 9.237. The compound of item 226, wherein d1 of formula (B-b) is 10.238. The compound of item 226, wherein d1 of formula (B-b) is 11.239. The compound of item 226, wherein d1 of formula (B-b) is 12.240. The compound of item 226, wherein d1 of formula (B-b) is 13.241. The compound of item 226, wherein d1 of formula (B-b) is 14.242. The compound of item 226, wherein d1 of formula (B-b) is 15.243. The compound of item 226, wherein d1 of formula (B-b) is 16.244. The compound of item 226, wherein d1 of formula (B-b) is 17.245. The compound of item 226, wherein d1 of formula (B-b) is 18.246. The compound of item 226, wherein d1 of formula (B-b) is 19.Ascendis Pharma A / S 145 CPX75146PC09 July 2025247. The compound of item 226, wherein d1 of formula (B-b) is 20.248. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 0.249. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 1.250. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 2.251. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 3.252. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 4.253. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 5.254. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 6.255. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 7.256. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 8.257. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 9.258. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 10.259. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 11.260. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 12.261. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 13.262. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 14.263. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 15.264. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 16.265. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 17.266. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 18.267. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 19.268. The compound of any one of items 226 to 247, wherein d2 of formula (B-b) is 20.269. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 0.270. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 1.271. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 2.272. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 3.273. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 4.274. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 5.275. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 6.276. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 7.277. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 8.278. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 9.279. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 10.280. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 11.Ascendis Pharma A / S 146 CPX75146PC09 July 2025281. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 12.282. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 13.283. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 14.284. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 15.285. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 16.286. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 17.287. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 18.288. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 19.289. The compound of any one of items 226 to 268, wherein d3 of formula (B-b) is 20.290. The compound of any one of items 226 to 289, wherein -R of formula (B-b) is -H.291. The compound of any one of items 226 to 289, wherein -R of formula (B-b) is methyl.292. The compound of any one of items 226 to 289, wherein -R of formula (B-b) is ethyl.293. The compound of any one of items 226 to 289, wherein -R of formula (B-b) is propyl.294. The compound of any one of items 226 to 289, wherein -R of formula (B-b) is isopropyl.295. The compound of any one of items 105 to 294, wherein -POL- of formula (B) is apolymeric moiety with a molecular weight of at least 3 kDa.296. The compound of any one of items 105 to 294, wherein -POL- of formula (B) is apolymeric moiety with a molecular weight of at least 3.5 kDa.297. The compound of any one of items 105 to 294, wherein -POL- of formula (B)is apolymeric moiety with a molecular weight of at least 4 kDa.298. The compound of any one of items 105 to 294, wherein -POL- of formula (B)is apolymeric moiety with a molecular weight of at least 4.5 kDa.299. The compound of any one of items 105 to 294, wherein -POL- of formula (B)is apolymeric moiety with a molecular weight of at least 5 kDa.300. The compound of any one of items 105 to 299, wherein the molecular weightof -POL- of formula (B) is less than 100 kDa.301. The compound of any one of items 105 to 299, wherein the molecular weightof -POL- of formula (B) is less than 80 kDa.302. The compound of any one of items 105 to 299, wherein the molecular weightof -POL- of formula (B) is less than 60 kDa.303. The compound of any one of items 105 to 299, wherein the molecular weightof -POL- of formula (B) is less than 40 kDa.304. The compound of any one of items 105 to 299, wherein the molecular weightof -POL- of formula (B) is less than 30 kDa.Ascendis Pharma A / S 147 CPX75146PC09 July 2025305. The compound of any one of items 105 to 299, wherein the molecular weightof -POL- of formula (B) is less than 20 kDa.306. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight ranging from 1 kDa to 80 kDa.307. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight ranging from 2 kDa to 60 kDa.308. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight ranging from 2.5 kDa to 50 kDa.309. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight ranging from 3 kDa to 40 kDa.310. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight ranging from 4 kDa to 30 kDa.311. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight ranging from 4 kDa to 20 kDa.312. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight ranging from 4 kDa to 15 kDa.313. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 2 kDa.314. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 2.5 kDa.315. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 3 kDa.316. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 3.5 kDa.317. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 4 kDa.318. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 4.5 kDa.319. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 5 kDa.320. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 6 kDa.321. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 7 kDa.Ascendis Pharma A / S 148 CPX75146PC09 July 2025322. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 8 kDa.323. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 9 kDa.324. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 10 kDa.325. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 11 kDa.326. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 12 kDa.327. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 13 kDa.328. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 14 kDa.329. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 15 kDa.330. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 16 kDa.331. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 17 kDa.332. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 18 kDa.333. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 19 kDa.334. The compound of any one of items 105 to 294, wherein -POL- of formula (B) has amolecular weight of about 20 kDa.335. The compound of any one of items 105 to 334, wherein -POL- of formula (B) comprisesa polymer selected from the group consisting of poly(2-methacryloyl-oxyethyl phosphoyl cholins), poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl phosphates),Ascendis Pharma A / S 149 CPX75146PC09 July 2025poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates), poly(hydroxyethyl-oxazolines), poly(hydroxymethacrylates), poly(hydroxypropylmethacrylamides), poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines), poly(iminocarbonates), poly(lactic acids), poly(lactic- co-glycolic acids), poly(methacrylamides), poly(methacrylates), poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters), poly(oxazolines), poly(propylene glycols), poly(siloxanes), poly(urethanes), poly(vinyl alcohols), poly(vinyl amines), poly(vinylmethylethers), poly(vinylpyrrolidones), silicones, celluloses, carbomethyl celluloses, hydroxypropyl methylcelluloses, chitins, chitosans, dextrans, dextrins, gelatins, hyaluronic acids and derivatives, functionalized hyaluronic acids, alginate, mannans, pectins, rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches and other carbohydrate-based polymers, xylans and copolymers thereof.336. The compound of any one of items 105 to 334, wherein -POL- of formula (B) is a PEG-based polymer.337. The compound of any one of items 105 to 334, wherein -POL- of formula (B) is ahyaluronic acid-based polymer.338. The compound of any one of items 105 to 336, wherein -POL- of formula (B) is offormula (XII-i).339. The compound of item 338, wherein y of formula (XII-i) is an integer ranging from 68to 1000.340. The compound of item 338, wherein y of formula (XII-i) is an integer ranging from 79to 800.341. The compound of item 338, wherein y of formula (XII-i) is an integer ranging from 90to 600.342. The compound of item 338, wherein y of formula (XII-i) is an integer ranging from 102to 500.343. The compound of item 338, wherein y of formula (XII-i) is an integer ranging from 113to 450.344. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 3 kDa.345. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 3.5 kDa.Ascendis Pharma A / S 150 CPX75146PC09 July 2025346. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 4 kDa.347. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 4.5 kDa.348. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 5 kDa.349. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 6 kDa.350. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 7 kDa.351. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 8 kDa.352. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 9 kDa.353. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 10 kDa.354. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 11 kDa.355. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 12 kDa.356. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 13 kDa.357. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 14 kDa.358. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 15 kDa.359. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 20 kDa.360. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 25 kDa.361. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 30 kDa.362. The compound of item 338, wherein y of formula (XII-i) is selected such that themolecular weight of -POL- is about 40 kDa.Ascendis Pharma A / S 151 CPX75146PC09 July 2025363. The compound of any one of items 1 to 104, wherein -L2- is of formula (XII-ii).364. The compound of item 363, wherein x of formula (XII-ii) is about 68.365. The compound of item 363, wherein x of formula (XII-ii) is about 90.366. The compound of item 363, wherein x of formula (XII-ii) is about 102.367. The compound of item 363, wherein x of formula (XII-ii) is about 113.368. The compound of item 363, wherein x of formula (XII-ii) is about 136.369. The compound of item 363, wherein x of formula (XII-ii) is about 160.370. The compound of item 363, wherein x of formula (XII-ii) is about 182.371. The compound of item 363, wherein x of formula (XII-ii) is about 204.372. The compound of item 363, wherein x of formula (XII-ii) is about 227.373. The compound of item 363, wherein x of formula (XII-ii) is about 250.374. The compound of item 363, wherein x of formula (XII-ii) is about 340.375. The compound of item 363, wherein x of formula (XII-ii) is about 455.376. The compound of item 363, wherein x of formula (XII-ii) is about 910.377. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 1.378. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 2.379. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 3.380. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 4.381. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 5.382. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 6.383. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 7.384. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 8.385. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 9.386. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 10.387. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 11.388. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 12.389. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 13.390. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 14.391. The compound of any one of items 363 to 376, wherein a of formula (XII-ii) is 15.392. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 1.393. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 2.394. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 3.395. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 4.396. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 5.Ascendis Pharma A / S 152 CPX75146PC09 July 2025397. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 6.398. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 7.399. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 8.400. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 9.401. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 10.402. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 11.403. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 12.404. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 13.405. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 14.406. The compound of any one of items 363 to 391, wherein b of formula (XII-ii) is 15.407. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 1.408. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 2.409. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 3.410. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 4.411. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 5.412. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 6.413. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 7.414. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 8.415. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 9.416. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 10.417. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 11.418. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 12.419. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 13.420. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 14.421. The compound of any one of items 363 to 406, wherein c of formula (XII-ii) is 15.422. The compound of any one of items 363 to 421, wherein -R1 of formula (XII-ii) is -H.423. The compound of any one of items 363 to 421, wherein -R1 of formula (XII-ii) ismethyl.424. The compound of any one of items 363 to 421, wherein -R1 of formula (XII-ii) is ethyl.425. The compound of any one of items 363 to 421, wherein -R1 of formula (XII-ii) is propyl.426. The compound of any one of items 363 to 421, wherein -R1 of formula (XII-ii) isisopropyl.427. The compound of any one of items 363 to 426, wherein -R2 of formula (XII-ii) is -H.Ascendis Pharma A / S 153 CPX75146PC09 July 2025428. The compound of any one of items 363 to 426, wherein -R2 of formula (XII-ii) ismethyl.429. The compound of any one of items 363 to 426, wherein -R2 of formula (XII-ii) is ethyl.430. The compound of any one of items 363 to 426, wherein -R2 of formula (XII-ii) is propyl.431. The compound of any one of items 363 to 426, wherein -R2 of formula (XII-ii) isisopropyl.432. The compound of any one of items 1 to 431, wherein -AB1 and -AB2 have a differentstructure.433. The compound of any one of items 1 to 431, wherein -AB1 and -AB2 have the samestructure.434. The compound of any one of items 1 to 433, wherein -AB1 has the structure of formula(A) wherein the dashed line indicates attachment to -L2-; -F0is of formula (a-1) wherein the dashed line indicates attachment to -LA-; -R0is selected from the group consisting of -CR1R1aR1b, -COOR1, -R1, -R1aand -R1bare selected from the group consisting of -H, methyl, ethyl, propyl and isopropyl; n is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24; -LA- is absent or is of formula (a-2) wherein the unmarked dashed line indicates attachment to -LB-; the dashed line marked with the asterisk indicates attachment to -F0;Ascendis Pharma A / S 154 CPX75146PC09 July 2025-Ra- is selected from the group consisting of and ,wherein the dashed line marked with the asterisk indicates attachment to -F0; the unmarked dashed line indicates attachment to the remainder of -LA- ; m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; p is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;-LB- is absent or is of formula (a-3) wherein the unmarked dashed line indicates attachment to -L2-; the dashed line marked with the asterisk indicates attachment to -LA; -Rd- is selected from the group consisting of C1-50 alkyl, C2-50 alkenyl and C2-50alkynyl, wherein C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl may be substituted with one or more -R1, which may be the same or different, and which C1-50alkyl, C2-50 alkenyl or C2-50 alkynyl may be interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R2)-, -S(O)2N(R2)-, -S(O)N(R2)-, -S(O)2-, -S(O)-, -N(R2)S(O)2N(R2a)-, -S-, -N(R2)-, -OC(OR2)(R2a)-, -N(R2)C(O)N(R2a)-, and -OC(O)N(R2)-; each -T- is independently selected from the group consisting of phenyl,naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-memberedheterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-memberedcarbopolycyclyl, and 8- to 30-membered heteropolycyclyl; whereineach -T- may independently be substituted with one or more -R1, which may bethe same or different; each -R1is independently selected from the group consisting of halogen, -CN, oxo (=O), -COOR3, -OR3, -C(O)R3, -C(O)N(R3R3a), -S(O)2N(R3R3a), -S(O)N(Ascendis Pharma A / S 155 CPX75146PC09 July 2025R3R3a), -S(O)2R3, -S(O)R3, -N(R3)S(O)2N(R3aR3b), -SR3,-N(R3R3a), -NO2, -OC(O)R3, -N(R3)C(O)R3a, -N(R3)S(O)2R3a, -N(R3)S(O)R3a, -N(R3)C(O)OR3a, -N(R3)C(O)N(R3aR3b), -OC(O)N(R3R3a), and C1-6alkyl; wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different; each -R2, -R2a, -R3, -R3aand -R3bis independently selected from the group consisting of -H, and C1-6alkyl, wherein C1-6alkyl may be substituted with one or more halogen, which may be the same or different; and -Re- is selected from the group consisting of -CH2-, 435. The compound of any one of items 1 to 434, wherein -AB2 has the structure of formula(A) (A), wherein the dashed line indicates attachment to -D-; -F0is of formula (a-1) wherein the dashed line indicates attachment to -LA-; -R0is selected from the group consisting of -CR1R1aR1b, -COOR1, -R1, -R1aand -R1bare selected from the group consisting of -H, methyl, ethyl, propyl and isopropyl; n is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24; -LA- is absent or is of formula (a-2) wherein the unmarked dashed line indicates attachment to -LB-; the dashed line marked with the asterisk indicates attachment to -F0;Ascendis Pharma A / S 156 CPX75146PC09 July 2025-Ra- is selected from the group consisting of and ,wherein the dashed line marked with the asterisk indicates attachment to -F0; the unmarked dashed line indicates attachment to the remainder of -LA- ; m is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 p is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;-LB- is absent or is of formula (a-3) wherein the unmarked dashed line indicates attachment to -D-; the dashed line marked with the asterisk indicates attachment to -LA; -Rd- is selected from the group consisting of C1-50 alkyl, C2-50 alkenyl and C2-50alkynyl, wherein C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl may be substituted with one or more -R1, which may be the same or different, and which C1-50 alkyl, C2-50alkenyl or C2-50alkynyl may be interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R2)-, -S(O)2N(R2)-, -S(O)N(R2)-, -S(O)2-, -S(O)-, -N(R2)S(O)2N(R2a)-, -S-, -N(R2)-, -OC(OR2)(R2a)-, -N(R2)C(O)N(R2a)-, and -OC(O)N(R2)-; each -T- is independently selected from the group consisting of phenyl,naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-memberedheterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-memberedcarbopolycyclyl, and 8- to 30-membered heteropolycyclyl; whereineach -T- may independently be substituted with one or more -R1, which may bethe same or different;Ascendis Pharma A / S 157 CPX75146PC09 July 2025each -R1is independently selected from the group consisting of halogen, -CN, oxo (=O), -COOR3, -OR3, -C(O)R3, -C(O)N(R3R3a), -S(O)2N(R3R3a), -S(O)N(R3R3a), -S(O)2R3, -S(O)R3, -N(R3)S(O)2N(R3aR3b), -SR3,-N(R3R3a), -NO2, -OC(O)R3, -N(R3)C(O)R3a, -N(R3)S(O)2R3a, -N(R3)S(O)R3a, -N(R3)C(O)OR3a, -N(R3)C(O)N(R3aR3b), -OC(O)N(R3R3a), and C1-6 alkyl; wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different; each -R2, -R2a, -R3, -R3aand -R3bis independently selected from the group consisting of -H, and C1-6 alkyl, wherein C1-6 alkyl may be substituted with one or more halogen, which may be the same or different; and -Re- is selected from the group consisting of -CH2-, 436. The compound of item 434 or 435, wherein -R0 of formula (a-1) is -COOR1.437. The compound of item 434 or 435, wherein -R0 of formula (a-1) is -CR1R1aR1b.438. The compound of item 434 or 435, wherein -R0 of formula (a-1) is .0 439. The compound of item 434 or 435, wherein -R of formula (a-1) is .440. The compound of any one of items 434 to 437, wherein -R1 of formula (a-1) is -H.441. The compound of any one of items 434 to 437, wherein -R1 of formula (a-1) is methyl.442. The compound of any one of items 434 to 437, wherein -R1 of formula (a-1) is ethyl.443. The compound of any one of items 434 to 437, wherein -R1 of formula (a-1) is propyl.444. The compound of any one of items 434 to 437, wherein -R1 of formula (a-1) isisopropyl.445. The compound of any one of items 434, 435 or 437 to 444, wherein -R1a of formula (a-1) is -H.446. The compound of any one of items 434, 435 or 437 to 444, wherein -R1a of formula (a-1) is methyl.447. The compound of any one of items 434, 435 or 437 to 444, wherein -R1a of formula (a-1) is ethyl.448. The compound of any one of items 434, 435 or 437 to 444, wherein -R1a of formula (a-1) is propyl.Ascendis Pharma A / S 158 CPX75146PC09 July 2025449. The compound of any of items 434, 435 or 437 to 444, wherein -R1a of formula (a-1) isisopropyl.450. The compound of any one of items 434, 435 or 437 to 449, wherein -R1b of formula (a-1) is -H.451. The compound of any one of items 434, 435 or 437 to 449, wherein -R1b of formula (a-1) is methyl.452. The compound of any one one of items 434, 435 or 437 to 449, wherein -R1b of formula(a-1) is ethyl.453. The compound of any one one of items 434, 435 or 437 to 449, wherein -R1b of formula(a-1) is propyl.454. The compound of any one one of items 434, 435 or 437 to 449, wherein -R1b of formula(a-1) is isopropyl.455. The compound of any one of items 434 to 454, wherein -LA- of formula (A) is offormula (a-2).456. The compound of any one of items 434 to 455, wherein -Ra- of formula (a-2) is ,wherein the unmarked dashed line indicates attachment to -LB- and thedashed line marked with the asterisk indicates attachment to -F0.457. The compound of any one of items 434 to 455, wherein -Ra- of formula (a-2) is ,wherein the unmarked dashed line indicates attachment to -LB- and thedashed line marked with the asterisk indicates attachment to -F0.458. The compound of any one of items 434 to 457, wherein -Rb- of formula (a-2) is.459. The compound of any one of items 434 to 457, wherein -Rb- of formula (a-2) is.460. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 1.461. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 2.462. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 3.463. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 4.464. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 5.Ascendis Pharma A / S 159 CPX75146PC09 July 2025465. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 6.466. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 7.467. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 8.468. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 9.469. The compound of any one of items 434 to 459, wherein m of formula (a-2) is 10.470. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 1.471. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 2.472. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 3.473. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 4.474. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 5.475. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 6.476. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 7.477. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 8.478. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 9.479. The compound of any one of items 434 to 469, wherein p of formula (a-2) is 10.480. The compound of item 434 or 435, wherein -LA- of formula (A) is absent.481. The compound of any one of items 434 to 480, wherein -LB- of formula (A) is offormula (a-3).482. The compound of any one of items 434 to 481, wherein -Rc- of formula (a-3) is.483. The compound of any one of items 434 to 481, wherein -Rc- of formula (a-3) is.484. The compound of any one of items 434 to 483, wherein -Re- of formula (a-3) is -CH2-.485. The compound of any one of items 434 to 483, wherein -Re- of formula (a-3) is .486. The compound of any one of items 434 to 483, wherein -Re- of formula (a-3) is .487. The compound of any one of items 434 to 480, wherein -LB- of formula (A) is absent.488. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-4).Ascendis Pharma A / S 160 CPX75146PC09 July 2025489. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-5).490. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-6).491. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-7).492. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-8).493. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-9).494. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-10).495. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-11).496. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-12).497. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-13).498. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-14).499. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-15).500. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-16).501. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-17).502. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-18).503. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-19).504. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-20).505. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-21).506. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-22).507. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-23).508. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-24).509. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-25).510. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-26).511. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-27).512. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-28).513. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-29).514. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-30).515. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-31).516. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-32).517. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-33).518. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-34).519. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-35).520. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-36).521. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-37).522. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-38).Ascendis Pharma A / S 161 CPX75146PC09 July 2025523. The compound of item 434 or 435, wherein -F0 of formula (A) is of formula (a-39).524. The compound of any one of items 488 to 523, wherein both -LA- and -LB- of formula(A) are absent.525. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-40).526. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-41).527. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-42).528. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-43).529. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-44).530. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-45).531. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-46).532. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-47).533. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-48).534. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-49).535. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-50).536. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-51).537. The compound of any one of items 434, 435 or 488 to 523, wherein -LA- of formula(A) is of formula (a-52).538. The compound of any one of items 434, 435 or 488 to 523, wher...

Claims

Ascendis Pharma A / S 224 CPX75146PC09 July 2025Claims1. A compound of formula (Ia) or (Ib)(Ib), wherein each -D- is independently a drug moiety;each -AB1and -AB2is independently an albumin-binding moiety; each -L1- is independently a linker moiety covalently and reversibly connected to -D-;each -L2- is independently a spacer moiety;x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25; and y is an integer selected from the group consisting of 2, 3, 4 and 5.

2. The compound of claim 1, wherein the compound is of formula (Ia) with x = 1.

3. The compound of claim 1 or 2, wherein -AB1 and / or -AB2 is / are independently offormula (A): (A), wherein the dashed line indicates attachment to -L2- or -D-, respectively;-F0is of formula (a-1)wherein the dashed line indicates attachment to -LA-; -R0is selected from the group consisting of -CR1R1aR1b, -COOR1,-R1, -R1aand -R1bare selected from the group consisting of -H, methyl, ethyl, propyl and isopropyl;Ascendis Pharma A / S 225 CPX75146PC09 July 2025n is 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24;-LA- is absent or is of formula (a-2)wherein the unmarked dashed line indicates attachment to -LB-; the dashed line marked with the asterisk indicates attachment to -F0; -Ra- is selected from the group consisting of,wherein the dashed line marked with the asterisk indicates attachment to -F0; the unmarked dashed line indicates attachment to the remainder of -LA- ;m is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 p is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10;-LB- is absent or is of formula (a-3)wherein the unmarked dashed line indicates attachment to -L2- or -D-;the dashed line marked with the asterisk indicates attachment to -LA;-Rd- is selected from the group consisting of C1-50 alkyl, C2-50 alkenyl or C2-50alkynyl, wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl may be substituted with one or more -R1, which may be the same or different, and which C1-50 alkyl, C2-50 alkenyl or C2-50 alkynyl may be interrupted by one or more groups selectedfrom the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R2)-, -S(O)2N(R2)-, -S(O)N(R2)-, -S(O)2-, -S(O)-, -N(R2)S(O)2N(R2a)-, -S-, -N(R2)-, -OC(OR2)(R2a)-, -N(R2)C(O)N(R2a)-, and -OC(O)N(R2)-;Ascendis Pharma A / S 226 CPX75146PC09 July 2025each -T- is independently selected from the group consisting of phenyl,naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-memberedheterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-memberedcarbopolycyclyl, and 8- to 30-membered heteropolycyclyl; whereineach -T- may independently be substituted with one or more -R1, which may bethe same or different; each -R1is independently selected from the group consisting of halogen, -CN, oxo (=O), -COOR3, -OR3, -C(O)R3, -C(O)N(R3R3a), -S(O)2N(R3R3a), -S(O)N(R3R3a), -S(O)2R3, -S(O)R3, -N(R3)S(O)2N(R3aR3b), -SR3,-N(R3R3a), -NO2, -OC(O)R3, -N(R3)C(O)R3a, -N(R3)S(O)2R3a, -N(R3)S(O)R3a, -N(R3)C(O)OR3a, -N(R3)C(O)N(R3aR3b), -OC(O)N(R3R3a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; each -R2, -R2a, -R3, -R3aand -R3bis independently selected from the group consisting of -H, and C1-6 alkyl, wherein C1-6 alkyl may be substituted with one or more halogen, which may be the same or different; and -Re- is selected from the group consisting of -CH2-,4. The compound of any one of claims 1 to 3, wherein -AB1 and / or -AB2 is independentlya peptidic albumin binding moiety.

5. The compound of any one of claims 1 to 4, wherein -L1- is of formula (II):, wherein the dashed line indicates attachment to a nitrogen, hydroxyl or thiol of -D-; -X- is selected from the group consisting of -C(R4R4a)-; -N(R4)-; -O-; -C(R4R4a)-C(R5R5a)-; -C(R5R5a)-C(R4R4a)-; -C(R4R4a)-N(R6)-; -N(R6)-C(R4R4a)-; C(R4R4a)-O-; -O-C(R4R4a)-; and -C(R7R7a)-; X1is selected from the group consisting of C; and S(O); -X2- is selected from the group consisting of -C(R8R8a)-; and -C(R8R8a)-C(R9R9a)-;Ascendis Pharma A / S 227 CPX75146PC09 July 2025=X3is selected from the group consisting of =O; =S; and =N-CN; -R1, -R1a, -R2, -R2a, -R4, -R4a, -R5, -R5a, -R6, -R8, -R8a, -R9, and -R9aare independently selected from the group consisting of -H; and C1-6alkyl; -R3, and -R3aare independently selected from the group consisting of -H; and C1-6alkyl, provided that in case one of -R3, -R3aor both are other than -H they are connected to N to which they are attached through an SP3-hybridized carbon atom; -R7is selected from the group consisting of -N(R10R10a); and -NR10-(C=O)-R11; -R7a, -R10, -R10a, and -R11are independently of each other selected from the group consisting of -H; and C1-6 alkyl; optionally, one or more of the pairs -R1a / -R4a, -R1a / -R5a, -R1a / -R7a, -R4a / -R5a, and -R8a / -R9aform a chemical bond; optionally, one or more of the pairs -R1 / -R1a, -R2 / -R2a, -R4 / -R4a, -R5 / -R5a, -R8 / -R8a, and -R9 / -R9aare joined together with the atom to which they are attached to form a C3-10 cycloalkyl; or 3- to 10-membered heterocyclyl;optionally, one or more of the pairs -R1 / -R4, -R1 / -R5, -R1 / -R6, -R1 / -R7a, -R4 / -R5, -R4 / -R6, -R8 / -R9, and -R2 / -R3are joined together with the atoms to which they are attached to form a ring A; optionally, R3 / R3aare joined together with the nitrogen atom to which they are attached to form a 3- to 10-membered heterocycle;A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3-10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8- to 11-memberedheterobicyclyl; and wherein -L1- is substituted with at least one -L2- and wherein -L1- is optionally furthersubstituted, provided that the hydrogen marked with the asterisk in formula (II) is notreplaced by -L2- or a substituent.

6. The compound of any one of claims 1 to 5, wherein -L1- is of formula (IIa)wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D-; and the unmarked dashed line indicates attachment to -L2-.Ascendis Pharma A / S 228 CPX75146PC09 July 20257. The compound of any one of claims 1 to 5, wherein -L1- is of formula (XIIa):wherein the unmarked dashed line indicates attachment to -D-; the dashed line marked with the asterisk indicates attachment to -L2-; -R2, -R4and -R8are independently selected from the group consisting of -H or C1-4 alkyl; -R3is C1-4alkyl or -R3and -R4together with the atoms to which they are attached form a 5- or 6-membered heterocyclic ring;-R5is -NH2; with the proviso that when -R4and -R3together with the atoms to which they are attached from a 5- or 6-membered heterocyclic ring -R2 is not -H; andwherein the -L1- of formula (XIIa) is optionally substituted.

8. The compound of any one of claims 1 to 7, wherein -L2- has a molecular weight rangingfrom about 3 kDa to about 20 kDa.

9. The compound of any one of claims 1 to 8, wherein -L2- comprises a polymeric moiety.

10. The compound of any one of claims 1 to 9, wherein -L2- is a spacer moiety of formula(B)wherein the unmarked dashed line indicates attachment to -L1-; the dashed line marked with the asterisk indicates attachment to -AB1; -POL- is a polymeric moiety; and-LD- and -LE- are independently absent or selected from the group consistingof -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry1)-, -S(O)2N(Ry1)-, -S(O)N(Ry1)-, -S(O)2-, -S(O)-, -N(Ry1)S(O)2N(Ry1a)-, -S-, -N(Ry1)-, -OC(ORy1)(Ry1a)-, -N(Ry1)C(O)N(Ry1a)-, -OC(O)N(Ry1)-, C1-50 alkyl,Ascendis Pharma A / S 229 CPX75146PC09 July 2025C2-50 alkenyl, and C2-50 alkynyl; wherein -T-, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more -Ry2, which are the same or different and wherein C1-50alkyl, C2-50alkenyl, and C2-50alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry3)-, -S(O)2N(Ry3)-, -S(O)N(Ry3)-, -S(O)2-, -S(O)-, -N(Ry3)S(O)2N(Ry3a)-, -S-, -N(Ry3)-, -OC(ORy3)(Ry3a)-, -N(Ry3)C(O)N(Ry3a)-, and -OC(O)N(Ry3)-; -Ry1and -Ry1aare independently of each other selected from the group consisting of -H, -T, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T, C1-50 alkyl, C2-50 alkenyl, and C2-50alkynyl are optionally substituted with one or more -Ry2, which are the same or different, and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consistingof -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(Ry4)-, -S(O)2N(Ry4)-, -S(O)N(Ry4)-, -S(O)2-, -S(O)-, -N(Ry4)S(O)2N(Ry4a)-, -S-, -N(Ry4)-, -OC(ORy4)(Ry4a)-, -N(Ry4)C(O)N(Ry4a)-, and -OC(O)N(Ry4)-; each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each T is independently optionally substituted with one or more -Ry2, which are the same or different; each -Ry2is independently selected from the group consisting of halogen, -CN, oxo (=O), -COORy5, -ORy5, -C(O)Ry5, -C(O)N(Ry5Ry5a), -S(O)2N(Ry5Ry5a), -S(O)N(Ry5Ry5a), -S(O)2Ry5, -S(O)Ry5, -N(Ry5)S(O)2N(Ry5aRy5b), -SRy5, -N(Ry5Ry5a), -NO2, -OC(O)Ry5, -N(Ry5)C(O)Ry5a, -N(Ry5)S(O)2Ry5a, -N(Ry5)S(O)Ry5a, -N(Ry5)C(O)ORy5a, -N(Ry5)C(O)N(Ry5aRy5b), -OC(O)N(Ry5Ry5a), and C1-6alkyl; wherein C1-6alkyl is optionally substituted with one or more halogen, which are the same or different; and each -Ry3, -Ry3a, -Ry4, -Ry4a, -Ry5, -Ry5aand -Ry5bis independently selected from the group consisting of -H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different.

11. The compound of any one of claims 1 to 10, wherein -L2- is of formula (XII-ii)Ascendis Pharma A / S 230 CPX75146PC09 July 2025wherein the dashed line marked with the asterisk indicates attachment to -L1-; the unmarked dashed line indicates attachment to -AB1; a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15; b is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15; c is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15; x ranges from 2 to 1000; -R1and -R2are independent of each other selected from the group consisting of -H and C1-6alkyl.

12. The compound of claim 11, wherein a of formula is 5, b is 2, c is 2, and both -R1 and -R2are -H.

13. The compound of claim 11 or 12, wherein x ranges from 45 to 600, from 65 to 500,from 79 to 450, from 90 to 350 or from 100 to 280.

14. The compound of any one of claims 1 to 13, wherein -D- or -D-AB2 is a GLP-1 receptoragonist moiety.

15. The compound of any one of claims 1 to 14, wherein -D-AB2 is selected from the groupconsisting of semaglutide, liraglutide, ecnoglutide, GZR18, GL0034, tirzepatide, cotadutide, BI-456906, pemvidutide, mazdutide, dapiglutide and retatrutide.

16. The compound of any one of claims 1 to 15, wherein -D-AB2 is semaglutide.

17. The compound of any one of claims 1 to 15, wherein -D-AB2 is tirzepatide.

18. The compound of any one of claims 1 to 17, wherein -AB1 is of formula (XIX)Ascendis Pharma A / S 231 CPX75146PC09 July 2025wherein the dashed line indicates attachment to -L2-; and a is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24.

19. The compound of claim 18, wherein a is 18.

20. The compound of any one of claims 1 to 19, wherein the compound is of formula (XIII)(XIII); wherein a is 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24; n is an integer ranging from 2 to 1000; the dashed line indicates attachment to a moiety, wherein the unmarked dashed line indicates attachment to the dashed line in formula (XIII); the dashed line marked with the asterisk indicates attachment to -D-; and e1 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14.

21. The compound of claim 20, wherein n ranges from 68 to 900, from 79 to 680, from 90to 450, from 90 to 400 or from 90 to 300.Ascendis Pharma A / S 232 CPX75146PC09 July 202522. A pharmaceutical composition comprising at least one compound of any one of claims1 to 21 and at least one excipient.

23. The pharmaceutical composition of claim 22, wherein the pharmaceutical compositioncomprises the at least one compound of the present invention in a concentration of at least 0.1 mg / ml, based on the molecular weight of -D-AB2.

24. The pharmaceutical composition of claim 22 or 23, wherein the pharmaceuticalcomposition has a pH ranging from pH 3 to pH 9.

25. The pharmaceutical composition of any one of claims 22 to 24, wherein thepharmaceutical composition is injectable through a 25 or higher gauge (G) needle.

26. The compound of any one of claims 1 to 21 or the pharmaceutical composition of anyone of claims 22 to 25 for use as a medicament.

27. The compound of any one of claims 1 to 21 or the pharmaceutical composition of anyone of claims 22 to 25 for use in the treatment of a disease that can be treated with H-D-AB2.

28. The compound of any one of claims 14 to 21 or a pharmaceutical compositioncomprising at least one such compound for use in the treatment of a disease selected from the group consisting of (i) all forms of diabetes, (ii) obesity, (iii) non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), (iv) cardiovascular disease, (v) neurodegenerative disorders, (vi) chronic kidney disease (CKD), (vii) diabetic kidney disease (DKD), (viii) peripheral arterial disease (PAD), and / or (ix) heart failure (HF).

29. The compound of any one of claims 14 to 21 or a pharmaceutical compositioncomprising at least one such compound for use in the treatment of a disease selected from the group consisting of dyslipidemia and / or diseases where one or more of thefollowing clinical outcomes are the treatment goal: lowering total serum lipids; increasing HDL; lowering small, dense LDL; lowering VLDL; lowering triglycerides;Ascendis Pharma A / S 233 CPX75146PC09 July 2025lowering cholesterol; lowering plasma levels of lipoprotein a (Lp(a)) in a human; inhibiting generation of apolipoprotein A (apo(A)).

30. The compound of any one of claims 14 to 21 or a pharmaceutical compositioncomprising at least one such compound for use in the treatment of a disease selected from the group consisting of Alzheimer´s disease and Parkinson´s disease.

31. The compound of any one of claims 14 to 21 or a pharmaceutical compositioncomprising at least one such compound for use in a treatment with one or moreadditional drugs selected from the group consisting of cardiovascular agents, antidiabetic agents, and anti-obesity agents.

32. The compound or the pharmaceutical composition for use of any one of claims 28 to31, wherein the compound or the pharmaceutical composition are administered in combination with a growth hormone.

33. The compound or the pharmaceutical composition for use of claim 32, wherein thegrowth hormone is lonapegsomatropin.

34. The compound or the pharmaceutical composition for use of claim 32, wherein thegrowth hormone is somatrogon.

35. The compound or the pharmaceutical composition for use of claim 32, wherein thegrowth hormone is somapacitan.

36. A prefilled container comprising at least one compound of any one of claims 1 to 21 orthe pharmaceutical composition of any one of claims 22 to 25.

37. The prefilled container of claim 36, wherein the container is a syringe, a vial, a bottle,a pouch, a carpule or an ampoule.

38. The prefilled container of claim 36 or 37, wherein the container is made of glass orplastic.Ascendis Pharma A / S 234 CPX75146PC09 July 202539. A kit of parts comprising at least one compound of any one of claims 1 to 21, at leastone pharmaceutical composition of any one of claims 22 to 25 or at least one prefilled container of any one of claims 36 to 38 and optionally instructions for use in apackaging, such as a box or pouch.

40. The kit of parts of claim 39, wherein the kit of parts further comprises an injectiondevice.

Images